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Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and 
it is a rare human cancer that has association with viral infection. In Mainland China, 
Southeast Asia and sub-Saharan Africa, over 8% of whole populations are HBV 
carriers. Long term consequence of chronic viral hepatitis infection will lead to many 
chronic liver diseases and finally death. In Hong Kong, HCC is the second 
commonest cause of cancer death and about 80% HCC patients are hepatitis B 
carriers. Therefore, hepatitis B infection is a major risk factor for the development of 
HCC, 100-fold increase risk of HCC development for chronic HBV carriers as 
compare with non-infected population. 
As cell proliferation, differentiation and tissue development are precise and strictly 
controlled by differentially expressed genes. The change in gene expression in HCC 
of local Chinese was investigated. Suppression subtractive hybridization is a 
powerful technique that can compare two populations of mRNA and obtain genes 
that are expressed in one population only. A PCR-based subtraction method was used 
by Mr. Yu Chi Hung from our laboratory in the construction of such a subtracted 
cDNA library. It is a unique method based on selective amplification of differentially 
expressed sequences, which can overcome technical limitations of traditional 
subtraction methods. With cDNA microarrays, it is possible to perform a large-scale 
analysis of differential expression of mRNA to identify candidate target genes 
vi 
Abstract 
stimultaneously. Therefore, PGR products of non-redundant clones from the 
subtracted-HCC, subtracted-surrounding normal counterpart, human surrounding 
normal counterpart and human HCC cDNA libraries were immobilized on the 
microarrays for further investigation of HCC. Twenty-eight genes were found to be 
differentially expressed in HCC. Their involvement and significance in 
hepatocarcinogenesis would be discussed in the final part of the thesis. 
In addition, a novel cDNA encoding a TBCl domain containing protein, which was 
isolated from the subtracted-HCC library, was shown to be differentially expressed in 
HCC. Therefore, the expression level in various human tissues, the subcellular 
localization and the potential interacting partners of the gene were studied to obtain 
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1.1 General introduction 
This thesis aims at reporting my present study, molecular studies of 
differentially expressed genes in hepatitis B virus (HBV)-induced 
hepatocellular carcinoma (HCC) by suppression subtractive hybridization and 
cDNA microarray analysis. This thesis will be divided into four chapters. In 
chapter one, the background information of HBV-induced HCC, the situation 
in Hong Kong and, the present screening methods and therapies for HCC will 
be presented. Then, the aims of present study will be stated and explained. The 
applications of expressed sequence tag in gene expression study and the 
suppression subtractive hybridization in differentially expressed gene study 
will be described. Finally, the construction of cDNA microchip for the 
determination of differential gene expression between HCC and its 
surrounding normal counterpart will be discussed. 
Chapter 2 will describe the strategies and methods employed in the 
construction of microchip, the study in differentially expressed gene in HCC 
and its surrounding normal counterpart by using the microchip and, the 
cloning and characterization of a novel gene which is overexpressed in HCC. 
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Chapter 3 will present the experimental results on cDNA microarray analysis 
and the results on the characterization of a novel gene,T2L522, in DNA and 
RNA levels, which provide the information of the novel gene on expression 
pattern and identification of interacting partners. 
The last chapter will discuss the significance of genes that showed differential 
expression in HCC or its surrounding normal counterpart from the cDNA 




1.2 HBV and its role in hepatocarcinogenesis 
1.2.1 Current situation of HBV infection and the HCC incidence in the 
world 
Hepatocellular carcinoma is among the most common malignant tumor in the 
world. It represents 4% of malignancies worldwide with an incidence of 
1,000,000 new cases annually. It has a male-to-female ratio of about 4:1. HCC 
is a highly endemic disease. In Mainland China, Southeast Asia and 
Sub-Saharan Africa, the incidence is 20 to 150 cases per 100,000 inhabitants 
but in western developed countries, the incidence is 1 to 4 cases per 100,000 
inhabitants only (Rustgi et al.’ 1987). 
HCC is a rare human cancer that has association with viral infection. The 
chronic infection with hepatitis B virus (HBV) (Yu et al” 1994) and hepatitis 
C vims (HCV) (Yu et al, 1991; Chang et al., 1994) are the major factors of 
HCC development. They account for about 0.46 million cases of primary 
causes of liver cancer deaths a year. Besides the vial infection, long-time 
exposure to dietary aflatoxin B1 (Kolar et al., 1992), excessive alcohol intake, 
cigarette smoking (Tanaka et al., 1992; Austin et al., 1986), hemochromatosis, 
a 1-antitrypsin deficiency also can cause HCC. 
Epidemiological studies have shown the association of HCC with HBV 
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infection. In Mainland China, Southeast Asia and Sub-Saharan Africa, about 
10-150/0 of the whole population has chronic hepatitis B infection. The HCC 
incidences in these areas are also high. The chronic HBV carriers have 
100-fold higher chance of HCC development than non-infected population 
(Beasley et al, 1981). 
1.2.2 Current situation of HBV infection and the HCC incidence in Hong 
Kong (Cancer Stat 1999 by Hong Kong Cancer Registry) 
In Hong Kong, liver cancer is the second major cause of cancer death that 
more than 1,000 people die of liver cancer annually. HCC is the histological 
subtype that represents 50.4% of the liver cancer death in 1998-1999. 
Although a high proportion (40%) was diagnosed without symptom, the death 
rate is also very high and that mortality-to-incidence ratio is about 0.9:1. 
Chronic hepatitis B infection is the major risk factor for the HCC and about 
8O0/0 of the patients are hepatitis B carriers. As about 8-10% of total population 
is hepatitis B carriers, HCC is still a major health problem in Hong Kong. 
1-2.3 Genetic organization of HBV 
The HBV DNA is a small, circular molecule with a highly compact genetic 
organization. Its genome consists of approximately 3.2k base pairs and four 
overlapping open reading frames (ORFs) in the complete or long (minus) 
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virion DNA strand. These ORFs encode the viral envelop that contains 
hepatitis B surface antigen (HBsAg) specificity, the viral nucleocapsid or core 
that contains hepatitis B core antigen (HBcAg) and a soluble protein with 
hepatitis B e antigen (HBeAg) (truncated form of the major core protein) 
specificities, the largest polyprotein that has reverse-transcriptase, RNAase 
activities and as the protein primer for viral minus DNA strand synthesis and, 
the small X protein (HBx) that has the capacity to transactivate transcription 
regulated by homologous and heterologous regulatory elements (Ono et aL, 
1983). 
1.2.4 Principle of hepatocarcinogenesis induced by HBV 
1-2.4.1 Role of chronic hepatitis in hepatocarcinogenesis 
Chronic hepatitis infection is an important risk factor for HCC. The chronic 
hepatitis was defined as an association of liver-cell necrosis, inflammation and 
thus cytokine synthesis and fibrosis. The inflammation response induces the 
synthesis of various cytokines, such as the tumor necrosis factor and 
interleukin 6 that can stimulate hepatocyte proliferation (Fansto et aL, 1993; 
Michalopoulos et al., 1997). The constitutive induction of hepatocyte 
progression into the cell cycle can overcome DNA repair mechanisms in the 
presence of mutational events. In the meanwhile, the extensive liver fibrosis 
disrupts the normal lobular structure and alters the cell-cell and 
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cell-extracellular matrix interactions. This may further lose the control over 
cell growth and the cells can escape from the programmed cell death and/or 
immune response. These chronic stimulations of the entry of hepatocyte into 
cell cycle are the risk factors for liver cancer. The histological end point of 
chronic hepatic inflammation and fibrosis is liver cirrhosis. Pervious reports 
showed that liver cirrhosis would increase the risk of HCC incidence (Paradis 
et al” 1998). 
1.2.4.2 Role of HBV in hepatocardnogenesis 
Hepatocarcinogenesis is a complex process that is associated with 
accumulation of a series of genetic and epigenetic changes. The direct 
oncogenic effect of HBV is caused by the integration of viral DNA sequences 
of HBV into hepatocyte DNA, which are near the genes involved in the control 
of proliferation and differentiation. It gives rise to activation of 
proto-oncogene, inactivation of tumor-suppressor genes and the over- or 
re-expression of growth factor (Wu et al., 1996). 
The HBV DNA integration can induce chromosomal rearrangements. Loss of 
heterozygosity (LOH) and low level of microsatellite instability are the 
common features of HCC. LOH from chromosome Ip, 4q, 6q, 8p, 9p, 13q, 16p, 
16q, 17p has been identified as the most frequent event. (Delpuech et al., 
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2002). In the HBV-associated HCC, p53 mutations are distributed along exon 
5-9. The mutation of p53 also has significant correlation with the loss of RB 
(13q LOH) at late tumor stage (Murakami et al” 1991). The HBx 
transactivates a large variety of cellular and viral genes, such as HBV 
enhancers, HIV long-terminal repeats, class II and III promoters and the 
proto-oncogenes such as c-jun, c-fos and c-myc (Murakami et al., 1999; Yen et 
al., 1996). HBx also activates cytokine-encoding genes such as tumor necrosis 
factor and transforming growth factor (Lara-Pezzi et al., 1998; Yoo et al.’ 
1996). HBx stimulates the transcription by interacting with cellular protein 
and/or protein involved in the signal transduction pathways such as the RPB5 
of RNA polymerase (Cheong et al., 1995), TATA-binding protein (Qadri et al., 
1995)，ras/raf/MAP-kinase and c-jun N-terminal kinase (Benn et al.’ 1996). 
1.2.5 Current screening tests for HCC 
HCC is a high death rate malignancy in human because the tumor is usually 
large in size before they give rise to symptoms. To increase the chance of 
intervention and to improve survival rate, early detection at the subclinical 
level is very important. 
Nowadays, the most widely used methods for screening HCC are elevation in 
the serum alpha-fetoprotein (AFP) concentration and abdominal ultrasound. 
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These two methods are widely used because they are less invasive. However, 
the sensitivity of AFP is relatively low. Only 50-70% of patients with HCC 
have elevated levels of AFP, which is about 20ng/ml (Johnson et al., 1997); 
and only about 30% of patients with HCCs smaller than 5 cm have a serum 
AFP concentration above 200ng/ml (Shinagawa et al., 1984). 
For abdominal ultrasound screening, the cirrhotic background of the liver 
makes the detection of small tumors more difficult. Only repeated ultrasound 
examinations can achieve about 90% sensitivity and specificity for tumor 
larger than 1 cm (Takayasu et al,, 1990). Besides, the low sensitivity and 
specificity of these two methods also give low positive predictive value i.e. a 
very low percentage of positive results is related to liver cancer. 
Many reports showed that repeated elevation of the serum AFP concentration 
every two months and abdominal ultrasound every three months could increase 
the detection rate of HCCs that are less than 3cm in diameter and those with 
less vein invasion. Therefore, more HCCs become resectable and the survival 
rate can also be increased (Kobayashi et al” 1985). However, repeating 
examinations are not cost-effective. In Hong Kong, the cost for performing 
one AFP test is estimated to be around $25 and one abdominal ultrasound is 
around $100 (in U.S. dollars) (Yuen et al, 2000). Therefore, the annual 
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screening cost to detect one HCC is very high. 
For further investigation to confirm the diagnosis, to determine stage of tumor 
and to assess the underlying liver disease, computer tomography (CT) 
angiography and percutaneous biopsy can be carried out. By using CT 
angiography, the detection rate for HCCs smaller than 2cm is about 72% and 
the specificity is also high because many particular vascular features of tumor 
are exhibited (Itoh et al., 1987). However, it is invasive that intra-arterial 
injection of lipiodol is needed. By using percutaneous biopsy, it may lead to 
tumor dissemination along the needle tract and convert a favorable tumor to an 
inoperable one. Therefore, it is not a perfect method for HCC screening. 
1.2.6 Current therapies for HCC 
There are many types of treatment for HCC. They are chemotherapy, 
radiotherapy, Transcatheter Aterial ChemoEmbolization (TACE), Percutaneous 
Ethanol Injection (PEI)，surgical resection and liver transplantation. 
Depending on the stage of the tumor, different types of treatment may be used 
at the same time, or one after the other. Actually, most of the treatments can 
only remove or destroy as much of the cancer cells as possible to prevent the 
tumor from growing, spreading or returning for as long as possible. At the 
worst condition, palliative treatment is used to relieve the symptoms only. 
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The conventional cancer therapies such as chemotherapy and radiotherapy are 
not efficient in treating HCCs because of the lack of effect and their toxicity. 
Chemotherapy is a treatment that uses the drugs to kill cancer cells. However, 
HCC is resistant to most of the chemotherapy drugs that cannot shrink the 
tumor effectively. And most studies showed that the systemic chemotherapy 
couldn't increase the survival rate of the HCC patients. 
Radiotherapy is a treatment that uses high-energy rays to kill or shrink cancer 
cells. A modified method, targeted radiotherapy, which can minimize the beam 
scatter and delivery of the required dose to the tumor more specifically. It is 
one of the palliative treatments that can shrink the tumor and relief the pain 
and it can provide a partial response rate of 64% and 3-years survival rate of 
41o/o (Ohto et al., 1995). However, the dose required to destroy the tumor cells 
also make the surrounding normal liver undergo hepatitis and even failure in a 
cirrhotic liver. 
Transcatheter aterial chemoembolization (TACE) is a treatment that can 
interrupt the blood flow of hepatic artery by selective catheterization of branch 
feeding the tumor and instillation of embolizing agents such as metallic coils, 
gelfoam or starch. It can provide a 3-years survival rate of 21.6% and 5-years 
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of 10.1% (Ueno et al., 2000). However, it also reduces the blood supply to the 
surrounding normal liver tissue that is dangerous for the patients with hepatitis 
and cirrhosis. 
Percutaneous ethanol injection (PEI) is a treatment that injects ethanol into the 
tumor within the liver by a fine needle to cause coagulative necrosis. It can 
almost completely destruct the tumor with minimal injury to the surrounding 
normal tissue because the difference in density between the soft tumor and the 
cirrhotic liver makes the HCC more sensitive to the effect of PEI. For small 
and cirrhotic patients, it provides 3-years survival rate of 63% and 5-years 
survival rate of 39% (Ohto et al., 1995). And the recurrence rates at one and 
two years are 28.3% and 54% respectively (Livraghi et al” 1992). 
At present, surgical resection and liver transplantation are the only forms of 
curative treatment available (Yuen et al, 2000). However, only 20% of 
patients are suitable for hepatic resection at the time of diagnosis. The surgical 
resection can only be carried out when the tumor is smaller than 5cm in 
diameter and without cirrhosis. The reports showed that the operative 
mortality varies from 2% to 16%, the 1-year survival rate between 56% and 
880/0 and 5-years survival rate between 28% and 59%. Although the hepatic 
resection has a relatively high survival rate, it also has a high recurrence rate. 
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The incidence of recurrence is between 20% and 64% within the first year, 
between 57% and 81% at 3-years and between 75% and 100% at 5-years (Chen 
et aL, 1994; Lai et al., 1995). 
Liver transplantation offers the prospect of treating HCC because it can 
overcome the constraints of surgical resection. However, the pervious results 
were disappointing in that liver transplantation led to advanced disease, with 
high recurrence rate, consequent on immunosuppression and poor long time 
survival. The 5-years survival rate is between 11% and 75% according to the 
stage of the tumor (Selby et al” 1995). Organ storage is also a main problem 
for liver transplantation. It leads to long waiting periods and inevitable 
progression of the tumor to a less favorable one. 
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1.3 Aim of the present study 
To reveal and study the principle of hepatocarcinogenesis and identify novel 
diagnostic maker(s), non-redundant cDNA clones from normal liver and liver 
cancer EST libraries, and subtracted-HCC and subtracted-normal counterpart 
liver libraries are used to construct a microchip for the screening of 
differentially expressed genes in HCC. 
Also, to study the relationship between a novel gene, T2L522, and various 
aspects of hepatocarcinogenesis and the role of this gene in HCC formation, 
molecular cloning and characterization of T2L522 were carried out. 
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1.4 Combining Expressed Sequence Tag (EST), Suppression 
Subtractive Hybridization and cDNA microarray for rapid 
differentially expressed genes screening 
In higher eukaryotes, every biological circumstance is mediated by precise 
programs of differential gene expression. The formation of HCC also involved 
multiple genetic changes, including the somatic mutation, activation or 
overexpression of oncogenes and inactivation of tumor suppressor genes. In 
order to expose the molecular principles of hepatocarcinogenesis, the 
differentially expressed genes of interest must be identified and studied in 
details. 
1.4.1 Expressed sequence tag (EST) 
Expressed sequence tags are the partial sequences of randomly selected cDNA 
clones from specific tissues or cell types cDNA libraries. Since the 
introduction of EST in 1991, it was widely used to discover new genes, 
mapping of the human genome and identification of the transcribed regions in 
genomic sequences (Adams et al., 1991; Okubo et al., 1992). EST pools can 
provide the data to carry out a meaningful statistical expression analysis in 
silico (Anderson et al., 1997; Lander et al., 1996) because the transcript 
composition is positively correlated to the abundance of mRNA and normally 
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the amount of protein. However, the EST libraries cannot provide obvious 
information of low abundance genes. 
1.4.2 cDNA subtraction 
Subtractive cDNA hybridization is an effective approach to identify and isolate 
cDNAs of differentially expressed genes. Up to now, various cDNA 
subtraction methods have been developed by the scientists. Those methods 
generally involve the conversion of mRNA into cDNA and hybridization of the 
two cDNA populations. The cDNA from our interested population was used as 
the tester. It will hybridize with the excess cDNA of the reference population, 
the driver. Then, the unhybridized target is separated from the hybridized 
common sequences by different ways. However, these methods need several 
round of hybridization that is tedious and the low-abundance sequences are 
lost during the process (Hara et al., 1991; Sargent et al., 1983). 
In 1996, a PCR-based cDNA subtraction method, suppression subtractive 
hybridization (SSH) was developed. Based on the suppression PGR effect, 
SSH can selectively amplify the differentially expressed cDNA fragments and 
suppress the non-target fragments amplification at the same time. It can highly 
enrich the differentially expressed genes of both high and low abundance for 
more than 1,000-fold (Diatchenko et al” 1996). 
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1.4.3 cDNA microarray 
Microarray is a miniaturized technology that allows a rapid and high 
throughput study in genotyping and gene expression profiling. The microchip 
is made by immobilization of identical single-stranded polymeric molecules of 
deoxyribonucleotides, mainly oligonucleotides or cDNAs, to a solid surface. 
The major advance of the microarray technology is that it allows parallel 
assessment of mRNA expression for hundreds or thousands of genes 
simultaneously. It can compare two populations of mRNA in a single 
experiment by using different fluorescently labelled nucleotides in the 
reverse-transcription reaction, Cy3 and Cy5 labelled dCTP or dUTP are the 
most commonly used nucleotides. The miniaturization of the hybridization 
allows using smaller amount of mRNA that can optimize the use of mRNA 
especially when the samples are limited. After the hybridization, the 
computerized scanning provides a quantitative value of the relative abundance 
comparing two samples, which can facilitate the data analysis. 
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Chapter 2 
Materials and Methods 
2.1 PCR-select cDNA subtraction 
The subtracted libraries were constructed by Mr. Yu Chi Hung in our laboratory. 
Suppression subtractive hybridization was carried out using PCR-Select cDNA 
subtraction kit from Clontech according to manufacturer's protocol. For the forward 
subtraction, HCC cDNA was used as the tester while its surrounding normal 
counterpart cDNA was used as the driver to construct subtracted HCC cDNA library. 
And vice versa for the reverse subtraction. 
2.1.1 Amplification of subtracted cDNA clones by PGR 
An aliquot of l|al of bacteria culture from the subtracted libraries was subjected to 
PCR in the presence of 50mM KCl, 1.5mM MgCb, 10 mM Tris-HCl, 200nM of 
each dNTP, 2.5 units Taq Polymerase (Amersham) and 200nM of each Nested PCR 
primer 1 (5'-TCGAGCGGCCGCCCGGGCAGGT-3') and Nested PCR primer 2 
(5'-AGCGTGGTCGCGGCCGAGGT-3') in a final volume of 50|il. The PCR 
reaction was subjected to 30 sec denaturation at 94�C, followed by 24 cycles of 
amplification (95�C, 30 sec; 68°C, 3minutes). The PCR product was analyzed on a 
1% agarose/EtBr gel run in IX TBE buffer. 
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2.1.2 Cycle sequencing of subtracted cDNA clones 
For dye-terminator cycle sequencing, PGR products from section 2.1.1 were used as 
the template for sequencing by DYEnamic ET dye terminator cycle sequencing kit 
(Amersham) in a 96-well plate format. 2\i\ of PGR product was premixed with 8^1 
of DYEnamic ET reagent, lOpmol of Nested PGR primer 1 in a final volume of 20|il. 
Cycle sequencing reaction was subjected to 30 cycles at 95°C, 10 sec; 50°C, 15 sec; 
60°C, 60 sec. Ethanol precipitation was carried out as post-reaction purification 
before gel electrophoresis. 2\A of 7.5M ammonium acetate and 2.5 volume of 100% 
ethanol were added to a final concentration of ethanol was 70%. Then the reaction 
was centrifuged at 4,000rpm for 30 minutes at 14°C. The plate was inverted and was 
centrifuged at 500rpm for 1 minute on a paper towel to remove the supernatant. 
lOOfil of 70% ethanol was added to wash the pellet. The plate was centrifuged at 
4,000rpm for 15 minutes at 14°C, and then it was inverted and was centrifuged at 
500rpm for another 1 minute. The pellet was allowed to air dry and was resuspended 
in lOfil of loading buffer (70% formamide and ImM EDTA). Then, the DNA 
sequences were acquired by MegaBACE 1000 automated DNA sequencer 
(Molecular Dynamics). 
2.1.3 Sequence analysis using BLAST server and the Stanford Online 
Universal Resource for Clones and ESTs (SOURCE) 
Sequences homology searches were performed using BLAST server at the National 
18 
Materials and Methods 
Center for Biotechnology Information (NCBI). Sequence similarity was considered 
statistically significant with an Expect value (E) smaller than e'^ ®, percentage 
matched is greater than 95% and the number of bases matched is more than 150 
base pairs. Then the resulted identities of the sequences were searched through 
SOURCE, a database that compiles information from several publicly accessible 
databases, to get detail information about the genes. 
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2.2 cDNA Microarray Analysis 
cDNA microarray is a technique that allows parallel assessment of gene expression 
for hundreds or thousands of genes in a single experiment. To facilitate the gene 
expression profiling of HCC, a microchip with 800 human liver cDNA clones is 
constructed. 
2.2.1 Array fabrication 
2.2.1.1 Amplification of cDNA clones by PCR 
An aliquot of 1 \x\ of bacteria culture from the subtracted libraries or 2 [i\ of phage 
culture from the EST libraries, was subjected to PCR in the presence of 50mM KCl, 
1.5mM MgCb, 10 mM Tris-HCl，300|aM of each dNTP, 2.5 units Tag Polymerase 
(Duncans) and 200nM of each primer (Nested PCR primer 1 and Nested PCR 
primer 2 for amplification of clones from subtracted libraries, Ml3 and XZap 
primers for amplification of clones from EST libraries) in a final volume of 50^1. 
The PCR reaction was subjected to 36 sec denaturation at 95�C, followed by 26 
cycles of amplification (95°C, 36 sec; 60°C, 36 sec; 72�C，60 sec) and final 
extension at 72°C for 10 minutes. The PCR product was analyzed on a 1% 
agarose/EtBr gel run in IX TBE buffer. 
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2.2.1.2 Purification of PGR products 
For efficient binding of target sequences to the slides, removal of unincorporated 
nucleotides and primers from the reaction products is essential. 96-well 
MultiScreen-PCR Plates (Millipore) for vacuum filtration were used for the 
purification of PGR products. 
The MultiScreen-PCR plate was pre-wet by adding 5fil of water. lOOjil of PGR 
products were loaded into wells. The plate was placed on the top of the vacuum 
manifold and vacuum was applied until wells were empty. 50|il of water was added 
into the wells and incubated for 15 minutes to reconstitute the samples. The purified 
PCR product from each well was retrieved by pipetting. The purified PGR product 
was analyzed on a 1% agarose/EtBr gel run in IX TBE buffer. 
2.2.1.3 Cycle sequencing for clones checking 
To prevent contamination and disorientation of clones during amplification and 
purification, eight of the purified products from each 96-well plate were randomly 
chosen for sequencing to confirm the clones' identities. 
For the dye-primer cycle sequencing, 2|il of the purified PCR product was used as 
template, in the presence of 30mM Tris-HCl at pH9.5, 7.5mM MgCb, 2\i\ of 
ThermoSequenase DNA polymerase (Amersham Pharmacia Biotech) and 5pmol of 
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fluorescein-labelled T7 primer (CY5-5'-GTAATACGACTCACTATAGGGC-3') in a 
final volume of 17.5|aL Then, 4\x\ of the reaction mix was mixed with 4|il 
corresponding dideoxyribonucleotide termination mix (150fiM of each dNTP and 
1-5|LIM corresponding ddNTP). The reactions were subjected to 26 cycles 
amplification (95°C, 36 sec; 50°C, 36 sec; 72°C, 90 sec) and final extension at iTC 
for 10 minutes. 4|il of stop solution (95% formamide，20mM EDTA) was added to 
stop the reactions. The sequencing products were stored at 4°C before separated on 
5.5% acrylamide gel using LI-COR automated sequencer. 
2.2.2 Microarray Printing 
2.2.2.1 Preparation of cDNA target 
Eight of the 96-wells purified target plates were relocated into two bar-coded 
384-well plates before printing. The IX target plates were prepared by adding equal 
volume of DMSO to the purified targets in a final volume of 20fil to give final 
targets concentration of 200-400 fmol/fil. The remaining products were concentrated 
to lOfil by SpeedVac. Then, the 2X target plates were prepared by adding equal 
volume of DMSO to the concentrated purified targets. Two IX target plates and two 
2X target plates were stored at -20°C before printing. 
2.2.2.2 Arraying 
The targets were spotted onto vapour phase coated slides (Amersham) by using 
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Generation III arrayer (Amersham). Dust was removed by blowing the slides with 
high-pressure nitrogen gas (without grease). 36 slides were placed on the slide tray 
of the arrayer. One Lucidea Microarray ScoreCard control plate, two 2X human 
liver target plates, two 2X rat heart target plates, two IX human liver target plates 
and two IX rat heart target plates were placed into the hotel of the arrayer in the 
ascending order. The PGR product was spotted onto the slides at 25 and 55% 
relative humidity. After spotting, the slides are allowed to dry inside the arrayer for 
30 minutes and the spotted DNA was UV-crosslinked under 50mJ by 
Spectrolinker™ (Spectronics). The spotted slides were stored in a light-tight slides 
box inside a desiccator at room temperature until hybridization. 
2.2.3 Screening of differentially expressed genes in Hepatocellular carcinoma 
and its surrounding normal counterpart by cDNA microarray 
2.2.3.1 Extraction ofRNA 
1ml of TRIzol Reagent (Life Technologies) was used to homogenize per 50mg of 
tissue using DREMEL FREE WHEELER™ homogenizer at 20,000rpm. The 
homogenized sample was incubated at room temperature for 5 minutes to permit the 
complete dissociation of nucleoprotein complexes. 0.2ml of chloroform per 1ml 
TRIzol reagent was added. The tubes were shaken vigorously by hand for 15 
seconds and incubated at room temperature for 3 minutes. The samples were 
centrifuged at 12,000 xg for 15 minutes at 4°C. Then the colourless upper aqueous 
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phase was transferred to a fresh tube. 0.5ml of isopropyl alcohol per 1ml TRIzol 
reagent used for initial homogenization was added to precipitate the RNA from the 
aqueous phase. The samples was incubated for 10 minutes at room temperature and 
then centrifuged at 12,000 xg for 10 minutes at 4°C. The supernatant was removed 
and 1ml of 75% ethanol was used to wash the RNA pellet. The sample was mixed 
by vortexing and centrifuged at 7,250 xg for 10 minutes at 4°C. At the end of the 
procedure, the RNA pellet was briefly dried at room temperature and then the RNA 
was redissolved by adding 10|il of DEPC-treated water. The RNA was analyzed on a 
1% agarose gel and run in IX TAE buffer. The A260/280 ratio was also measured. 
2.2.3.2 RNA Labelling 
2.2.3.2.1 Synthesis of fluorescence labelled probe 
For primer annealing, 100|ag total RNA from HCC or its surrounding normal 
counterpart was mixed with 600pmol of anchored oligo-dT primer, 3|il of Cy3 or 
Cy5 mRNA spike mix in the Cy3 or Cy5 labelling reactions in a total volume of 
20.51^1. The reactions were incubated at 65 °C for 10 minutes. The reaction mixtures 
with 50mM Tris-HCl, 75mM KCl, lOmM DTT, 2.5mM MgCh, 200nM of each 
unlabelled dATP, dGTP, dTTP, 200|iM unlabelled dCTP, 100|iM ofCyanine 3-dCTP 
NEL 567 or Cyanine 5-dCTP NEL 577 (PerkinElmer), 16.875 units of MMLV 
reverse-transcriptase (Duncan's) in a final volume 19.5|al. The reactions were 
subjected to 42 °C for an hour. 8.125 units of MMLV-RT was added to each reaction 
24 
Materials and Methods 
as booster and incubated at 42 for an additional hour. 20|al of O.IN NaOH and 
2mM EDTA was added to the reactions and incubated at 65 for 30 minutes to 
degrade RNA and stop the reactions. 20|il of O.IN HCl was added for neutralization. 
2.2.3.2.2 Purification of fluorescence labelled probe 
AutoSeq G-50 column (Amersham) was used to remove unincorporated nucleotides 
and short oligomers. AutoSeq G-50 column contains Sephadex G-50 DNA grade F 
for trapping the small size unincorporated nucleotides and oligomers. 
The resin in the column was resupended by vortexing gently. The cap was removed 
and the bottom closure was snapped off. The column was placed into a 1.5ml 
microcentrifuge tube for support and then was spun at 2,000 xg for 1 minute to 
remove the equilibrated buffer. The column was placed into a new 1.5ml 
microcentrifuge tube and the sample was slowly applied to the center of the angled 
surface of the compacted resin bed. The column was spun at 2,000 xg for 1 minute. 
The purified sample was collected at the bottom of the tube. The above procedures 
were repeated twice to thoroughly remove the unincorporated nucleotides and short 
oligomers. 
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2.2.3.3 Microarray hybridization 
2.2.3.3.1 Concentration of fluorescence labelled probe 
As a probe with high concentration can give a higher signal, Amicon® 
Microcon®-PCR Centrifugal Filter Device was used to concentrate the probe before 
hybridization. 
3 0 0 o f sterile water and the purified Cy3 and Cy5 probes were loaded into the 
sample reservoir of the Amicon® Microcon®-PCR Centrifugal Filter Device. The 
filter unit was centrifuged at 5,000 xg until 20|il of probe was left. The reservoir was 
inverted into a clean vial and centrifuged at 5,000 xg for 2 minutes. Then, the probe 
was ready for hybridization. 
2.2.3.3.2 Preparation of fluorescence labelled probe for hybridization 
25% Microarray Hybridization Buffer Version 2 (Amersham, Cat#: RPK0325), 
16.25nM polyA RNA (Sigma #P9403)，16.25nM cotl human DNA (Gibco-BRL) 
were added into 25% mixed labelled probe and was subjected to 95 °C for 2 minutes 
to denature the probe. 50% formamide (Sigma F9037) was added to the denatured 
probe in a final volume of 80|al. 
2.2.3.3.3 Hybridization 
All particulates were removed by dusting the slide surface and the LifterSlip™ 
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Cover Glass (Erie Scientific Company) with compressed air. The denatured probe 
was injected from the comer of the cover slip. The probe was allowed to spread 
under the slip via capillary action. The remaining solution was dispensed at both 
edges of the slip. Then the slide was placed inside an air chamber and was 
hybridized at 42 for 18 hours. 
2.2.3.3.4 Post-hybridization treatment 
The slide was removed from the hybridization chamber and placed into Wash lA, 
2X SSC, 0.03% SDS，chamber. The cover slip was removed carefully with the aid of 
forceps and care was taken not to agitate until the cover slip was safely removed. 
Then the chamber was agitated gently at room temperature for 2 minutes. The slide 
was removed by forceps and transferred to the Wash IB, 2X SSC, from the chamber. 
The slide was washed by submersion and agitation at room temperature for 2 
minutes in Wash IB chamber, then for 2 minutes in Wash 2, IX SSC and Wash 3, 
0.5X SSC. The slide was spun dry by centrifugation in MSE Mistral 2000 at 1,200 
xg for 10 minutes at room temperature. Then the slide was ready for scanning. 
2.2.3.4 Collection of data 
2.2.3.4.1 Scanning of slide 
ScanArray® 4000 Microarray Analysis System (Packard Bioscience, BioChip 
Technologies) was used for array scanning. The slide was scanned at 10|im by Cy3 
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and Cy5 laser. The power of each laser and the PMT gain, which give balance 
fluorescence and greatest dynamic range respectively, were adjusted to get the 
optimum parameter for the images scan. 
2.2.3.4.2 Image processing: spots finding and quantitation 
After scanning, the image of the slide was analyzed by a program called Dapple 
(from University of Washington). It is a tool for microarray segmentation, 
spot-finding and quantitation. A 16-bit, grayscale TIFF image of the both channels 
of the array was loaded. Array geometry was set to perform mostly-automated grid 
placement. For our slide, the grids were set as 12 rows times 2 column for arrays 
and 9 rows times 32 column for spots. The grids were adjusted to the most 
satisfactory place manually. Then the spots were found and circled by the program 
automatically. The spots were inspected and marked as "accept", "marginal" and 
"reject" by clicking over the spot. A popup image was shown and the grid can be 
moved manually to the most suitable position. Once the spots were inspected and 
edited, they were quantified by the program. The data was exported by choosing 
output as text files. 
2.2.3.5 Data normalization and analysis 
2.2.3.5.1 Normalization of signal by Lucidea Microarray ScoreCard 
After the spots quantification, the data was normalized and analysed by Lucidea 
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Microarray ScoreCard (Amersham). As the format of the output file from Dapple 
was not compatible with the input format of the ScoreCard, this output file was 
converted into a list that contained information of the element (clone position), 
DxA(density x area, sum of all pixels in spot) and sDxA(backgroimd subtracted 
intensity). 
Then, the converted file was input to the Lucidea Microarray ScoreCard. The 
control plate position (recommended as the first plate), sample-channel assignment 
and colour coded method were set for analysis. After data processing, a quality 
report and normalized data file with associated clone information were produced. 
These tab-delimited text files were viewed by the Excel program for clarity. 
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2.3 Molecular cloning and characterization of novel gene 
differentially expressed in HCC 
As the screening methods for HCC are not specific and sensitive enough and the 
principle of HBV-induced hepatocarcinogenesis is still unclear. Molecular cloning 
and characterization of novel clones can provide a clearer picture for 
hepatocarcinogenesis. 
i 
2.3.1 Tissue distribution of T2L522 gene 
2.3.1.1 Northern hybridization 
The Human Multiple Tissue Northern (MTN) blot was purchased from clontech. 
The MTN blot contained approximately 1 |Lig of poly A+ RNA per lane from twelve 
different human tissues. The integrity of the poly A+ RNA on the blot was examined 
by denaturing gel electrophoresis and probed with a digoxigenin-labelled human 
p-actin cDNA control probe (Product analysis certificate of Human 12-Lane MTN® 
Blot, Clontech). 
2.3.1.1.1 Amplification of probe by PGR 
An aliquot, 8|LI1 of human liver cDNA was subjected to PGR in the presence of 
40mM Tricine-KOH, 15mM KOAc，3.5mM Mg(0Ac)2, 3.75|ig/ml BSA, 300nM of 
each dNTP, 0.5|al SOX Advantage cDNA Polymerase Mix and 200nM of each 
forward primer (5-AGCAGACATCGCAGATGGCAGCAG-3') and reverse primer 
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(5'-TACTAGACAGGGAGCTATCCAGAT-3') in a final volume of SOfil. The PGR 
reaction was subjected to 5 minutes denaturation at 95°C, followed by 38 cycles of 
amplification (94°C, 36 sec; 56°C, 36 sec; 68°C, 40sec) and final extension at 12°C 
for 10 minutes. The PCR product was analyzed on a 1% agarose/EtBr gel run in IX 
TAE buffer. 
2.3.1.1.2 Purification of probe 
The probe was purified by GENECLEAN™ II Kit (Bio 101 Inc., La Jolla, U.S.A.). 
The PCR product was electrophoresed on a 1% agarose/EtBr gel run in IX TAE 
buffer. The DNA target containing agarose gel was excised and three volume of 
sodium iodine was added. The gel was placed into a 55�C water bath for 10 min for 
melting. 5|LI1 of GLASSMILK suspension was added and incubated in room 
temperature for an hour with continuous gentle shaking. The GLASSMILK/DNA 
complex was pelleted by centrifugation at 13,000 xg for one minute. The complex 
was resuspensed by 200 |il of NEW Wash and then pelleted by centrifugation at 
13,000 xg for one minute. The washing step was repeated. 10 |il of water was used 
to elute the DNA. 2 |il of gene clean product was analyzed on a 1% agarose/EtBr gel 
run in IX TAE buffer. 
2.3.1.1.3 Synthesis of radioactive-labelled probe 
The purified cDNA was random-primed labelled by Ready-To-Go DNA Labelling 
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Beads (-dCTP) from Pharmacia with [a-^^P] dCTR The labelling bead consists of 
buffet, dATP, dGTP, dTTP, FPLCpure™ Klenow Fragment (7-12units) and random 
oligodeoxyribonucleotides, primarily 9-mers. Sterile water was added to 50ng of 
purified cDNA to the final volume of 45\i\. The cDNA was denatured by heating for 
3 minutes at 100°C and placed on ice immediately for 2 minutes, then centrifuged 
briefly. 45)il of denatured cDNA was loaded into the tube containing the Reaction 
Mix bead and mixed by pipetting up and down several times. SOfiCi of [ a -^^P] 
dCTP (3000Ci/mmol, Amersham) was added to the reaction mix and incubated at 37 
�C for 15 minutes. 
The unincorporated [a-^^P] dCTP was removed by CHROMA SPIN™+STE 100 
size exclusion chromatography column (Clontech). The gel matrix of the column 
was resupended and centrifuged at 700 xg for 5 minutes to purge the equilibration 
buffer from the column. The labelled cDNA probe was applied to the column and 
centrifuged at 700 xg for 5 minutes. The purified probe was collected at the bottom 
of the tube. 
2.3.1.1.4 Hybridization of the Northern blot 
The Multiple Tissue Northern (MTN™) Blot was pre-hybridized in 5ml 
ExpressHyb™ Hybridization Solution alone at 68°C for 40 minutes. Then the blot 
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was hybridized in 5ml ExpressHyb Hybridization Solution in addition with the 
denatured, labelled cDNA probe at 68°C for one and a half hour. Pre-hybridization 
and hybridization were preformed in the hybridization bottle incubated in a rotatory 
hybridization oven (Hybaid) with continuous agitation. After hybridization, the blot 
was washed several times until a final stringency of 0.5X SSC, 0.25% SDS at 68°C 
was achieved. The blot was exposed to Kodak BioMax MS film with an intensifying 
screen at -80°C for one to seven days. Then the band intensities were quantified by 
densitometer. 
2.3.1.2 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
nn» # 
Multiple Tissue cDNA (MTC ) panels were purchased from Clontech. The Human 
MTC Panel I and II comprised of cDNA from poly A+ or total RNA, isolated from 
16 different human tissues. The cDNA was normalized with four different 
housekeeping genes, a-tubulin, p-actin, glyceraldehyde-3 -phosphate dehydrogenase 
(G3PDH) and phospholipase A2. 
An aliquot of 2\i\ of tissue cDNA was subjected to PGR in the presence of 50mM 
KCl, 1.5mM MgCl2, 10 mM Tris-HCl, 300|aM of each dNTP, 2.5 units Taq 
Polymerase (Duncans) and 200nM of each Forward PGR primer 
(5 '-AATTCTTCCAAAACAAAACTAG-3') and Reverse PGR primer 
(5'-TACTAGACAGGGAGCTATCCAGAT -3') in a final volume of 25^1. The PGR 
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reaction was subjected to 5 minutes denaturation at 95°C, followed by 39 cycles of 
amplification (94�C，36 sec; 55°C, 36 sec; 72�C, 40 sec). 5^1 of PCR product was 
collected every three cycles starting from the cycle. The PCR product was 
analyzed on a 1% agarose/EtBr gel run in IX TAE buffer. The expression levels of 
T2L522 in different tissues were quantitated by the program UVIBAND Analysis. 
2.3.2 Expression level of T2L522 in HCC and its surrounding normal 
counterparts 
The expression levels of T2L522 in HCC and its surrounding normal counterpart 
were determined by RT-PCR. Three cDNA pairs from HCC and normal counterpart 
tissue were use as templates, \0\x\ of tissue cDNA was subjected to PCR in the 
presence ofSOmM KCl, 1.5mM MgCb, 10 mM Tris-HCl, 300|iM of each dNTP, 2.5 
units Tag Polymerase (Duncan's) and 200nM of each Forward PCR primer 
(5 '-AATTCTTCCAAAACAAAACTAG-3') and Reverse PCR primer 
(5，-TACTAGACAGGGAGCTATCCAGAT -3') in a final volume of 30|al. The PCR 
reaction was subjected to 5 min denaturation at 95°C, followed by 33 cycles of 
amplification (94°C, 36 sec; 55/62°C, 36 sec; 72°C, 40 sec) and final extension at 
'72°C for 10 minutes. 10|al PCR product was analyzed on a 1% agarose/EtBr gel run 
in IX TBE buffer. 
34 
Materials and Methods 
2.3.3 Identification of interacting partners of T2L522 using the yeast 
two-hybrid assay 
2.3.3.1 Cloning of T2L522 gene into the yeast two-hybrid DNA-BD 
vector, pGBKTT 
2.3.3.1.1 Amplification of T2L522 gene by PGR 
An aliquot, \[i\ of liver cancer cDNA library was subjected to PGR in the presence 
of 40mM Tricine-KOH, 15mM KOAc, 3.5mM Mg(0Ac)2, 3.75ng/ml BSA, SOO^M 
of each dNTP, 0.5^1 SOX Advantage cDNA polymerase mix and 200nM of each 
Forward PGR primer (S'-TAGGGCCCATGGAGAATTCTTCCAAAACAAAACTA 
GAACTGC-3’) and Reverse PGR primer (5,-TAGGGCGTCGACGTGTTGCAAT 
CTCTCCTGCAGAGCTGT-3') in a final volume of 50|^ L Each primer contains an 
end clamp, TAGGGC, to facilitate the cleavage by restriction enzymes. An Ncol and 
Sail site, shown as underlined bases, were present in the forward and reverse 
primers respectively. The PGR reaction was subjected to 2 min denaturation at 95°C, 
followed by 34 cycles of amplification (95°C, 30 sec; 55°C, 36 sec; 68�C, 3 min and 
30 sec). The PGR product was analyzed on a 1% agarose/EtBr gel run in IX TAB 
buffer. The PGR product was purified by the GENECLEAN™ II Kit as described in 
section 2.3.1.1.2. 
2.3.3.1.2 Restriction enzyme digestion 
lOfil purified PGR product was subjected to the restriction enzymes digestion 
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reaction in the presence of 2X One-Phor-All PLUS buffer (Amersham), 1 i^l of the 
EcoRl and Sail restriction enzymes (Amersham) in a final volume of 40}il. The 
digestion was carried out at 37 for 3 hours. Restriction enzyme digestions of the 
pGBKT7 expression vector were performed in parallel. After digestion, the digested 
PGR product and the pGBKT7 expression vector were purified by GENECLEAN'^^ 
II Kit as described in section 2.3.1,1.2. 
2.3.3.1.3 DNA Ligation 
10|Lil digested and purified product was subjected to ligation in the presence of 3^1 
digested and purified pGBKT7 expression vector, IX ligation buffer, 1 unit T4 DNA 
ligase in a final volume of 10|il. The ligation reaction mixes were incubated at 16 °C 
overnight. A control reaction was performed in parallel. 
2.3.3.1.4 Transformation of plasmid DNA into competent Escherichia 
coli cells 
200^1 frozen competent cells, DH5a, were incubated on ice until the cell suspension 
was just thawed. 20^1 digestion reaction mix was added to the cells and mixed with 
gentle stirring. The tube was chilled on ice for an hour and then was heat shocked at 
42 for 2 minutes. The tube was chilled on ice immediately after heat shock for 2 
minutes and 800nl of LB medium was added. The tube was incubated at 37 °C for 
90 minutes with shaking at 250 rpm. Then the transformed cells were spun down at 
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13,000 xg for 1 minute. The cells were resuspended by 150|al LB medium and were 
spread onto LB agar plate containing 30fiM kanamycin. 
2.3.3.1.5 Small-scale preparation of plasmid DNA 
Recombinant plasmid was screened after transformation by Rapid Plasmid Miniprep 
(Life Technologies). A transformant was inoculated from the agar plate into 1ml of 
LB medium containing 30|iM kanamycin. The culture was incubated at 37 
overnight with shaking at 250 rpm. The cells were spin down and the supernatant 
was discarded. 250^1 Cell Suspension Buffer was added to the cell pellet to suspend 
the cells until homogeneous. 250|j,l Cell Lysis Solution was added and was mixed 
gently by inverting the tube 5 times. Then the mixture was incubated at room 
temperature 5 times. 350|il of Neutralization Buffer was added and was mixed 
immediately by inverting the tube 5 times. The mixture was centrifuged at 12,000 
xg for 10 minutes. The cartridge was placed into a 2ml wash tube. The supernatant 
from the pervious step was loaded into the cartridge and centrifuged at 12,000 xg for 
1 minute. The flow-through was discarded. 700fil of Wash Buffer was added to the 
cartridge and centrifuged at 12,000 xg for 1 minute. The flow-through was discarded 
and centrifuged again at 12,000 xg for 1 minute to remove residue wash buffer. The 
cartridge was placed into a 1.5ml recovery tube. 60|il of sterile water was added 
directly to the center of the cartridge. The cartridge was incubated at room 
temperature for 2 minutes and then centrifuged at 12,000 xg for 2 minutes to collect 
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the plasmid eluate. The plasmid eluate was analyzed on a 1% agarose/EtBr gel run 
in IX TBE buffer. 2|il of plasmid was used as template for cycle sequencing to 
confirm the identity of cloned transcript. The sequencing reaction was carried out as 
described in section 2.2.1.3. 
2.3.3.1.6 Large-scale preparation of plasmid DNA 
Large scale preparation was performed by QIAGEN Plasmid Midi Kit. A single 
colony was picked from a freshly streaked LB agar plate containing kanamycin and 
was inoculated into a culture of 100ml LB medium containing kanamycin. The 
culture was inoculated at 37 °C overnight with shaking at 280rpm.The bacterial cells 
were centrifuged at 6,000 xg at 4 °C for 15 minutes. The bacterial pellet was 
resuspended in 6ml Cell Suspension Buffer. 6ml of Cell Lysis Buffer was added and 
was mixed gently by inverting the tube 5 times. Then the mixture was incubated at 
room temperature for 5 minutes. During the incubation, the cap was screwed onto 
the outlet nozzle of the QIAfilter Midi Cartridge and the cartridge was placed into a 
convenient tube. 6ml of Neutralization Buffer was added and was mixed 
immediately by inverting the tube 5 times. The lysate was poured into the barrel of 
the cartridge immediately and was incubated at room temperature for 10 minutes. At 
the same time, a HiSpeed Midi Tip was equilibrated by applying 4ml Equilibrium 
Buffer and the column was allowed to empty by gravity flow. The cap was removed 
from the outlet nozzle of the cartridge and the plunger was inserted into the 
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cartridge to filter the lysate into the previously equilibrated HiSpeed Midi Tip. The 
cleared lysate entered the resin by gravity flow. The HiSpeed Midi Tip was washed 
by 20ml Washing Solution. Then, the DNA was eluted with 5ml Buffer QF. 3.5ml 
room-temperature isopropanol was added to the eluted DNA for DNA precipitation. 
The solution was mixed and incubated at room temperature for 5 minutes. The 
eluate/isopropanol mixture was filtered through the QIAprecipitator using constant 
pressure. The DNA was washed by pressing 2ml 70% ethanol through the 
QIAprecipitator. The membrane was dried by pressing air through the 
QIAprecipitator quickly and forcefully. Finally, 500|il sterile water was added to 
elute the DNA. The plasmid eluate was analyzed on a 1% agarose/EtBr gel run in 
IX TBE buffer. 2|LI1 of plasmid was used as template for cycle sequencing to 
confirm the identity of cloned transcript. The sequencing reaction was carried out as 
described in section 2.2.1.3. The recombinant clone containing T2L522 inserted in 
the pGBKT7 vector was named T2L522-BD. 
2.3.3.2 Transformation of the yeast competent cells 
3 colonies of PJ692A (Clontech) were transferred to a 500ml flask containing 200ml 
of YPDA medium and were incubated at 30�C overnight with shaking at 250rpm to 
stationary phase (OD6oo>1.5). The overnight culture was diluted with YPDA 
medium to produce a culture with ODeoo二0.2-0.3. The culture was incubated at 30°C 
with shaking at 250rpm until the OD6oo=0.5土0.1. Then the culture was centrifuged 
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at 1,000 xg for 5 minutes at room temperature. The supernatant was discarded and 
the cell pellets were resuspended by vortexing in 25ml of sterile water. The cells 
were centrifuged at 1,000 xg for another 5 minutes at room temperature. The 
supernatant was decanted and the cell pellet was resuspended in 1.5ml of freshly 
prepared, sterile IX TE/LiAc. The tube containing 0.1 ^g of T2L522-BD vector 
construct and 0.1 mg of Herring testes carrier DNA (denatured at 100�C for 20 
minutes and then chilled on ice) were added into a sterile 1.5ml microcentrifuge 
tube. Then, 0.1ml of yeast competent cells, PJ692A was added and was mixed by 
vortexing. 0.6ml of sterile PEG/LiAc solution was added and was mixed by 
vortexing at high speed. The tube was incubated at 30�C for 30 minutes with 
shaking at 200rpm. 70|LI1 of DMSO was added and was mixed by gentle inversion. 
The tube was subjected to heat shock for 15 minutes in 42°C water bath and then 
was chilled on ice for 2 minutes. The cells were centrifuged at 14,000rpm for 1 
minute at room temperature. The supernatant was removed and the cells were 
resuspended by 0.5ml of IX TE. 100|LI1 of cells were spread on a SD/-Trp plate and 
incubated at 30°C until colonies was appeared. 
2.3.3.3 Mating of T2L522-BD with pretransformed human liver cDNA library 
An overnight culture of the transformed bait strain, PJ692A with T2L522-BD was 
prepared by inoculating one large and fresh colony into 50 ml SD/-Trp. The culture 
was incubated at 30�C overnight with shaking at 270 rpm. The cells were spin down 
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at 1,000 xg for 5 minutes when the ODeoo was greater than 0.8. The cell pellet was 
resuspended in the residual medium by vortexing. One frozen aliquot of 
pretransformed Human Liver MATCHMAKER cDNA Library culture (Clontech, 
HY4024AH) was thawed out in an ice bath. The entired PJ692A with T2L522-BD 
culture and 0.5ml library were combined in a 2L sterile flask. 45ml 2X YPDA 
containing 50|Lig/ml kanamycin was added and swirl gently. 1ml of 2X YPDA/Kan 
was used to rinse cells from the library tube. The mating culture was incubated at 
30°C for 24 hours with swirling at 50 rpm. After 24 hours of mating, the cells were 
spin down by centrifuging at 1,000 xg for 10 minutes. Meanwhile, the mating flask 
was rinsed two times with 50ml 2X YPDA/Kan. The rinses were used to 
resuspended the first cell pellet. The cells were spin again at 1,000 xg for 10 minutes. 
The cell pellet was resupended in 5ml 0.5X YPDA/Kan. The total volume of cells 
and medium was measured. 100|il of a 1:10,000, 1:1,000, 1:100 and 1:10 dilution of 
the mating culture were spread on 90mm SD/-Leu, SD/-Trp and SD/-Leu/-Trp plates 
for mating efficiency control. The remaining mating culture was spread on 30 
150mm SD/-Ade/-His/-Leu/-Trp (QDO) plates, at 200|il per plates. Then, the plates 
were incubated at 30°C until colonies appeared. The growth on the SD/-Leu, 
SD/-Trp and SD/-Leu/-Trp plates was scored for calculating the mating efficiency 
and number of clones screened. 
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2.3.3.4 Colony lift p-galactosidase filter assay 
The colonies grew in the QDO plates was streaked to a 90mm QDO plate and 
incubated at 30°C until the colonies appeared again. 
In situ colony lift filter assay for blue/white screening of p-galactosidase activity 
was performed by lifting out the colonies from the agar plates onto a paper filter. A 
sterile VWR grade paper filter for each 90mm plate of transformants was presoaked 
with 1ml of freshly prepared Z buffer/X-gal solution (60mM Na2HP04, 40mM 
Na2H2P04�lOmM KCl, 0.1 mM MgSC^�50mM p-mercaptoethanol, 0.33mg/ml 
X-gal). Another paper filter was placed over the surface of the agar plate containing 
the transformants. Then the transformants were lifting out from the agar plate onto 
the filter and was permeabilized by submerging into liquid nitrogen for 10 seconds. 
The filter was thawed at room temperature and placed on the presoaked filter with 
colonies side up and incubated at 30°C for 2 hours. Library clones that activated the 
lacZ and His3 reporter genes only in the presence of pGBKT7-T2L522 were chosen 
for PCR and automated DNA sequencing. 
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2.3.4 Subcellular localization of T2L522 gene by tagging with green 
fluorescence protein (GFP) 
2.3.4.1 Cloning of T2L522 gene into the eukaryotic GFP expression vector, 
pEGFP-Cl 
An aliquot, l|il of liver cancer cDNA library was subjected to PGR in the presence 
of 40mM Tricine-KOH, 15mM KOAc, 3.5mM Mg(0Ac)2, 3.75ng/ml BSA, 300|iM 
of each dNTP, 0.5|al 5OX Advantage cDNA polymerase mix and 200nM of each 
Forward PGR primer (5'- TAGGGCGAATTCTAATTCTTCCAAAACAAAACTAG 
-3') and Reverse PGR primer (5,-TAGGGCGTCGACGTGTTGCAATCTCTCCTG 
CAGAGC-3') in a final volume of 50fil. The PCR reaction was subjected to 2 min 
denaturation at 95°C, followed by 34 cycles of amplification (95 30 sec; 55°C, 
36 sec; 68 3 min and 30 sec). Each primer contains an end clamp, TAGGGC, to 
facilitate the cleavage by restriction enzymes. An EcoRl and Sail site, shown as 
underlined bases, were present in the forward and reverse primers respectively. The 
cloning procedures were the same as described previously. 
2.3.4.2 Transfection of pEGFP-T2L522 into HepG2 cell 
The subcellular localization of T2L522 was performed by using GFP tagging. 
Before transfection, 1x10^ of HepG2 cells were seeded on a cover slip inside a well 
of 6-wells plate in 2ml RPMI with 10% fetal bovine serum (GibcoBRL) and were 
incubated at 37°C for 24 hours with 5% CO2. l|ig of pEGFP-T2L522 was diluted by 
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100|Lil of RPMI without serum. 6|LI1 of PLUS reagent (mix before use) was added to 
diluted pEGFP-T2L522 and was mixed. The pEGFP-T2L522 and PLUS reagent 
were incubated at room temperature for 15 minutes to allow the formation of 
pre-complex. The LIPOFECTAMINE reagent was diluted by 100|il of RPMI 
without serum in a second tube. The pre-complexed DNA was mixed with the 
diluted LIPOFECTAMINE reagent and was incubated at room temperature for 15 
minutes. While the complexes were forming, the medium on the cells was replaced 
by 0.8ml RPMI without serum. The DNA-PLUS- LIPOFECTAMINE reagent 
complexes were added to the well containing fresh medium on cells. The complexes 
were mixed into the medium gently and were incubated at 37�C for 3 hours with 5% 
CO2. After 3 hours incubation, the transfection medium was replaced by 2ml RPMI 
with 10% fetal bovine serum and was incubated at 37°C for 24 hours with 5% CO2. 
The cover slips were mounted on microscope slides and the fluorescent patterns 
were viewed under Axioskop fluorescence microscope (Zeiss AG). Control pEGFP 





3.1 PCR-select cDNA subtraction 
3.1.1 The sequencing results of subtracted-HCC cDNA clones 
Three hundred and two more subtracted-HCC cDNA clones were amplified and 
sequenced from the subtracted-HCC library. The DNA sequencing reactions were 
carried out by MegaBACE automated sequencer. The newly sequenced DNA 
transcripts together with 659 transcripts sequenced by Mr. Yu Chi Hung were 
searched through the Basic Local Alignment Search Tool for Nucleotide (BLASTN) 
program provided by National Center for Biotechnology Information (NCBI) and the 
Stanford Online Universal Resource for Clones and ESTs (SOURCE) database 
provided by Stanford Genome Centers. 
A new database including the accession number, the appearance frequency, clone 
number, putative identity, sequence length of transcript, Expect value and the 
percentage match of the best sequence alignment, chromosomal location, summary 
of function and subcellular localization was established. 
3.1.2 Categorization of ESTs sequenced from subtracted-HCC library 
For the homology search through the human UniGene and BLATSN server, sequence 
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similarity was considered statistically significant with an Expect value (E) smaller 
than e-20, a "percentage matched" that is greater than 95% and the number of bases 
matched that is more than 150 base pairs. Otherwise, the clone is classified as "no 
database match". The 961 sequences were divided into three groups, 245 clones were 
matched with known human genes, 558 clones were matched only with other ESTs 
and 158 clones were those without significant database match (Table 1). 
The 803 clones with database match were categorized into 10 groups according to 
their putative functions (Table 2). The genes involved in other metabolism appeared 
in the highest frequency, account for 32.9% of all genes. It was followed by the 
genes involved in transcription and translation, 11.2%; extracellular matrix, 7.2%; 
signal transduction and cell cycle regulation, 7.1%; secretory protein, 4.1%; energy 
metabolism, 2.7%; cytoskeletal related, 0.4% and, hormone and hormonal control, 
0.2%. The remaining 32.8% of genes were put into the category of miscellaneous as 
no information was provided for classification. 
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Table 1. Summary of sequences from subtracted-HCC library 
BLASTN search result Number of clones Percentage(yo) 
Match only with ESTs 558 58.1 
Match with known genes 245 25.5 
No database match 16.4 
Grand total 961 100.0 
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Table 2. Functional categorization of subtracted-HCC cDNA clones. 
Category Frequency Percentage (%) 
Cytoskeletal related 3 0.4 
Energy metabolism 22 2.7 
Extracellular matrix 58 7.2 
Hormone and hormonal control 2 0.2 
Membrane associated 11 1.4 
Miscellaneous 263 32.8 
Other metabolism 264 32.9 
Secretory protein 33 4.1 
Signal transduction/ cell cycle regulation 57 7.1 




3.2 Microarray analysis 
3.2.1 Array fabrication 
In the pilot study of cDNA microarray, a cDNA chip with 377 genes form the 
subtracted-HCC library, 153 genes from the subtracted normal library and 215 genes 
from the EST libraries were fabricated. The amplification and purification of the 
targets were performed in a 96-well plate format. Positive control (P-actin), and 
negative control (no template PCR) were placed in two comers of each 96-well plate 
as control. 
3.2.1.1 Amplification of cDNA microarray targets 
As the optimal concentration of the cDNA target for array printing is 200-400 
fmol/nl, the amplification of the targets should give a high yield to meet the 
requirement. During the optimization of PCR reaction, dNTP was found to be one of 
the limiting factors. 
0.2mM, 0.4mM and 0.8mM of dNTP in final concentration were used in different 
PCR reaction. After 35 and 40 cycles, the reaction with 0.2mM of dNTP, which was 
the suggested concentration of dNTP in most of the PCR reaction, gave the lowest 
yield of PCR products and with a higher dNTP concentration, a higher yield of PCR 
products was observed (Figure 1). However, too high dNTP concentration leads to 
inhibition in some of the reactions. Therefore, a final concentration of 0.3mM dNTP 
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was chosen for PGR amplification. 
After PCR amplification, the products were analysed in the ethidium bromide stained 
agarose gel. The amplified clones showing no band or more than one band in the 
agarose gelwere discarded and amplified again using an improved protocol. The 
success rate of amplification was more than 80%. 
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Figure 1. Ethidium bromide stained agarose gel showing the PCR products in 
different final dNTP concentration. Lane 1，7: PCR products of clone 1 in 0.2mM 
dNTP final concentration reaction, Lane 2，8: PCR products of clone 1 in 0.4mM 
dNTP final concentration reaction, Lane 3, 9: PCR products of clone 1 in 0.8mM 
dNTP final concentration reaction, Lane 4, 10: PCR products of clone 2 in 0.2mM 
dNTP final concentration reaction, Lane 5,11: PCR products of clone 2 in 0.4mM 
dNTP final concentration reaction, Lane 6, 12: PCR products of clone 2 in 0.8mM 
dNTP final concentration reaction. Lane 1-6 for 35 cycles and lane 7-12 for 40 
cycles. 
1 2 3 4 5 6 7 8 9 10 11 12 
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3.2.2 Microarray printing 
For the microarray printing, DMSO optimized vapour phase coated plain glass, Type 
5 slide purchased from Amersham Pharmacia Biotech was used. The amino silane 
slide coating carried covalent attached primary amines on the surface that allows 
formation of ionic bonds with the phosphate backbone at neutral pH. This vapour 
phase coating slide is a low fluorescence glass that can improve spot deposition, 
uniformity and reproducibility, and uniform target retention. The UV crosslinkage 
after printing can induce the radical-based coupling between thymidine residues on 
the DNA and carbons on alkyl amine of the substrate. 
For a better evaluation of microarray experimental results, minimizing the variations 
in the measurements can provide an accurate comparison within an experiment and 
across multiple experiments. The use of control samples can relate the experimental 
data to the control data in a quantitative manner for minimizing the variation. 
Therefore, a Lucidea Microarray ScoreCard control plate was also printed on the 
slide. The control plate is a 384-well microplate that contains 12 replicates of 32 
control samples. Two total human DNA/complex target acted as positive control 
because they always produce measurable signals despite the tissue-specific mRNA 
was used for hybridization. Eleven housekeeping genes served as additional positive 
control and they are used for comparative analysis of the slides within an experiment 
and across multiple experiments. Six dynamic range controls derived from intergenic 
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regions in yeast only hybridize with a spiked mix of the corresponding mRNA but do 
not hybridize with mammalian cDNAs. These dynamic range controls are used to 
evaluate the dynamic range and sensitivity of the system. Four ratio controls also 
derived from intergenic regions in yeast, which are references for measuring 
differential expression. Two negative controls, a plant gene and polydA 
oligonucleotide are used for evaluating the degree of the background signal levels of 
non-specific hybridization. 
For the target plates, the amount of target for spotting recommended by the 
manufacturer is 200-400fmol/|al but they also claimed that 100-1600fmol/fil is also 
acceptable to maintain a linear response with probe. Then, 2 different amounts of 
targets, IX and 2X that within the range of 200-800fmol/|Lil, were printed on the slide. 
It provided a better view on the target concentration that can help us to optimize our 
future work. 
The microchips, Hs8Rn5, which contained one control, four human liver and four rat 
heart 384-well plates of clones, were produced. As we just concentrated on the 
human liver clones, the gene list with gene position on the slide, accession number 
and the gene identity of the control samples and human liver clones were shown in 
Appendix. And the position of the genes on the microchip was shown in Figure 2. 
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Figure 2. Array geometry showing the position of genes on the microchip. Row 1 
of each array row is the genes from Lucidea Microarray ScoreCard control plate. 
Row 2 and 3 are the genes from 2X Hs800 plate 1 and 2 respectively. Row 6 and 7 
are the genes from IX Hs800 plate 2 and 1 respectively. 
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3.2.3 Microarray analysis of differentially expressed genes in 
Hepatocellular carcinoma and its surrounding normal counterpart 
To determine the expression profile of HCC, three HCC/surrounding normal 
counterpart pairs (Table 3) were used for cDNA microarray analysis. The RNA from 
the tissues pairs were labelled by using Cyanine 3-dCTP NEL 567 (maxima 
wavelength of excitation and emission are 550nm and 568nm respectively) or 
Cyanine 5-dCTP NEL 577 (maxima wavelength of excitation and emission are 
650nm and 668nm respectively). For each tissue pair, the surrounding normal 
counterpart was labelled with Cy3 fluorescence dye and the tumor was labelled with 
Cy5 fluorescence dye, with duplication. Reciprocal labelling was also done with 
duplication to eliminate the difference in labelling efficiency between dyes. 
Therefore, four sets of data from each tissues pairs were collected. 
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Table 3. Identity of HCC/surrounding normal counterparts tissue pairs. RNA 
from patients A, B and C are used for microarray studies. cDNA from patients B, C 
and are used for RT-PCR studies. 
Patient Sex Age Tumor Size (cm) Details  
A M % 4 Viral type B 
B M 58 4x4.5 HBsAg +ve, HBeAg -ve, Anti-HCV -ve 
C M 43 8.3 x5 / 
D M 51 / Anti-HCV +ve  
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3.2.4 Data collection 
The differential gene expression was assessed by scanning the hybridized arrays 
using confocal laser scanner that can scan both the Cy3- and Cy5- labelled probes 
and produce separate TIFF images for each. 
The ScanArray® 4000 Microarray Analysis System was used to scan our slides. This 
scanner uses green Helium-Neon laser operating at 543nm to excite Cy3 and red 
Helium-Neon laser operating at 633nin to excite Cy5. We chose a small resolution 
value, 10jj.m, to obtain maximium information from the slides. 
The images of the hybridized slides provide raw data of differentially expressed 
genes. The genes that were up-regulated in Cy3-labelled dye would show green spots. 
The genes that were up-regulated in Cy5-labelled dye would show red spots. The 




Figure 3. Hybridization of mRNA from patient A to Hs8Rn5 chip. RNA from 
tumor tissue and its surrounding counterpart of patient A was labelled by Cy5 and 





Figure 4. Hybridization of mRNA from patient B to Hs8Rn5 chip. RNA from 
tumour tissue and its surrounding counterpart of patient B was labelled by Cy5 and 





Figure 5. Hybridization of mRNA from patient C to Hs8Rn5 chip. RNA from 
tumour tissue and its surrounding counterpart of patient C was labelled by Cy3 and 
Cy5 fluorescent dye respectively. The probe was hybridized with the Hs8Rn5 chip. 
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3.2.5 Image processing: spots finding and quantitation 
Dapple is a tool for microarray segmentation, spot-finding and quantitation for fast, 
accurate and convenient analysis of microarray. 
The output file about the quantitation of the available spots on the array containing 
the following information: the first line stated the number of spots on the microchip 
and number of channels quantitated per spots, coordinates of the spots, rated quality, 
foreground intensity, medium of local background intensity, standard deviation of the 
background pixel population, number of pixels in the foreground and background 
samples for the spot and the ratio of first to second channel intensity. 
3.2.6 Data normalization and analysis 
As the format of output file from Dapple was not compatible with the input format of 
the ScoreCard, a Macro called "dp2sc" was written by Dr. Stephen Chim for data 
conversion. 
After inputing the data file, control plate position, sample-channel assignment and 
colour-coded method were set before data processing. Then, the Lucidea Microarray 




The Control Data Scatter Plot shows the relationship between the averaged Cy3 and 
Cy5 signal values for the dynamic range controls, ratio controls and housekeeping 
genes. This plot provides a view of the dynamic range of the experiment and the 
performance of the ratio control. The dynamic range controls plot should be 
approximately linear over three logs and the slope would be approximately 1 under 
perfect experimental conditions. In our experiments, most of the dynamic range 
control plots (Figure 6) appeared approximately linear which mean that the 
conditions of our experiments were acceptable. 
The Ratio Analysis Table (Figure 6) shows the target ratio against the observed ratios 
for the ratio controls and dynamic range controls. The observed average ratios are the 
antilog of the average uncorrected log ratio ofCyS to Cy5 signal of the controls. The 
normalized average ratios are the antilog of the average normalized log ratio of Cy3 
to Cy5 signal of the controls. The normalization calculation corrected the differences 
in rate of incorporation, stability and fluorescence of Cy3 and Cy5, and the 
experimental errors. Therefore, the normalized values should closely match with the 
corresponding target values. The software highlighted the observed or normalized 
values when the fold difference between the observed or normalized value and the 
target value is greater than the threshold (1.5-fold difference). The reliability of the 
experimental data is high when the normalized values are closely matched with the 
target. In our experiment, all of the normalized ratios in 4 of 12 slides were fall into 
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the expected values. Four of the slides had more than seven normalized ratios which 
fall into the expected values and the other four slides had more than five normalized 
ratios which also fall into the expected values. These results mean that the 
normalization calculation can eliminate the difference between dyes and the 
experimental error, and the reliability of the results is high. 
The Ratio Precision Table (Figure 6) shows the Actin NLR SD (the standard 
deviation of the normalized log ratio for the 48 replicate actin spots) and the Mean 
NLR SD (the average standard deviation of the normalized log ratio for the dynamic 
range controls, ratio controls, housekeeping genes and positive controls). These NLR 
SD values indicate the reproducibility of gene expression ratios for the hybridization 
experiment. Smaller NLR SD values represent more precise gene expression ratios. 
In our experiment, the Actin NLR SD are 0.029 to 0.110; the mean NLR SD are 
0.072 to 0.108，both of them are smaller than the threshold value (0.150). These 
mean the reproducibility of gene expression ratios for our hybridization experiments 
are high. 
The Detection Limits Table (Figure 6) shows the following data: Detection Limit 
Signal (average signal value of the negative controls for Cy3 and Cy5 plus 3 times 
standard deviation) that allows comparison of detection limits between slides within 
or across experiments, DL/Actin Ratio (ratio of detection limit to average actin gene 
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signal; smaller the ratio, the greater the sensitivity) that measures the sensitivity 
relative to the actin gene and uses to check the detection limits within or across 
experiments, Dynamic Range (ratio of the maximum sDxA value to the detection 
limit signal) that higher the dynamic range values, the lower the background noise, 
%>DL (percent of all signal values that are greater than the detection limits) that low 
%>DL indicates high background noise or poor hybridizing sample quality. In our 
experiments, more than 60% the Detection Limit Signal were in negative values. 
These results mean that the background signal were relatively low. The %>DL in our 
slides ranged from 15-27%. It is relatively low because the genes from rat in the 
same slide that had no detectable signal were also counted for the calculation of 
%>DL. Therefore, the level of background signal and the hybridization quality were 
acceptable. 
The Actin Gene Performance Table (Figure 6) shows Signal (average actin gene 
signal), SD (corresponding standard deviation) and the %CV (corresponding percent 
coefficient of variation). The %CV can indicate spot-to-spot variation and data 
reproducibility. The high %CV indicates a damage pen or high local background. In 
our experiments, the actin gene signal and the SD can fall into the reasonable range, 
only %CV of some experiments were exceeded the threshold (50). In two of the 
slides, %>DL are also very low which means that the background noise of these slide 
may be too high. Besides, the system validation information also showed that the 
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percent of pen variation were higher than the default threshold (25%) that means the 
pen may be damaged. 
The Normalized Control Plate Data Grid (Figure 7) shows Cy3 signal and Cy5 signal 
(Cy3 or Cy5 average signal values for replicates), Cy3 %CV and Cy5, %CV (percent 
coefficient of variation for the Cy3 or Cy5 signal values), Cy3/Cy5 uncorrected log 
ratio (average uncorrected log ratio of Cy3 signal to Cy5 signal), Cy3/Cy5 
normalized log ratio (average normalized log ratio of Cy3 signal to Cy5 signal), 
Cy3/Cy5 SD for the uncorrected log ratio and normalized log ratio (standard 
deviations of the uncorrected log ratio and normalized log ratio) and mean (overall 
mean and the mean standard deviation of the uncorrected and normalized log ratios 
for the dynamic range, ratio and hosekeeping gene control elements) of particular 
control element. 
The Normalized Date File (Figure 8) is the most important file that shows 
normalized data of our slides. The normalized data file included detection limit flag 
(<Cy3 DL，<Cy5 DL) (flags indicated whether the signals fall below the detection 
limit. 1 indicates the signal is below the detection limit. 0 indicates the signal is 
above the detection limit), spot ULR (uncorrected log ratio), spot NLR (normalized 
log ratio)，norm Cy3 (normalized Cy3 signal that is Cy5 signal • 10 (spotNLR)), u^Rl 
and ULR2 (uncorrected log ratio in spot set 1 and 2) and, NLRl and NLR2 
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(normalized log ratio in spot set 1 and 2) of a particular spot. 
The data provided by the normalized data file were used for further analysis. The 
data fall below either detection limits were eliminated because these data are not 
reliable. Log (Cy3/Cy5) ratios were used to plot a graph showing uncorrected log 
ratio of the genes (Figure 9). Then, log (normCy3/Cy5) ratios were used to plot 
another graph showing the corrected log ratio of the genes (Figure 10). By 
comparing these two graphs, we detected that the log ratios of the genes were not 
clustered around zero before normalization. After exponentially normalized by the 
Lucidea ScoreCard, the log ratios of the genes were clustered around zero. The 
results showed that the exponential normalization method provided by the Lucidea 
ScoreCard is reliable because we know most of the genes are not differentially 
expressed in a particular stage. 
According to the normalized data file, the NLR value of the genes is greater than 
0.301 or smaller than -0.301 are defined as up-regulated or down-regulated genes 
respectively. In our experiments, the genes that showed differential expression in 
more than 2 out of 3 tissues pairs were taken out for further investigation. Finally, 6 
genes showed up-regulation in HCC and 22 genes showed down-regulation in HCC 
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Results 
Figure 9. The graph showing the distribution of log ratio of genes before 
normalization. Before normalization, the log ratio was not clustered around zero. 
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Figure 10. The graph showing the distribution of log ratio of genes after 
exponential normalization by ScoreCard. After normalized by ScoreCard，the log 
ratio was clustered around zero. 
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Table 4. Candidate genes differentially expressed in HCC. 
Gene up-regulated in HCC : 
Dominating Average Literature 
Acession No. Gene identity Library ratio cited 
Extracellular matrix protein 
Hs.313 secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early Ts 7.5 5 
T-lymphocyte activation 1) 
Protein involved in other metabolism 
Hs. 119597 stearoyl-CoA desaturase (delta-9-desaturase) Ts 3.3 5 & 9 
Proteins involved in transcription and translation 
Hs. 181307 H3 histone, family 3A Ts 3.6 
Hs.275865 ribosomal protein SI8 Ts 2.5 
Miscellaneous proteins 
Hs.74335 heat shock 90kD protein 1, beta Ts 3.0 
XM_013095 thymosin, beta 4, X chromosome (TMSB4X), Ts 3.1 
Novel protein 
Hs.277431 hypothetical protein FLJ23356 Ts 11.3 
Gene down-regulated in HCC : 
Dominating Average Literature 
Acession No. Gene identity Library ratio cited 
Membrane associated protein 
XM—004236 solute carrier family 22 (organic cation transporter), member 1 Rs 3.3 
(SLC22A1) 
Proteins involved in other metabolism 
Hs.234234 aldolase B, fructose-bisphosphate Rs 7.5 2 ,5 & 8 
Hs. 174220 cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), Rs 4.8 4, 5, 6 & 8 
polypeptide 8 
Hs.75183 cytochrome P450, subfamily IIE (ethanol-inducible) Rs 6.7 4’ 7 & 8 
Hs.329704 cytochrome P450, subfamily IIIA (niphedipine oxidase), Rs 6.5 
polypeptide 3 
Hs.275215 hydroxysteroid (11-beta) dehydrogenase 1 Rs 6.6 2，5，7 & 8 
Secretory proteins 
Hs. 184411 albumin Rs 5 5 
Hs.76177 alpha-1-microglobulin/bikunin precursor R 4.7 
XM_003294 alpha-2-HS-glycoprotein (AHSG) Ts 4.6 1 , 4 & 7 
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Hs.74561 alpha-2-macroglobulin Rs 6.6 2 
Hs.93194 apolipoprotein A-I R 3.4 
Hs.268571 apolipoprotein C-I Js 6.0 7 
Hs.73849 apolipoprotein C-III R 5.O 2 & 8 
Hs.90765 fibrinogen, A alpha polypeptide Rs 4.2 8 
Hs.7645 fibrinogen, B beta polypeptide Rs 3.5 
Hs.76461 retinol-binding protein 4, interstitial (AFl 19868) R 7.3 2 
Hs. 194366 transthyretin (prealbumin, amyloidosis type I) Rs 5.3 2 & 8 
Miscellaneous proteins 
Hs.1290 complement component 9 Rs 3.1 5 
M17614 transferrin gene, exon 17 Rs 8.5 
Novel proteins 
Hs. 12969 hypothetical protein FLJ23094 Rs 5.6 
AB037799 KIAA1378 Ts 3.3 
AF090936 EST Rs i 6 2 
Dominating library: 
Rs: Subtracted-normal cDNA library 
Ts: Subtracted-HCC cDNA library 
R: Human surrounding normal counterpart cDNA library 
T: Human HCC cDNA library. 
Literature cited: 
1. Delpuech et al., 2002 
2. Kim et al., 2001 
3.Kondoh et al., 1999 
4丄au et al., 2000 
5. Okabe et al., 2001 
6. Shirota et al” 2001 
7. Xu et fl/., 2001a 
8. Xu et a/., 2001b 
9. Li et al., 2000 
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3.3 Molecular cloning and characterization of a novel cDNA 
clone differentially expressed in HCC 
A human novel clone, T2L522 was isolated from the subtracted-HCC 
library. It is believed as a candidate gene that is overexpressed in HCC. 
From the BLASTN search result, the DNA sequence showed about 98% 
similarity to a gene called KIAA1108 (Accession number: AB029031). 
However, AB029031 is 682 base pair shorter at the 5,end. The whole 
coding sequence was predicted by merging the human ESTs form the 
GenBank. Then, specific primers were designed to fish out the whole 
coding sequence. A sequence nearly identical to T2L522 was published 
as XM_035618 in GenBank in 13 May, 2002. Tissue distribution analysis, 
yeast two-hybrid assay and subcellular localization were done to obtain 
more information about the expression pattern and function(s) of 
T2L522. 
The coding sequence of T2L522 was amplified from the liver cancer 
cDNA library. The PCR product was cloned into the plasmid pGBKT7. 
The DNA sequence of the open reading frame (ORF) of T2L522 was 
verified by automated sequencing. Excluding the vector sequence, 
T2L522 cDNA insert is 2,814 base pairs in length and that encodes a 
protein of 937 amino acids (Figure 11). 
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Figure 9. The cDNA and predicted amino acid sequences of T2L522. In the DNA 
sequence, the phosphotyrosine-binding domain was underlined and the TBC domain 
was in bold. 
1 CGGCCGCGTGACGGTGGCGCACAAGAAGGCTCCGCCGGCC 4 0 
4 1 CTGATCGACGAGTGCATCGAGAAGTTCAATCACGTCAGCGGCAGCCGGGGGTCCGAGAGC 1 0 0 
1 0 1 CCCCGCCCCAACCCGCCCCATGCCGCGCCCACAGGGAGCCAGGAGCCTGTGCGCAGGCCC 1 6 0 
1 6 1 ATGCGCAAGTCCTTCTCCCAGCCCGGCCTGCGCTCGCTGGCCTTTAGGAAGGAGCTGCAG 2 2 0 
I M R K S F S Q P G L R S L A F R K E L Q 2 0 
2 2 1 GATGGGGGCCTCCGAAGCAGCGGCTTCTTCAGCTCCTTCGAGGAGAGCGACATTGAGAAC 2 8 0 
2 1 D G G L R S S G F F S S F E E S D I E N 4 0 
2 8 1 CACCTCATTAGCGGACACAATATTGTGCAGCCCACAGATATCGAGGAAAATCGAACTATG 3 4 0 
4 1 H L I S G H N I V Q P T D I E E N R T M 6 0 
3 4 1 CTCTTCACGATTGGCCAGTCTGAAGTTTACCTCATCAGTCCTGACACCAAAAAAATAGCA 4 0 0 
6 1 L F T I G Q S E V Y L I S P D T K K I A 8 0 
4 0 1 TTGGAGAAAAATTTTAAGGAGATATCCTTTTGCTCTCAGGGCATCAGACACGTGGACCAC 4 6 0 
8 1 L E K N F K E I S F C S Q G I R H V D H 1 0 0 
4 6 1 TTTGGGTTTATCTGTCGGGAGTCTTCCGGAGGTGGCGGCTTTCATTTTGTCTGTTACGTG 5 2 0 
1 0 1 F G F I C R E S S G G G G F H F V C Y V 1 2 0 
5 2 1 TTTCAGTGCACAAATGAGGCTCTGGTTGATGAAATTATGATGACCCTGAAACAGGCCTTC 5 8 0 
1 2 1 F Q C T N E A L V D E I M M T L K Q A F 1 4 0 
5 8 1 ACGGTGGCCGCAGTGCAGCAGACAGCTAAGGCGCCAGCCCAGCTGTGTGAGGGCTGCCCC 6 4 0 
1 4 1 T V A A V Q Q T A K A P A Q L C E G C P 1 6 0 
6 4 1 CTGCAAAGCCTGCACAAGCTCTGTGAGAGGATAGAGGGAATGAATTCTTCCAAAACAAAA 7 0 0 
1 6 1 L Q S L H K L C E R I E G M N S S K T K 1 8 0 
7 0 1 CTAGAACTGCAAAAGCACCTGACGACATTAACCAATCAGGAGCAGGCGACTATTTTTGAA 7 6 0 
1 8 1 L E L Q K H L T T L T N Q E Q A T I F E 2 0 0 
7 6 1 GAGGTTCAGAAATTGAGACCGAGAAATGAGCAGCGAGAGAATGAATTGATTATTTCTTTT 8 2 0 
2 0 1 E V Q K L R P R N E Q R E N E L I I S F 2 2 0 
8 2 1 CTGAGATGTTTATATGAAGAGAAACAGAAAGAACACATCCATATTGGGGAGATGAAGCAG 8 8 0 
2 2 1 L R C L Y E E K Q K E H I H I G E M K Q 2 4 0 
8 8 1 ACATCGCAGATGGCAGCAGAGAATATTGGAAGTGAATTACCACCCAGTGCCACTCGATTT 9 4 0 
2 4 1 T S Q M A A E N I G S E L P P S A T R F 2 6 0 
9 4 1 AGGCTAGATATGCTGAAAAACAAAGCAAAGAGATCTTTAACAGAGTCTTTAGAAAGTATT 1 0 0 0 
2 6 1 R L D M L K N K A K R S L T E S L E S I 2 8 0 
1 0 0 1 TTGTCCCGGGGTAATAAAGCCAGAGGCCTGCAGGAACACTCCATCAGTGTGGATCTGGAT 1 0 6 0 
2 8 1 L S R G N K A R G L Q E H S I S V D L D 3 0 0 
1 0 6 1 AGCTCCCTGTCTAGTACATTAAGTAACACCAGCAAAGAGCCATCTGTGTGTGAAAAGGAG 1 1 2 0 
3 0 1 S S L S S T L S N T S K E P S V C E K E 3 2 0 
1 1 2 1 GCCTTGCCCATCTCTGAGAGCTCCTTTAAGCTCCTCGGCTCCTCGGAGGACCTGTCCAGT 1 1 8 0 
3 2 1 A L P I S E S S F K L L G S S E D L S S 3 4 0 
1 1 8 1 GACTCGGAGAGTCATCTCCCAGAAGAGCCAGCTCCGCTGTCGCCCCAGCAGGCCTTCAGG 1 2 4 0 
3 4 1 D S E S H L P E E P A P L S P Q Q A F R 3 6 0 
1 2 4 1 AGGCGAGCAAACACCCTGAGTCACTTCCCCATCGAATGCCAGGAACCTCCACAACCTGCC 1 3 0 0 
3 6 1 R R A N T L S H F P I E C Q E P P Q P A 3 8 0 
1 3 0 1 CGGGGGTCCCCGGGGGTTTCGCAAAGGAAACTTATGAGGTATCACTCAGTGAGCACAGAG 1 3 6 0 
3 8 1 R G S P G V S Q R K L M R Y H S V S T E 4 0 0 
1 3 6 1 ACGCCTCATGAACGAAAGGACTTTGAATCCAAAGCAAACCATCTTGGTGATTCTGGTGGG 1 4 2 0 
4 0 1 T P H E R K D F E S K A N H L G D S G G 4 2 0 
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1 4 2 1 ACTCCTGTGAAGACCCGGAGGCATTCCTGGAGGCAGCAGATATTCCTCCGAGTAGCCACC 1 4 8 0 
4 2 1 T P V K T R R H S W R Q Q I F L R V A T 4 4 0 
1 4 8 1 CCGCAGAAGGCGTGCGATTCTTCCAGCAGATATGAAGATTATTCAGAGCTGGGAGAGCTT 1 5 4 0 
4 4 1 P Q K A C D S S S R Y E D Y S E L G E L 4 6 0 
1 5 4 1 CCCCCACGATCTCCTTTAGAACCAGTTTGTGAAGATGGGCCCTTTGGCCCCCCACCAGAG 1 6 0 0 
4 6 1 P P R S P L E P V C E D G P F G P P P E 4 8 0 
1 6 0 1 GAAAAGAAAAGGACATCTCGTGAGCTCCGAGAGCTGTGGCAAAAGGCTATTCTTCAACAG 1 6 6 0 
4 8 1 E K K R T S R E L R E L W Q K A I L Q Q 5 0 0 
1 6 6 1 ATACTGCTGCTTAGAATGGAGAAGGAAAATCAGAAGCTCCAAGCCTCTGAAAATGATTTG 1 7 2 0 
5 0 1 I L L L R M E K E N Q K L Q A S E N D L 5 2 0 
1 7 2 1 CTGAACAAGCGCCTGAAGCTCGATTATGAAGAAATTACTCCCTGTCTTAAAGAAGTAACT 1 7 8 0 
5 2 1 L N K R L K L D Y E E I T P C L K E V T 5 4 0 
1 7 8 1 ACAGTGTGGGAAAAGATGCTTAGCACTCCAGGAAGATCAAAAATTAAGTTTGACATGGAA 1 8 4 0 
5 4 1 T V W E K M L S T P G R S K I K F D M E 5 6 0 
1 8 4 1 AAAATGCACTCGGCTGTTGGGCAAGGTGTGCCACGTCATCACCGAGGTGAAATCTGGAAA 1 9 0 0 
561 K M H S A V G Q G V P R H H R G E I W K 580 
1 9 0 1 TTTCTAGCTGAGCAATTCCACCTTAAACACCAGTTTCCCAGCAAACAGCAGCCAAAGGAT 1 9 6 0 
5 8 1 F L A E Q F H L K H Q F P S K Q Q P K D 600 
1 9 6 1 GTGCCATACAAAGAACTCTTAAAGCAGCTGACTTCCCAGCAGCATGCGATTCTTATTGAC 2 0 2 0 
6 0 1 V P Y K E L L K Q L T S Q Q H A I L I D 620 
2 0 2 1 CTTGGGCGAACCTTTCCTACACACCCATACTTCTCTGCCCAGCTTGGAGCAGGACAGCTA 2 0 8 0 
621 L G R T F P T H P Y F S A Q L G A G Q L 640 
2 0 8 1 TCGCTTTACAACATTTTGAAGGCCTACTCACTTCTAGACCAGGAAGTGGGATATTGCCAA 2 1 4 0 
641 S L Y N I L K A Y S L L D Q E V G Y C Q 660 
2 1 4 1 GGTCTCAGCTTTGTAGCAGGCATTTTGCTTCTTCATATGAGTGAGGAAGAGGCGTTTAAA 2 2 0 0 
661 G L S F V A G I L L L H M S E E E A P K 680 
2 2 0 1 ATGCTCAAGTTTCTGATGTTTGACATGGGGCTGCGGAAACAGTATCGGCCAGACATGATT 2 2 6 0 
681 M L K F L M F D M G L R K Q Y R P D M I 700 
2 2 6 1 ATTTTACAGATCCAGATGTACCAGCTCTCGAGGTTGCTTCATGATTACCACAGAGACCTC 2 3 2 0 
7 0 1 I L Q I Q M Y Q L S R L L H D Y H R D L 720 
2 3 2 1 TACAATCACCTGGAGGAGCACGAGATCGGCCCCAGCCTCTACGCTGCCCCCTGGTTCCTC 2 3 8 0 
721 Y N H L E E H E I 6 P S L Y A A P W F L 740 
2 3 8 1 ACCATGTTTGCCTCACAGTTCCCGCTGGGATTCGTAGCCAGAGTCTTTGATATGATTTTT 2 4 4 0 
7 4 1 T M F A S Q F P L G F V A R V F D M I F 760 
2 4 4 1 CTTCAGGGAACAGAGGTCATATTTAAAGTGGCTTTAAGTCTGTTGGGAAGCCATAAGCCC 2 5 0 0 
761 L Q G T E V I F K V A L S L L G S H K P 780 
2 5 0 1 TTGATTCTGCAGCATGAAAACCTAGAAACCATAGTTGACTTTATAAAAAGCACGCTACCC 2 5 6 0 
7 8 1 L I L Q H E N L E T I V D F I K S T L P 8 0 0 
2 5 6 1 AACCTTGGCTTGGTACAGATGGAAAAGACCATCAATCAGGTATTTGAAATGGACATCGCT 2 6 2 0 
8 0 1 N L G L V Q M E K T I N Q V F E M D I A 8 2 0 
2 6 2 1 AAACAGTTACAAGCTTATGAAGTTGAGTACCACGTCCTTCAAGAAGAACTTATCGATTCC 2 6 8 0 
8 2 1 K Q L Q A Y E V E Y H V L Q E E L I D S 8 4 0 
2 6 8 1 TCTCCTCTCAGTGACAACCAAAGAATGGATAAATTAGAGAAAACCAACAGCAGCTTACGC 2 7 4 0 
8 4 1 S P L S D N Q R M D K L E K T N S S L R 8 6 0 
2 7 4 1 AAACAGAACCTTGACCTCCTTGAACAGTTGCAGGTGGCAAATGGTAGGATCCAAAGCCTT 2 8 0 0 
8 6 1 K Q N L D L L E Q L Q V A N G R I Q S L 8 8 0 
2 8 0 1 GAGGCCACCATTGAGAAGCTCCTGAGCAGTGAGAGCAAGCTGAAGCAGGCCATGCTTACC 2 8 6 0 
8 8 1 E A T I E K L L S S E S K L K Q A M L T 9 0 0 
2 8 6 1 TTAGAACTGGAGCGGTCGGCCCTGCTGCAGACGGTGGAGGAGCTGCGGCGGCGGAGCGCA 2 9 2 0 
9 0 1 L E L E R S A L L Q T V E E L R R R S A 9 2 0 
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2 9 2 1 GAGCCCAGCGACCGGGAGCCTGAGTGCACGCAGCCCGAGCCCACGGGCGACTGACAGCTC 2 9 8 0 
9 2 1 E P S D R E P E C T Q P E P T G D * 9 3 8 
2 9 8 1 TGCAGGAGAGATTGCAACACCATCCCACACTGTCCAGGCCTTAACTGAGAGGGACAGAAG 3 0 4 0 
3 0 4 1 ACGCTGGAAGGAGAGAAGGAAGCGGGAAGTGTGCTTCTCAGGGAGGAAACCGGCTTGCCA 3 1 0 0 
3 1 0 1 GCAAGTAGATTCTTACGAACTCCAACTTGCAATTCAGGGGGCATGTCCCAGTGTTTTTTT 3 1 6 0 
3 2 6 1 TGTTGTTTTTAGATACTAAATCGTCCCTTCTCCAGTCCTGATTACTGTACACAGTAGCTT 3 2 2 0 
3 2 2 1 TAGATGGCGTGGACGTGAATAAATGCAACTTATGTTTT 3 2 5 8 
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3.3.1 Tissue distribution of T2L522 
3.3.1.1 Northern hybridization 
For the northern blot hybridization, the radioactively labelled T2L522 
cDNA probe was used to hybridize with ploy A+ RNA of various human 
tissues, and then the tissue distribution of T2L522 mRNA was revealed. 
The integrity of the poly A+ RNA on the blot was examined by denaturing 
gel electrophoresis and probed with a digoxigenin-labelled human 
p-actin cDNA control probe (Product analysis certificate of Human 
12-Lane MTN® Blot, Clontech). The results showed the lanes 
corresponding to the kidney and placenta tissues gave the relatively high 
signals. Moderately low signals can be found in heart, skeletal muscle, 
spleen and small intestine tissues. And very low signals showed in colon, 
thymus and liver tissues and virtually no signal in brain, lung and 
peripheral blood leukocyte tissues (Figure 12). The results show that 
T2L522 RNA expressed in most of the tissues with different levels of 
expression. The expression level of T2L522 in liver tissue is very low, 
which suggests that T2L522 is a rare transcript in liver tissue. This result 
is supported by our sequencing results from the EST and subtracted 
libraries because T2L522 can only be isolated from the subtracted-HCC 
library, which has enriched the rare transcripts during the subtraction 
experiment, but not in the EST libraries. 
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Figure 12. Tissue distribution of T2L522 mRNA revealed by northern 
hybridization in various human tissues. Lane 1: brain. Lane 2: heart. 
Lane 3: skeletal muscle. Lane 4: colon. Lane 5: thymus. Lane 6: spleen. 
Lane 7: kidney. Lane 8: liver. Lane 9: small intestine. Lane 10: placenta. 
Lane 11: lung. Lane 12: peripheral blood leukocyte. 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 
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3.3.1.2 Reverse-transcriptase polymerase chain reaction (RT-PCR) 
For the RT-PCR, gene specific primers were designed to perform the PCR. 
RT-PCR has higher sensitivity to increase the possibility to detect those 
transcripts that cannot be detected in Northern blots and allow us to 
determine differences between tissues over a broader linear range. As the 
T2L522 is a rare transcript, RT-PCR was also used to determine the 
tissue distribution. The amount of cDNA in the panel was normalized by 
the following housekeeping genes: a-tubulin, P-actin, 
glyceraldehydes-3-phosphate dehydrogenase (G3PDH), phospholipase 
A2 and ribosomal protein S29. 
The result showed that T2L522 is expressed in all the tissue samples. The 
lanes corresponding to placenta, kidney and testis gave relatively high 
signals. Moderate signals were detected in lung, liver, skeletal muscle, 
pancreas, spleen, thymus, ovary and peripheral blood leukocyte. And low 
signals in heart, whole brain, prostate, small intestine without mucosal 
lining and colon (Figure 13). The results are similar to the results of 
Northern blot and it also showed the expression level of some tissues that 
cannot be detected in the Northern blot. 
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Figure 13. Tissue distribution of T2L522 mRNA revealed by RT-PCR 
in various human tissues. Lane 1: heart. Lane 2: whole brain. Lane 3: 
placenta. Lane 4: lung. Lane5: liver. Lane 6: skeletal muscle. Lane 7: 
kidney. Lane 8: pancreas. Lane 9: spleen. Lane 10: thymus. Lane 11: 
prostate. Lane 12: testis. Lane 13: ovary. Lane 14: small intestine 
without mucosal lining. Lane 15: colon. Lane 16: peripheral blood 
leukocyte. 
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
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3.3.2 Expression level of T2L522 in hepatocellular carcinoma and its 
surrounding normal counterpart 
As T2L522 was isolated from the subtracted-HCC library, it was 
suspected to be overexpressed in HCC. RT-PCR was carried out to 
determine the expression level of T2L522 in HCC and it surrounding 
normal counterpart. For RT-PCR, gene specific primers were designed to 
perform the PCR. Three pairs of HCC and surrounding normal 
counterpart tissue cDNA were prepared from the paired tissue samples of 
HCC patients. These cDNA templates were normalized by 
ubiquinol-cytochrome c reductase core protein II. For patient B, it 
showed more than 8-fold up-regulation in HCC (Figure 14). For patient C, 
it showed more than 2-fold of up-regulation in HCC (Figure 15). For 
patient D, it also showed more than 5-fold of up-regulation in HCC 
(Figur 16). As T2L522 showed higher expression level in HCC in all of 
the three samples, it was believed that T2L522 is up-regulated in HCC. 
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Figure 14. Expression level of T2L522 in hepatocellular carcinoma 
and its surrounding normal counterpart of patient B. Lane 1 & 2: IX 
template of normal counterpart. Lane 3 & 4: 0.5X template of normal 
counterpart. Lane 5 & 6: O.IX template of normal counterpart. Lane 7 & 
8: IX template of tumor tissue. Lane 9 & 10: 0.5X template of tumor 
tissue. Lane 11 & 12: O.IX template of tumor tissue. Lane N & T: O.IX 
template of normal or tumor tissues normalized by ubiquinol-cytochrome 
c reductase core protein II 
1 2 3 4 5 6 N 




Figure 15. Expression level of T2L522 in hepatocellular carcinoma 
and its surrounding normal counterpart of patient C. Lane 1 & 2: IX 
template of normal counterpart. Lane 3 & 4: 0.5X template of normal 
counterpart. Lane 5 & 6: O.IX template of normal counterpart. Lane 7 & 
8: IX template of tumour tissue. Lane 9 & 10: 0.5X template of tumour 
tissue. Lane 11 & 12: O.IX template of tumour tissue. Lane N & T: O.IX 
template of normal or tumor tissues normalized by ubiquinol-cytochrome 
c reductase core protein II 
1 2 3 4 5 6 N 
n^m B 
7 8 9 10 11 12 T g 
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Figure 16. Expression level of T2L522 in hepatocellular carcinoma 
and its surrounding normal counterpart of patient D. Lane 1 & 2: IX 
template of normal counterpart. Lane 3 & 4: 0.5X template of normal 
counterpart. Lane 5 & 6: O.IX template of normal counterpart. Lane 7 & 
8: IX template of tumour tissue. Lane 9 & 10: 0.5X template of tumour 
tissue. Lane 11 & 12: O.IX template of tumour tissue. Lane N & T: O.IX 
template of normal or tumor tissues normalized by ubiquinol-cytochrome 
c reductase core protein II 
1 2 3 4 5 6 N 
w^m B 
7 8 9 10 11 12 T 
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3.3.3 Identification of interacting partner of T2L522 using yeast 
two-hybrid assay 
The yeast two-hybrid assay was used to identify the interacting protein 
partners of T2L522 protein in vivo. In the assay, at least 5x10^ cDNA 
clones from pretransformed liver library were screened. With T2L522 as 
the "bait", 5 positive clones were picked and sequenced from the first 
round of screening (Table 5). Small-scale confirmation of interacting 
partner will be done to eliminate the false positive clones. 
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Table 5. Potential interacting partner of T2L522 from the first round 
of yeast two-hybrid screening. 
Accession No. Description Frequency 
BC006541 integrin, beta 5 2 
NM—001622 alpha-2-HS-glycoprotein (AHSG) 1 
XM_003195 kininogen (KNG) 1 
XM—035419 transthyretin (prealbumin, amyloidosis type I) 1 
86 
Results 
3.3.4 Subcellular localization of GFP tagged T2L522 
To obtain more insight into the possible function of T2L522, subcellular 
localization of T2L522 was determined by using the green fluorescence 
protein tagged T2L522. 
The HepG2 cells with transient transfection with pEGFP-T2L522 or 
pEGFP were examined after fixing. Green fluorescence signals were 
detected for both pEGFP-T2L522 and pEGFP transfected cells. T2L522 
was localized all around the cells and with a higher expression in 
cytoplasm (Figure 171). For the control cells with pEGFP only, the green 
fluorescence signal was diffused through out the cells (Figure 17II). 
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Figure 17. Subcellular localization of GFP and T2L522 in HepG2 cells. 
I: control GFP, green fluorescent signal. II: GFP-T2L522, green 
fluorescent signal. 








4.1 EST analysis on subtracted-HCC cDNA library 
Suppression subtractive hybridization is a technique that can compare two 
populations of mRNA and isolate the clones that are differentially expressed. This 
technique was employed to study the gene differentially expressed in HBV-induced 
HCC in our laboratory. The SSH selection step increases the number of 
differentially expressed genes by eliminating the multiple "housekeeping" genes. It 
is less time-consuming and cost-effective when compared with the EST analysis on 
traditional non-subtracted library. 
From the sequencing results on subtracted-HCC cDNA library, the composition of 
the subtracted-HCC library is very different from the HCC cDNA library and its 
surrounding normal counterpart cDNA library (Table 6). It may due to the 
elimination of the "housekeeping" genes and the normalization of differentially 
expressed genes during the subtraction hybridization. 
The differentially expressed secretory protein decreased in the subtracted-HCC 
cDNA library. It may be due to the fact that cellular functions including the 
synthesis of secretory protein of the hepatocytes are lost during 
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hepatocarcinogenesis. The genes that are involved in the category of other 
metabolism appeared with the highest frequency. They are involved in the major 
function of liver for the detoxification and excretion of end-products of metabolism. 
Elevated expression of genes that are involved in other metabolism in HCC reflected 
the fact that the actively dividing cancer cells have a high metabolic rate and is 
involved in complicated metabolic pathways. The genes involved in energy 
metabolism are also overexpressed because much more energy was spent by the 
active cancer cells to fulfill their high metabolic rate for their survival. As the cancer 
cells can divide indefinitely, large amount of proteins were synthesized during 
hepatocarcinogenesis. The genes involved in transcription and translation are 
increased because they have to synthesize a large amount of various proteins to 
support their cells division and complex metabolic pathways. The genes involved in 
extracellular matrix play an important role in cell differentiation, proliferation and 
cell-cell interaction. Overexpression of these genes can fulfill the requirement of the 
active cancer cells during HCC development. 
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Table 6. Functional categorization of EST sequenced from cDNA libraries. 
Subtracted-normal cDNA library (Rs)，subtracted-HCC cDNA library (Ts), human 
surrounding normal counterpart cDNA library (R) and human HCC cDNA library. 
Category Rs Ts R T 
Cytoskeletal related 0.0% 0.4% 1.5% 2.0% 
Energy metabolism 0.6% 2.7% 4.3% 6.9% 
Extracellular matrix 0.8% 7.2% 0.8% 1.1% 
Hormone and hormonal control 0.6% 0.2% 1.1% 0.5% 
Membrane associated 0.6% 1.4% 3.4% 2.8% 
Miscellaneous 39.4% 32.8% 8.4% 10.2% 
Other metabolism 30.7% 32.9% 14.6% 22.5% 
Secretory protein 9.2% 4.1% 44.2% 17.1% 
Signal transduction/ cell cycle regulation 13.4% 7.1% 4.1% 6.5% 
Transcription and translation 4.7% 11.2% 17.7% 30.4% 
Total 100.0% 100.0% 100.0% 100.0% 
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4.2 cDNA Microarray Analysis 
cDNA microarray allows parallel assessment of gene expression for hundreds or 
thousands of genes in a single experiment. It is a high throughput screening method 
that can overcome the tedious and ineffective screening by carrying out Northern 
blot analysis and the semi-quantitative RT-PCR. cDNA microchip with EST clones 
from the subtracted-normal, subtracted-HCC, human surrounding normal 
counterpart and human HCC cDNA libraries was constructed for high throughput 
screening of differentially expressed genes in HCC. 
4.2.1 Generation of reliable data using cDNA microarray 
For cDNA microarray analysis, the data reliability from the experiments are 
dependent on the reproducibility of signals and normalized ratios between replicates, 
the accuracy of respective signal intensities that representing the message abundance, 
the achievement of the best detection limit and, the accuracy and precision of 
methods for analyzing, evaluating and managing gene expression data. 
4.2.1.1 Reproducibility of signals and normalized ratio 
The reproducibility of signals and normalized ratios between replicates is affected 
by the uniformity of slide coating and target deposition, uniformity and specificity 
of hybridization, uniformity of detection over the slide and, the accuracy of spot 
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identification and quantitation. 
In our pilot study, DMSO optimized vapor phase amino silane coating slide was 
used to improve the surface uniformity. The uniformly coated slide is a low 
fluorescence background glass that can maintain uniform spot size, spot morphology 
and target DNA retention and, reduce the spot-to-spot variation. 
To maintain uniform target retention and improve the spot size and morphology, 
purification of targets is essential to remove the unused primers, unincorporated 
dNTP and the detergents in the PCR buffer. The recommended target concentration 
is 400fmol/|il. The range from 100fmol/|al to 1600fmol/|il is also acceptable while 
maintaining a linear response with the probes. In our slides, the target concentration 
is from 200fmol/|al to 800fmol/|Lil. From the hybridization results, we found that 
some of the IX spots gave higher signal intensity than the 2X one. In general, the 
signal intensity is determined by the amount of DNA spotted, the amount retained 
and the efficiency of hybridization. In our case, we assumed that the percentage of 
retention and the efficiency of hybridization are the same for each spot, the lower 
signal intensity for 2X target may be due to the high target concentration that 
inhibited the hybridization. 
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To produce the uniformly deposited slides, the Generation III Arrayer (Gen III 
Arrayer) was used for our slide printing. The twelve capillary pens used in the Gen 
III Arrayer were matched to ensure reproducible performance between pens. 
Therefore, the variation between pens or spots should be very low. The pens can also 
minimize sample waste, only 200nl of target was sucked by the pen to spot 36 slides 
with duplication. Then, the target variations produced during amplification and 
purification can be minimized because each stock target plate can used to spot more 
than 1,500 slides. 
To improve the uniformity and specificity of hybridization, the background signal 
should be kept in the lowest level. The non-specific background signals are mainly 
derived from the non-specific binding of probe and the free Cy dCTR In our 
experiments, the Cy dye-labelled probes were purified by the AutoSeq™G-50. 
AutoSeq™G-50 is a Sephadex column that can remove the unincorporated 
nucleotides and short products from the labeling reaction to reduce the background. 
To minimize the non-specific binding of labeled cDNA to the slide that deplete the 
probe and produce high background, poly A RNA and Cotl human DNA were added 
in our probe mixture for hybridization. The polyA RNA was used to prevent the 
polyT tail on the cDNAs interacting non-specifically with A-rich regions on the 




To maintain the uniformity of detection over the slide, the scanner must be 
consistent over the whole scanned area in both x and y directions, it must not vary 
for the two channels (Cy3 and Cy5) and must not drift over time or vary from one 
scan to the next. ScanArray® 4000 Microarray Analysis System was used to scan 
our slide for producing the reliable images. 
To improve the accuracy of spot identification and quantitation, Dapple (a program 
provided by the University of Washington) was used for spot finding. Dapple's spot 
finder takes advantage of consistent spot circularity to increase its robustness to both 
image noise and variability in spot position and size. Dapple finds spots by detecting 
their edge and intensity. Then spots with different sizes are circled. This method can 
eliminate the artifacts that with heterogeneous brightness, shape and size. Besides, 
this program can also be trained by the user during the spot finding process. After 
training, the spot finder can reprocess parts of the image on that the spot finder has 
likely erred. Therefore, the spots can be found in a faster way under the requirement 
provided by the user. 
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4.2.2 Comparison of data between multiple slides 
In my research project, the genes differentially expressed in HCC and its 
surrounding normal counterpart from different HCC patients were studied. How can 
we compare the data from the same patient across experiments and different patient 
across experiment? Lucidea Microarray ScoreCard control plate provides a set of 
data that can used to assess the data quality and compare the data from multiple 
slides. It provides some guideline for accepting or rejecting slides from the 
experiments. 
4.2.2.1 Assession of data quality and statistical significance 
The reproducibility of signals within a channel was determined by the signal level 
and the %CV in the Actin Gene Performance table. Smaller %CV indicates more 
reproducible actin signal across the slide, and high uniformity of background and 
hybridization. However, the actin gene was found to be differentially expressed in 
HCC, the other housekeeping genes were used to determine the reproducibility of 
the signal levels across slides in our experiments. 
The system sensitivity and verify the non-specific binding can be assessed by the 
information in the Detection Limits table. The detection limit signal data indicated 
the sensitivity if the array system and the quality of the hybridization. The lower the 
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signal detected, the greater the sensitivity. And the higher the signal detected, the 
lower the specificity of hybridization. 
The accuracy and precision of the ratios was determined by the data from the Ratio 
Analysis table and the Ratio Precision table. The average standard deviation of the 
normalized log ratio (Mean NLR SD) in the Ratio Precision table was acceptable if 
the value is less than the default threshold value i.e. 0.150. The values of the 
normalized ratio and dynamic range controls in the Ratio Analysis table was 
acceptable if the normalized log ratios were not more than 1.5-fold compare to the 
target values. 
4.2.2.2 Interpretation of gene expression data from single and multiple 
hybridizations 
The output data from the Lucidea Microarray ScoreCard was used to obtain gene 
expression ratios and combine data across multiple hybridizations. 
The spot NLR value in the normalized data file showed the log in the base 10 of the 
Normalized Cy3 signal to Cy5 signal ratio. The gene expression ratio of each spot 
was calculated by taking the antilog of Spot NLR by raising 10 to the power of 
(Spot NLR). It represents the ratio of the amount of message in the Cy3-labelled 
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mRNA to the amount of message in the Cy5-labelled mRNA. To combine the data 
from multiple spots within a slide, the average normalized log ratio (NLR) for each 
spot was calculated by raising 10 to the power of the average NLR. To combine the 
data from multiple replicate slides, the NLR values for all the replicate spots of each 
gene were averaged before transforming the values from NLRs to gene expression 
ratios. In our dye-reversal replicate hybridizations, the sign of the NLR values were 
reversed before calculating the average NLR values. Then, the NLR values were 
transformed to the gene expression ratios as described previously to verify 
expression pattern of the genes in HCC. 
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4.3 Candidate genes differentially expressed in HCC and its 
surrounding normal counterpart 
By using the above information provided by the Lucidea ScoreCard, 4 slides from 
each patient were compared. The genes with expression ratio greater than 2 or 
smaller than 0.5 in at least two out of the three tissue pair samples were defined as 
up-regulated or down-regulated. Finally, 7 genes showed up-regulation in HCC and 
22 genes showed down-regulation in HCC were defined (Table 4). And the genes 
differentially expressed in each patient were also shown in the Appendix. 
4.3.1 Protein up-regulated in HCC 
The genes showed up-regulation in HCC could be divided into four categories. They 
are extracellular matrix, other metabolism, transcription and translation, and novel 
protein. All the up-regulated proteins found from the microarray analysis are 
dominant in the subtracted-HCC library (Table 4). This mean they showed 
up-regulation in both EST and microarray analysis. 
4.3.1.1 Extracellular matrix protein 
Osteopontin (OPN) is a secreted adhesive glycosylated phosphoprotein. It is 
believed that OPN provides an adhesive matrix that can facilitate the interaction of 
cell surface receptors between tumor cells and tumor stroma. It is suitable for the 
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tumor survival and invasion (Wu et al, 2000). Previous studies showed that OPN 
could induce the migration of mammary carcinoma cells (Tuck et al, 1999) and was 
up-regulated in HCC (Okabe et al, 2001). 
4.3.1.2 Protein involved in other metabolism 
Stearoyl-CoA desaturase (SCD) is an iron-containing enzyme that catalyzes the 
synthesis of unsaturated fatty acids. The main product of SCD is oleic acid that is 
formed by desaturation of stearic acid. The stearic acid and oleic acid ratio is 
involved in the regulation of cell growth and differentiation by affecting the 
cell-membrane fluidity and signal transduction (Zhang et al., 1999). Previous 
reports found that increased SCD mRNA levels were related with tumors derived 
from oesophagus, colon and HCC (Li et al, 1994; Okabe et al., 2001). 
4.3.1.3 Protein involved in transcription and translation 
H3 histone is a hepatocytes proliferation marker. It plays a central role in 
nucleosome formation and expresses during the S-phase of the cell cycle. H3 histone 
mRNA-expressing hepatocytes were identified on in situ hybridization in patients 
with acute or chronic active hepatitis and active cirrhosis, but not inactive cirrhosis 
(Vemuru et al” 1992). Therefore, the up-regulation of H3 histone may be due to the 
chronic active hepatitis. 
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Ribosomal protein S18 encodes a ribosomal protein that is a component of the 40S 
subunit. The protein belongs to the S13P family of ribosomal proteins, which 
involved in the binding of fmet-trna and hence in the initiation of translation. It is 
not surprised that the gene involved in the initiation of translation is overexpressed 
in actively divided cancer cells. 
4.3.2 Protein down-regulated in HCC 
The genes showed down-regulation in HCC could be divided into five catergories. 
They are membrane associated protein, miscellaneous proteins, proteins involved in 
other metabolism, secretory proteins and novel proteins. The down-regulated 
proteins found from the microarray analysis are dominant in the normal liver library 
or the subtracted-normal library (Table 6), except the apolipoprotein CI, 
alpha-2-HS-glycoprotein and one EST are come from the subtracted-HCC library. 
These mean the results from the microarray hybridization are complementary to the 
EST analysis. 
4.3.2.1 Membrane associated protein 
Solute carrier family 22 (organic cation transporter), member 1 (SLC22A1) is a 
high-affinity glucose transporter, which is indispensable for growth on low 
glucose-containing media. The data from Stanford Human Genome Center showed 
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that the normalized expression level of SLC22A1 in non-cancerous liver tissue 
(28.04%) is a bit higher than the hepatocellular carcinoma (27.41%). 
4.3.2.2 Protein involved in other metabolism 
Aldolase B, fructose bisphosphate is an enzyme catalyses the specific and reversible 
cleavage of fructose-1,6-bisphosphate (FBP) and fructose-1 -phosphate (FIP) into 
dihydroxyacetone phosphate and glyceraldehydes-3 -phosphate or glyceraldehyde 
respectively. In adult, aldolase B is produced in liver. Many reports also show aldose 
B, fructose bisphosphate is down-regulated in HCC (Kim et aL, 2001; Lau et al, 
2000; Okabe et al, 2001; Xu et al., 2001b). It may be due to dysfunction of the liver 
in producing this enzyme. 
Cytochrome P450，subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8 
(CYP2C8), cytochrome P450, subfamily HE (ethanol-inducible) (CYP2E) and 
cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3 (CYP3A3) 
are genes that encodes members of cytochrome P450 superfamily of enzymes. The 
cytochrome P450 proteins are heme-thiolate monooxygenases that catalyze many 
reactions such as drug metabolism and synthesis of cholesterol, steroids and other 
lipids. Many reports showed these three cytochrome P450 subfamily are 
down-regulated in HCC (Lau et al, 2000; Okabe et al., 2001; Xu et al.’ 2001a; Xu L. 
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et al., 2001b). 
CYP2C8 involves in the NADPH-dependent electron transport pathway. It can also 
oxidize the steroids, fatty acids and xenobiotics. The data from Stanford Human 
Genome Center showed that the normalized expression level of CYPC8 in 
hepatocellular carcinoma (45.48%) is a bit lower than its corresponding 
non-cancerous liver tissue (44.49%). 
CYP2E metabolizes both endogenous substrates, such as ethanol, acetone, and 
acetal, and exogenous substrates such as benzene, carbon tetrachloride, ethylene 
glycol, and nitrosamines. As this enzyme can metabolize so many substrates, it is 
believed to be involved in various processes such as gluconeogenesis，hepatic 
cirrhosis, diabetes, and cancer. The expression level of CYP2E in hepatocellular 
carcinoma (19.61%) is much lower than its corresponding non-cancerous liver tissue 
(49.48%). 
CYP3A3 is believed to be a transcript variant of CTP3A4 that is involved in the 
metabolism of approximately half the drugs using today. It can also metabolize some 
steroids and carcinogens. 
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Hydroxysteroid (11-beta) dehydrogenase (HSDllB) is an enzyme expressed 
predominantly in liver. It is active in reductase and dehydrogenase activities (Kong 
et al., 2002). Previous studies also showed that HSDllB involved in xenobiotic 
metabolism. It is an important detoxification mechanism that protects the organisms 
from damage by the accumulation of toxic carbonyl compounds (Maser et al., 1997). 
As detoxification is one of the major functions of liver, it is not surprising that the 
expression level of HSDllB was decreased in HCC. 
4.3.2.3 Secretory protein 
The secretory proteins are down-regulated in HCC. According to Table 9, the 
proportion of secretory proteins dropped from 44.2% in normal liver to 17.1% in 
HCC. The down-regulation of secretory protein shows that during the development 
of hepatocarcinoma, the hepatocytes already lost many of their cellular functions 
such as the synthesis of secretory proteins. 
Albumin (ALB) is a soluble, monomelic protein, which comprises about one-half of 
the blood serum protein. Albumin acts as a carrier protein for steroids, fatty acids, 
and thyroid hormones and plays a role in stabilizing extracellular fluid volume. The 
severe liver damage such as the severe hepatitis and cirrhosis will lead to the 
increase in the level of serum albumin. It is a surrogate marker for screening liver 
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disease and pervious reports showed that albumin is down-regulated in HCC (Kim 
et al, 2001; Okabe et aL, 2001; Xu et al.’ 2001a). 
Alpha-1 -microglobulin/bikunin precursor (AMBP) expressed exclusively in the liver 
(Tyagi et al., 2002). Its expression is strictly controlled by a potent and liver specific 
enhancer, which is controlled by several hepatocyte-enriched nuclear factors. 
However, the regulatory mechanisms of the intracellular levels of the AMBP protein 
are still not clear. 
Alpha-2-HS-glycoprotein (AHSG) is a plasma glycoprotein, which is synthesized by 
the hepatocytes. Pervious report also showed that the serum AHSG level was 
decreased in patients with liver cirrhosis and hepatocellular cancer (Kalabay et al., 
2002). 
Alpha-2-macroglobulin (A2M) is an acute phase proteins that is produced by 
hepatocytes and stellate cells at the site of inflammation and liver fibrosis. The 
increased synthesis of A2M inhibits the catabolism of matrix proteins and enhances 
fibrotic processes. It is one of the surrogate markers for fibrosis. The HCC with liver 
fibrosis would increase the serum A2M level (Poynard et al., 2002). In our 
experiments, the expression levels of A2M in HCC samples are decreased. It may 
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due to the heterogeneity of HCC or there were no fibrosis in our samples. And our 
result is supported by another research group that also found A2M down-regulated 
A2M in HCC (Xu et al, 2001a). 
Apolipoprotein Al plays a role in production of HDL particles and functions in 
reverse cholesterol transport (Gratl et al., 2002). Apolipoprotein CI is a minor 
component of chylomicrons, VLDL, IDL, and HDL, which plays a role in the 
binding of chylomicrons and VLDL to the LDL receptor and to the LDL 
receptor-related protein (LRP). It can also block the uptake of lipoproteins by the 
liver (Ginsberg et al, 1998). Apolipoprotein Al was found to be down-regulated in 
HCC ( K i m e t a l . i m ) . 
Apolipoprotein CIII is a major component of VLDL and present on chylomicrons, 
IDL, and HDL. It inhibits both LPL action and hepatic uptake of chylomicron and 
VLDL remnants. The absence of apolipoprotein CIII would alter the triglyceride 
catabolism (Gotto et al, 1986). Report showed that it is down-regulated in HCC (Xu 
et fl/., 2001a) 
Fibrinogen, A alpha polypeptide and fibrinogen, B beta polypeptide encode the 
alpha and beta component of fibrinogen respectively. During vascular injury, 
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fibrinogen is cleaved by thrombin to form fibrin which is the major component of 
blood clots and various cleavage products of fibrinogen and fibrin are involved in 
the regulation of cell adhesion. From the SOURCE database, fibrinogen, A alpha 
polypeptide and fibrinogen, B beta polypeptide showed a higher normalized 
expression level in non-cancerous liver tissue (9.56% and 18.04%) than 
hepatocellular carcinoma (2.76% and 9.12%) respectively. 
Retinol-binding protein 4 (RBP4) is a specific carrier of retinal in the blood. It 
delivers retinol from the liver stores to the peripheral tissues. From the SOURCE 
database, RBP4 showed much higher normalized expression level in non-cancerous 
liver tissue (30.52%) than hepatocellular carcinoma (19.07%). 
Transthyretin (prealbumin) plays a role in the transport of both thyroid hormone and 
retinal in the circulation. Synthesis of prealbumin is primarily in the liver (Blaner et 
a l , 1991). The prealbumin expression level was also shown to be down-regulated by 
other research groups (Kim et al, 2001; Xu et al., 2001a). 
4.3.3 Novel proteins differentially expressed in HCC 
There are four novel proteins that were found to be differentially expressed in HCC. 
Their functions in the cells are unknown. As these novel proteins are differentially 
expressed in HCC, they may participate in the progress of hepatocarcinogenesis. 
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4.4 TBCl domain containing protein, T2L522 
During the random sequencing analysis of the subtracted-HCC library, a novel 
cDNA encoding a TBCl domain containing protein was identified. The complete 
coding sequence of the gene was cloned. The TBCl domain containing gene is 
2,814 base pairs in length which encoding a protein with 937 amino acids. The 
TBCl domain was found in the region of the 566出 to 785出 amino acid and a 
phosphotyrosine-binding domain was found in a region of the 50出 to 127出 amino 
acid. The predicted pi value of human T2L522 protein is 6.13 and its molecular 
weight is lOV.OkDa. 
Member 1 of the TBC (tre-2/USP6, BUB2，cdcl6) domain family is a cDNA that 
contains a domain that is homologous to the regions of human Tre-2 oncogene 
(named as USP6 now) (Huebner et al, 1988; Onno et al, 1992 & 1993) and the 
yeast mitotic regulatory protein BUB2 (Hoyt et al., 1988) and cdcl6 (Chang et al., 
1993; Fankhauser et al., 1993). Based on the role of BUB2 and cdcl6 as mitosis 
regulators, TBCl may play a role in altering the cell cycle coordinately with the 
differentiation program (Richardson et al” 1995). 
Phosphotyrosine-binding (PTB) domains are structurally conserved modules 
important for protein-protein interaction. It was discovered as an alternative to the 
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src homology 2 (SH2) domain for phosphotyrosine recognition. It can also be found 
in proteins involved in numerous biological processes including signaling through 
cell-surface receptor and protein trafficking. 
As T2L522 is only present in the subtracted-HCC library and is absent in the 
subtracted-normal, the HCC cDNA and the surrounding normal liver counterpart 
cDNA libraries; T2L522 is believed as a rare transcript up-regulated in HCC, which 
was amplified during the suppression subtractive hybridization. It contains the 
TBCl and PTB domains, which are involved in the differentiation and regulation of 
cell growth, and the signaling pathway respectively. Therefore, we believe that 
T2L522 may play a role in hepatocarcinogenesis and further characterization was 
carried out to obtain more information about this novel gene. 
4.4.1 Possible involvement of T2L522 gene in HCC 
As T2L522 was isolated from the subtracted-HCC library that genes are 
overexpressed in HCC and it contains a domain that showed homology with region 
of human Tre-2 oncogene, the possible involvement of T2L522 gene in HCC was 
determined by RT-PCR. From the results, all of the three HCC/surrounding normal 
counterpart cDNA pairs showed a higher T2L522 expression in HCC. Therefore, 
T2L522 is believed to play a role in the progress of hepatocarcinogenesis. 
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4.4.2 Tissue distribution and expression pattern of T2L522 
From the results of Northern hybridization and RT-PCR on various human tissues, 
the expression patterns of T2L522 were showed. T2L522 is expressed in most of the 
tissues in a very low level. Sharp bands and relatively high signals could be detected 
in kidney and placenta only in the Northern hybridization. And relative high signal 
also detected in testis in the RT-PCR. The expression pattern is similar to the TBCl 
gene that is expressed in highest levels in hematopoietic cells, such as testis and 
kidney (Richardson et al, 1995). Moderate signals were showed in lung, liver, 
skeletal muscle, pancreas, spleen, thymus, ovary and leukocyte, peripheral blood. 
Low signals were observed in heart, whole brain, prostate and small intestine 
without mucosal lining. Our results showed that T2L522 is not a tissue specific 
protein. The smear in various tissues in the Northern blot could be due to RNA 
degradation or it might be a possibility of alternative splice forms of T2L522. It may 
be the reason why kidney and placenta showed relatively high expression level of 
T2L522 but no cancer occur in these organs while T2L522 is believed to play a role 
in carcinogenesis. 
4.4.3 Potential interacting partners of T2L522 
From the first round of yeast two-hybrid screening, 4 proteins were shown to be the 
potential interacting partners of T2L522 (Table 5). We found that some of the 
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partners have similar functions with the TBCl domain that they are involved in the 
cell differentiation, proliferation and even cancer related. 
As mentioned before, alpha-2-HS-glycoprotein (AHSG) is a plasma glycoprotein, 
which is synthesized by the hepatocytes. AHSG is a major protein in blood and brain 
during mammalian development (Brown et al., 1992). It suggested that AHSG might 
involve in the development-association functions (Banine et al., 2000). Pervious 
report also showed that the serum AHSG level was decreased in patients with liver 
cirrhosis and hepatocellular cancinoma (Kalabay et al, 2002). 
Integrin, beta 5 is a transmembrane protein that has been involved in regulation of 
cell proliferation and differentiation (Reinartz et al., 1995). The alterations of 
integrin levels on the cellular surface occur as an essential regulatory process during 
development, differentiation, proliferation, apoptosis and cell migration (Yin et al.’ 
1999). 
The two-chain high molecular weight kininogen is a novel inhibitor of angiogenesis 
(Zhang et aL, 2000). The data in SOURCE showed that the expression level of 
kininogen (KNG) is higher in surrounding normal tissue than HCC. As we know 
that the growth of mmor is angiogenesis dependent (Folkman et al., 1995), 
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kininogen may delay the growth of tumor. 
4.4.4 Subcellular localization of T2L522 
The results of subcellular localization of T2L522 by using the green fluorescent 
protein tagging showed that T2L522 is expressed over the whole cell with a higher 
expression in cytoplasm than nucleus. Thus no specific localization was found. 
It is surprising that T2L522 is a cytoplasmic protein because previous report showed 
that the TBCl domain containing protein is a nucleus protein (Richardson et al, 
1995) and as we believe that T2L522 is involved in differentiation and regulation of 
cell growth, T2L522 would more likely be a nucleus protein. However, we have 
only studied one cell type and that the post-translation modification may affect the 
subcellular localization at this stage. Therefore, the subcellular localization of 
T2L522 should be confirmed by using different cell types under different conditions 




Hepatocarcinogenesis is a complex and heterogeneous process that is very difficult 
to use a single marker for effective diagnosis. Moreover, the available markers are 
not specific and sensitive enough for diagnosis. A combination of several markers 
and novel markers may enhance the specificity and sensitivity of the HCC diagnosis. 
In our laboratory, the EST sequences from the subtracted-normal, subtracted tumor, 
human normal counterpart and human HCC cDNA libraries can provide the 
information about the whole set of genes in hepatocarcinogenesis. As a number of 
candidate genes immobilized in our microchip are involved in cancer development 
and some of them are novel genes that with unknown function. This information can 
facilitate the studies to explore the principle of hepatocarcinogenesis and discovery 
of a set of novel diagnostic markers by using the tissue samples of HCC at different 
stages. The application of cDNA microarray can speed up the studies of 
carcinogenesis in our laboratory and large batch of data can be generated in a short 
period of time. On the other hand, further studies on the candidate genes especially 
the novel genes may be helpful to explore the carcinogenesis mechanism and the 




Gene list of microchip Hs8Rn5. Presented are genes from subtracted-HCC library, 
subtracted-normal library, EST libraries and Lucidea Microarray ScoreCard control 
plate, which were printed on the slide. The position on the slide, the accession 
number and the gene identity were shown in the list. The first number of the element 
represented the array row. "*" represented the array row 1 to 12. "_" represented the 
array column 1 and 2. “#,, represented the row 2 and 7. "^"represented the row 3 and 
6. The fouth number represented the column number. 
Element Accession number Gene identity 
ZZ999777 Positive control 1，Total human DNA/complex target 
*，_’ 1,2 ZZ999777 Negative control 1 ’ Arabidopsis thalianaputative transmembrane protein G1 p 
*’_，1,3 ZZ999777 Dynamic range 1, relative abundance 3.3%, Yeast intergenic region from chrom XI 
*，_> 1，4 7x999111 Dynamic range 2, relative abundance 1 %, Yeast intergenic region from chrom XIV 
*’_，1’5 ZZ999777 Dynamic range 3，relative abundance 0.1%, Yeast intergenic region from chrom VII 
*’一’ 1,6 ZZ999777 Dynamic range 4’ relative abundance 0.033%, Yeast intergenic region from chrom VII 
*’J1 ’7 ZZ999777 Dynamic range 5，relative abundance 0.01 %, Yeast intergenic region from chrom XII 
*，_J，8 ZZ999777 Dynamic range 6, relative abundance 0.0033%, Yeast intergenic region from chrom XII 
*’_, 1,9 ZZ999777 PC Ratio control 1:3, Yeast intergenic region from chrom XII 
一 ’ 1 ’ 10 ZZ999777 PC Ratio control 3:1, Yeast intergenic region from chrom XII 
1,11 ZZ999777 PC Ratio control 1:10，Yeast intergenic region from chrom XII 
12 ZZ999777 PC Ratio control 10:1, Yeast intergenic region from chrom XIII 
13 ZZ999777 Negative control 2’ PolydAoligonucleotide 
*>_,!,14 Hs. 14376 Housekeeping gene 1, actin gamma-1 
*’_’ 1 ’ 15 Hs. 169476 Housekeeping gene 2’ glyceraldehyde-3-phosphate dehydrogenase 
*,_’1，16 Hs. 173554 Housekeeping 3, ubiquinol-cytochrome c reductase core protein II 
17 Hs. 165843 Housekeeping gene 4’ Casein kinase II beta polypeptide 
18 ZZ999777 Reseved for future use 1 
19 ZZ999777 Reseved for future use 2 
*，_, 1，20 ZZ999777 Reseved for future use 3 
*,_,!,21 ZZ999777 Reseved for future use 4 
22 Hs. 173684 Housekeeping gene 5’ Est highly similar to NY-REN-37 antigen 
23 ZZ999777 Negative control 3’ 50%DMSO 
*’_’1，24 Hs.831 Housekeeping gene 6,human hydroxymethyl glutaryl-CoA lyase 
*，_’1，25 Hs.69855 Housekeeping gene 7, neuroblastoma RAS viral oncogene homolog 
*’_’1’26 Hs. 129673 Housekeeping gene 8’ eukaryotic translation initiation factor 4A, isoform 1 
*’jl，27 Hs. 173554 Housekeeping gene 9，ubiquinol-cytochrome c reductase core protein II 
* , j l ’ 2 8 Hs.76394 Housekeeping gene 10,enoyl Coenzyme A hydrotase, short chain 1 
*,_’1,29 Hs. 14376 Housekeeping gene 11, actin gamma-1 
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*,_,!,30 ZZ999777 Negative control 4，Bacillus subtilis diaminopimelate decarboxylase lysA 
*’_，1,31 ZZ999777 Negative control 5,Bacillus subtilis phenylalanine biosynthesis associated protein pheB 
*,_, 1,32 ZZ999777 Positive control 2, Total human DMA/complex target 
1 AK026747 cDNA; FLJ23094 fis, clone LNG07379 
!,_,#,2 NM_005141 fibrinogen, B beta polypeptide 
1 ,_,#,3 AL359650 EST from clone 251760 
1,_’#’4 NM_000963 prostaglandin-endoperoxide synthase 2 
1 ’_,#’5 NM_000670 alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4) 
1 ,_,#,6 NM_001074 UDP glycosyltransferase 2 family, polypeptide B7 (UGT2B7) 
!,_,#,7 NM_000607 orosomucoid 1 (ORMl) 
8 AA501226 cDNAFLJ 11059 fis, clone PLACE 1004 
9 AL080234 cDNADKFZp586L081 
!,_,#, 10 NM_003130 sorcin (SRI) 
1 ,_,#, 11 NM_018018 hypothetical protein FLJ10191 
12 API53821 alcohol dehydrogenase IB (class I), beta polypeptide 
1 ’_，#, 13 ZZ999777 Housekeeping gene control 21，Beta-actin 
14 NM_001101 Housekeeping gene control 22, actin, beta, clone MGC:5475 
1 ,_,#, 15 ZZ999777 Negative control 11 no template PCR 
16 ZZ999777 Negative control 11 no template PCR 
17 NM_002936 ribonuclease HI 
18 NM—005917 malate dehydrogenase 1, NAD (soluble) 
!,_,#, 19 BC001412 eukaryotic translation elongation factor 1 alpha 1 
1 ’_，#,20 XM_012088 ferritin, heavy polypeptide 1 (FTH1) 
1’_’#’21 NM_002047 glycyl-tRNA synthetase 
22 NM_031371 cDNADKFZp434P176 
1 ,_,#,23 XM_008062 ribosomal protein S15a (RPS15A) 
1 ,_,#,24 NM_020299 aldo-keto reductase family 1，member B10 (aldose reductase) 
1’—，#’25 NM_015918 hypothetical protein 
1 ,_,#,26 NM_001015 ribosomal protein S11 
NM_016127 HSPC035 protein 
1’_’#，28 NM_006149 lectin, galactoside-binding, soluble, 4 (galectin 4) 
!,_,#,29 XM一010550 ribosomal protein L7 (H. sapiens) (LOC65293) 
30 AL137800 clone RP1-127C7 on chromosome lq25.1-31.1 
1，_>#，3丨 NM_000483 apolipoprotein C-II 
32 BC007259 ribosomal protein L4 
1，_,A，丨 AB040955 KIAA1522 protein 
1，_广，2 NM_000277 phenylalanine hydroxylase 
1,_A3 NM_000988 ribosomal protein L27 
l，_/\4 AL109659 clone RP5-1024N4 on chromosome lp32.1-33 
1 ,_’A’5 XM_013095 thymosin, beta 4，X chromosome (TMSB4X) 
l ’_ / \6 NM_006294 ubiquinol-cytochrome c reductase binding protein 
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1，一’A，7 NM_001545 immature colon carcinoma transcript 1 
1 ’_’A’8 XM_006972 60S ribosomal protein LI 5 (EC45) 
l，_/\9 AF279903 ribosomal protein LI5 
l , _ A i o NM_000384 apolipoprotein B (including Ag(x) antigen) 
1,_A11 NM一018322 cDNA DKFZp434H012 
1,_A12 AV656241 cDNA clone IMAGE: 1752079 3' 
1�_/\13 ZZ999777 Housekeeping gene control 21, Beta-actin 
1，_A 14 7x999111 Housekeeping gene control 21, Beta-actin 
1 ’_’A, 15 ZZ999777 Negative control 11 no template PCR 
1，_，A’ 16 Z Z 9 9 9 7 7 7 Negative control 11 no template PCR 
1’_，A’17 NM—015965 CGI-39 protein; cell death-regulatory protein GRIM 19 
1 � �1 8 NM_007194 protein kinase Chk2 
1，_’A’19 NM_018487 hepatocellular carcinoma-associated antigen 112 
l�_/\20 NM_001562 interleukin 18 (interferon-gamma-inducing factor) 
1 1 NM_013448 bromodomain adjacent to zinc finger domain, 1A 
1,_A22 NM_000030 alanine-glyoxylate aminotransferase 
1 ’_，A，23 NM_00332 丨 Tu translation elongation factor, mitochondrial 
1’_,，24 NM_001028 ribosomal protein S25 
1,_ 广’ 25 NM_001713 betaine-homocysteine methyltransferase 
1，_A26 NM_017750 hypothetical protein FLJ20296 
1 ’_ , ,27 ZZ999999 hepatocellular carcinoma-associated gene TD26 (LOC55908) 
1,_A28 NM_000973 ribosomal protein L8 
1，_，A，29 NM_004708 programmed cell death 5 
1’_’A’30 NM_016332 selenoprotein X, 1 
1 ’_’A,31 ZZ999999 macrophage migration inhibitory factor (glycosylation-inhibiting factor) 
1 ’_A32 ZZ999999 v-fos FBJ murine osteosarcoma viral oncogene homolog (FOS) 
2’_A 1 NM_001769 CD9 antigen (p24) 
2’_，#，2 NC_001807 DC48 mRNA 
2’_,#，3 AK024386 glyoxylate reductase/hydroxypyruvate reductase 
2，_,#’4 NM_005514 major histocompatibility complex, class I’ B 
2’_，#,5 NM_001801 cysteine dioxygenase, type I 
2，—,#，6 NM_016509 C-type lectin-like receptor-2 
2，_，#，7 NM_014033 DKFZP586A0522 protein 
2，j#’8 XM_004357 glutathione S-transferase A2 (GSTA2) 
2，一，#’9 NM_017460 cytochrome P450, subfamily IlIA (niphedipine oxidase), polypeptide 4 
2’_,#’ 10 AK024941 cDNA: FLJ21288 fis, clone COLO 1927 
2,_’#, 11 NM_004894 chromosome 14 open reading frame 2 
2’_>#, 12 NM_004417 dual specificity phosphatase 1 
2’_>#，13 ZZ999777 Housekeeping gene control 21, Beta-actin 
2，_’#，14 ZZ999777 Housekeeping gene contro丨 23 
15 ZZ999777 Negative control 11, no template PCR 
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2,_,#, 16 ZZ999777 Negative control 11，no template PCR 
2,_,#,17 NM_004039 annexinA2 
2,_,#, 18 NM_003128 spectrin, beta, non-erythrocytic 1 
19 NM_020299 aldo-keto reductase family 1 ’ member B10 (aldose reductase) 
2,_,#,20 AL 136640 PABP-interacting protein 2 
2，_’#,21 NM_005563 leukemia-associated phosphoprotein p i 8 (stathmin) 
2,_,#,22 ALl 10202 cDNA DKFZp586I2022 
2,_，#’23 NM_001889 crystallin, zeta (quinone reductase) 
2’_’#’24 M26880 ubiquitin C 
2,一，#’25 NM_006420 brefeldin A-inhibited guanine nucleotide-exchange protein 2 
2’_’#，26 NM_022771 hypothetical protein FLJ12085 
2，_，#’27 AF007152 Homo s �i e n s clone 23649 and 23755 unknown mRNA, partial cds 
2,—,#，28 NM_004800 transmembrane 9 superfamily member 2 
2，_，#，29 NM_001304 carboxypeptidase D 
2’—,#’30 NM_000096 ceruloplasmin (ferroxidase) 
2’_，#’31 AP002078 chromosome 4q22-q24, clone:2126N15 
2’ j# ,32 NM_003605 0-linked N-acetylglucosamine (GlcNAc) transferase 
2’_’A，1 NM_004508 isopentenyl-diphosphate delta isomerase 
2’—’A,2 XM_003959 signal recognition particle 19kD (SRP19) 
2，_’A,3 NM_006 122 mannosidase, alpha, class 2A’ member 2 
2’_’A，4 AK025773 cDNA: FLJ22120 fis, clone HEP 18874 
2’_’A’5 XM_006215 Friend leukemia virus integration 1 (FLI1) 
2,_,A，6 NM_018060 hypothetical protein FLJ 10326 
2’_A7 NM_006899 isocitrate dehydrogenase 3 (NAD+) beta 
2’_’A’8 NM_005437 nuclear receptor coactivator 4 
2，_广’9 AL445928 clone RP11-305E17 on chromosome 1 
2，一,�10 NM—005426 tumor protein p53-binding protein, 2 
2’jA，i 1 XM_007411 chromosome 14 open reading frame 3 (C140RF3) 
2’_，A,12 AB007916 KIAA0447 gene product 
2，_’A，13 ZZ999777 Housekeeping gene control 21 ’ Beta-actin 
2’—广，14 ZZ999777 Housekeeping gene control 21，Beta-actin 
2’_’A’ 15 ZZ999777 Negative control 11 no template PCR 
2’一’A，16 ZZ999777 Negative control 11 no template PCR 
2 ,_A17 NM_004034 annexin A7 
2’_广，18 NM_003150 signal transducer and activator of transcription 3 (acute-phase response factor) 
2,_,A’19 AF257175 hepatocellular carcinoma-associated antigen 64 (HCA64) 
2，_,A，20 ZZ999999 profilin 1 (PFNl) 
2 ,_ / \21 NM_001185 alpha-2-glycoprotein 1，zinc 
2，_’A’22 M65066 protein kinase, cAMP-dependent, regulatory, type I’ beta 
2，_/V23 BF131637 metallothionein 2A 
2,_,A，24 AK025353 ribosomal protein SIO 
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2，_/,25 NM_002823 prothymosin, alpha (gene sequence 28) 
2，_A26 XM_004176 HLA-B associated transcript-3 (D6S52E) 
2，_A27 XM_011914 ribosomal protein S24 (RPS24) 
2,_’A’28 NM_001818 aldo-keto reductase family 1, member C4 
2，_,A,29 NM_006400 dynactin 2 (p50) 
2’_A30 NM一003627 prostate cancer overexpressed gene 1 
2，_A31 NM_002229 jun B proto-oncogene 
2，一’A,32 NM_001642 amyloid beta (A4) precursor-like protein 2 
3’_,#,1 NM_001798 cyclin-dependent kinase 2 
3，_,#,2 NM_005143 haptoglobin 
3，_，#’3 AL353804 anti-Entamoeba histolytica immunoglobulin kappa light chain (V-C region) 
3，_，#，4 AK024974 immunoglobulin kappa constant 
3，一，#’5 NM_001033 ribonucleotide reductase Ml polypeptide 
3’_’#,6 AF055029 Homo sapiens clone 24711 mRNA sequence 
3’一,#’7 NM_001076 UDP glycosyltransferase 2 family, polypeptide B15 
3,_’#，8 M17614 transferrin gene, exon 17 
3,_，#,9 NM_000064 complement component 3 
3’_’#’10 XM_006461 gIucose-6-phosphatase, transport (glucose-6-phosphate) protein 1 (G6PT1) 
3,_’#，11 NM_002080 glutamic-oxaloacetic transaminase 2, mitochondrial (aspartate aminotransferase 2) 
3，_,#，12 XM_005799 integrin, beta 1 
3’_’#’13 AF086735 microsomal NAD+-dependent retinol dehydrogenase 4 
3 4 NM_000456 sulfite oxidase 
3,_，#’ 15 NM_030878 cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8 
3,_，#，16 NM_018004 hypothetical protein FLJ10134 
3’_^#’17 NM_001358 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 15 
3’_’#’ 18 NM_005348 heat shock 90kD protein 1，alpha 
3,_’#’19 AK026295 cDNA: FLJ22642 fis, clone HSI06970 
3’_A20 NM_014495 angiopoietin-like 3 
3。#，21 NM_014585 solute carrier family 11 (proton-coupled divalent metal ion transporters), member 3 
3’_A22 D87445 KIAA0256 gene product 
3，_’#’23 NM_001498 glutamate-cysteine ligase, catalytic subunit 
3’_，#’24 XM_004177 
3,_,#,25 NM_016454 hypothetical protein 
3’_’#，26 NM_001122 adipose differentiation-related protein 
3’_’#，27 NM_001686 ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
3,一’#,28 NM_013230 CD24 antigen (small cell lung carcinoma cluster 4 antigen) 
3,_’#’29 AC007653 apolipoprotein M (G3A) 
3，_,#’30 AL 13 7294 hypothetical protein FLJ22351 
3，_，#，31 NM_014165 HSPC125 protein 
3’_>#，32 NM_007269 syntaxin binding protein 3 
3，_A1 NM_014366 putative nucleotide binding protein, estradiol-induced 
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AF239815 asparagine synthetase gene, promoter and exon 1 
3，_��3 NM_021173 polymerase (DNA-directed), delta 4 
3，_，A，4 NM_003600 serine/threonine kinase 15 
3 ’ _ �, 5 NM_002140 heterogeneous nuclear ribonucleoprotein K 
3，_��6 NM_006745 sterol-C4-methyl oxidase-like 
3,_广’7 NM_015339 activity-dependent neuroprotective protein 
3,—，A，8 NM_000313 protein S (alpha) 
3，_’A’9 AK000299 dynactin 4 (p62) 
3 , _ ’ V 0 NM_021139 UDP glycosyltransferase 2 family, polypeptide B4 
3，_广，11 NM_000715 complement component 4-binding protein, alpha 
3’_,A’ 12 AC007192 asparagine synthetase gene, promoter and exon 1 
3’_’A，13 AK026983 adaptor-related protein complex 3，mu 1 subunit 
3，_’A,14 AF052I59 clone 24416 mRNA sequence 
3’jA，15 NM_004236 thyroid receptor interacting protein 15 
3，_,A，16 XM_001656 deiodinase, iodothyronine, type I (DIOl) 
3’_’A，17 NM_001343 disabled (Drosophila) homolog 2 (mitogen-responsive phosphoprotein) 
3’_’A’ 18 NM_006472 upregulated by 1,25-dihydroxyvitamin D-3 
3’_，A，19 NM_005505 CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 1 
3，_，A，20 NM_000224 keratin 18 
3,_A,’21 NM一013258 apoptosis-associated speck-like protein containing a CARD 
3’_A’，22 ZZ999999 tumor susceptibility gene 101 (TSGlOl) 
3 ,_A23 NM_007242 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 19 (Dbp5, yeast, homolog) 
3，_，A，24 NM_000799 erythropoietin 
3’_A25 ZZ999999 cDNA: FLJ22666 fis, clone HSI08344 
3,_’A’26 XM_010011 suppression of tumorigenicity 13 (colon carcinoma) 
3’—，A,27 AK026164 myosin, light polypeptide 6’ alkali, smooth muscle and non-muscle 
3，_，A’28 NM—003295 tumor protein, translationally-controlled 1 
3,_广,29 ZZ999999 apolipoprotein A-I (APOAl) 
3’—’A,30 AFl 19897 cDNA: FLJ22881 fis, clone KAT03571 
3，_’A，31 NM_000918 procollagen-proline 
3’_A32 NM_000301 plasminogen 
NM_001937 dermatopontin 
4’_^#’2 NM_000596 insulin-like growth factor binding protein 1 
4,_,#,3 NM_000508 fibrinogen, A alpha polypeptide 
4’一，#，4 NM一005923 mitogen-activated protein kinase kinase kinase 5 
4，一’#,5 AF3347I0 pyruvate dehydrogenase kinase 4 
4，_’#，6 NM_000776 cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3 
4,_,#,7 NM_000893 kininogen 
4，_’#’8 NM_001964 early growth response 1 
4’_’#’9 XM一001654 chromosome 1 open reading frame 8 (C10RF8) 
4’_’#’ 10 NM_002166 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein 
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1 BG696410 ESTs, Weakly similar to T26686 hypothetical protein Y38F1A.6 [C.elegans] 
4,_，#’12 BC006342 glucose phosphate isomerase 
4，_，#，13 AK027187 ribosomal protein S6 
4，j#，14 NM_003217 testis enhanced gene transcript (BAX inhibitor 1) 
4’_>#’15 NM_000508 fibrinogen, A alpha polypeptide 
4，_’#’ 16 NM_000166 connexin 32, Charcot-Marie-Tooth neuropathy, X-linked 
4,_,#,17 AC023880 clone RP5-999D10 
4，_，#, 18 NM_003118 secreted protein, acidic, cysteine-rich (osteonectin) 
4’_，#,19 AJ249921 apolipoprotein C-I 
4，_，#，20 XM一006388 ribosomal protein S13 (RPS13) 
4,_，#，21 NM—004360 cadherin 1，type 1, E-cadherin (epithelial) 
4，_，#，22 NM_001436 fibrillarin 
4,_’#,23 NM_014624 SI00 calcium-binding protein A6 (calcyclin) 
4’_,#’24 AK026985 cDNA: FLJ23332 fis, clone HEP 12754 
4’_’#,25 NM_001064 transketolase (Wernicke-Korsakoff syndrome) 
4’_,#,26 NM_002788 proteasome (prosome, macropain) subunit, alpha type, 3 
4，—’#，27 NM_018471 uncharacterized hypothalamus protein HTO10 
4’_，#,28 NM_006527 stem-loop (histone) binding protein 
4,_，#,29 AL161952 glutamate-ammonia iigase (glutamine synthase) 
4’_’#，30 XM一009954 eukaryotic translation initiation factor 3’ subunit 7 (zeta, 66/67kD) (EIF3S7) 
4’_’#,31 BF243005 ESTs, Weakly similar to AF164793 1 protein x 013 [H.sapiens] 
4,_’#,32 NM一031243 heterogeneous nuclear ribonucleoprotein A2/B1 
4，_，A’1 XM_004020 ribosomal protein S23 (RPS23) 
4’_,A’2 NM_001494 GDP dissociation inhibitor 2 
4,_,A,3 AB046854 KIAA1634 protein 
4，_��4 NM_014764 DAZ associated protein 2 
4’_’A,5 NM一001233 caveolin 2 
4’_’A’6 NM_002870 RAB 13’ member RAS oncogene family 
4,_，A，7 AB014548 KIAA0648 protein 
4’_’A，8 NM_006287 tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) 
4,_’A，9 NM_001428 enolase 1, (alpha) 
4’_，A’10 NM_014765 translocase of outer mitochondrial membrane 20 (yeast) homolog 
4’_’A’ 11 NM_002157 heat shock I OkD protein 1 (chaperonin 10) 
4，一，A, 12 AL 109928 clone RP4-551D2 on chromosome 20ql3.2-13.33 
4，_’A,13 NM_0 14044 DKFZP564G0222 protein 
4，_�’14 NM_016630 acid cluster protein 33 
4，_��15 AC005034 BAC clone RPl 1-342K6 from 2 
4’_广，16 NM_002113 H factor (complement)-lilce 1 
4’_,A，17 NM_001633 alpha-1 -microglobulin/bikunin precursor 
4’_，A, 18 AK026547 cDNA: FLJ22894 fis, clone KAT04907 
4 ’ � ’ 19 AK024167 cDNA FLJ14105 fis, clone MAMMA 1001202 
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4，_,’20 NM—012423 ribosomal protein LI3a 
4，_/\21 AK026570 cDNA: FLJ22917 fis, clone KAT06430 
4，_A22 AK026558 cDNA: FLJ22905 fis, clone KAT05654 
4，_A23 NM_000997 ribosomal protein L37 
4,_，A’24 NM_012138 apoptosis antagonizing transcription factor 
4’_’A，25 XM_006507 cofilin 1 (non-muscle) (CFLl) 
4，_A26 NM_000999 ribosomal protein L38 
4,_广，27 XM—006219 ribosomal protein S3 (RPS3) 
4’_,A’28 XM_007633 cathepsin H (CTSH) 
4，jA，29 NM—000583 group-specific component (vitamin D binding protein) 
4，_，A’30 NM_003089 small nuclear ribonucleoprotein 70kD polypeptide (RNP antigen) 
4,一’A’31 NM_016139 丨 6.7Kd protein 
4 ,_ / \32 NM—016292 heat shock protein 75 
5,_’#，1 NM_006066 aldo-keto reductase family 1’ member A1 (aldehyde reductase) 
5’_’#，2 NM_001752 catalase 
5’_，#,3 NM_004306 annexinA13 
5,_JA NM_001920 decorin 
5，_,#,5 NM_0022 18 inter-alpha (globulin) inhibitor H4 (plasma Kallikrein-sensitive glycoprotein) 
5，_,#，6 NM_000993 ribosomal protein L31 
5’_’#,7 NM_001735 complement component 5 
5,_，#’8 AL049309 cDNA DKFZp564B 176 (from clone DKFZp564B 176) 
5，_，#,9 NM_002982 small inducible cytokine A2 
5,_,#,10 NM一017750 hypothetical protein FLJ20296 
5’_’#,11 NM_002591 phosphoenolpyruvate carboxykinase 1 (soluble) 
5，_A12 NM_025195 phosphoprotein regulated by mitogen ic pathways 
5’_>#，13 NM一003810 tumor necrosis factor (ligand) superfamily, member 10 
5，一,#’14 NM_031469 SH3 domain binding glutamic acid-rich protein like 2 
5’_,#, 15 AK025683 cDNA: FLJ22030 fis, clone HEP08669 
5’一’#’16 AA203139 ESTs, Weakly similar to T33987 hypothetical protein T12B3.4[C.elegans] 
5’ j#’17 NM_014315 host cell factor homolog 
5’_’#’18 NM_003564 transgelin 2 
5’_,#，19 U79258 mitochondrial ribosomal protein S21 
5，_，#，20 AB037799 KIAA1378 protein 
5’_’#’21 XM_005309 2,4-dienoyl CoA reductase 1, mitochondrial (DECR1) 
5,一’#’22 Z62860 CpG island DNA genomic Msel fragment 
5’_,#’23 NM_018123 hypothetical protein FLJ10517 
5，_>#’24 AC026794 chromosome 5 clone CTD-2276B5 
5’—’#,25 NM一004927 chromosome 11 open reading frame 4 
5’_A26 NM一002295 laminin receptor 1 (67kD, ribosomal protein SA) 
5,_’#’27 AFl 19897 cDNA: FU22881 fis, clone KAT03571 
5,_,#,28 NM_006708 glyoxalase I 
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5u#’29 NM_005642 TATA box binding protein (TBP)-associated factor, RNA polymerase II，F, 55kD 
5，_’#’30 NM_000108 dihydrolipoamide dehydrogenase 
5,_，#，31 NM_014953 KIAA1008 protein 
5，j#，32 AC008116 3p25-26 BAC CTB-187P1 
5，_’A,1 NM_020353 phospholipid scramblase 4 
5’_>A’2 NM_006430 chaperonin containing TCPl, subunit 4 (delta) 
AB029031 KIAA1108 protein 
5,_A4 NM_006894 flavin containing monooxygenase 3 
5,_，A,5 NM_0 14394 PTDOlO protein 
5 ’_�’6 AB034205 cisplatin resistance-associated overexpressed protein 
5’_,A’7 AB033054 KIAA1228 protein 
5，_’A’8 NM_006070 TRK-fused gene 
5，� �,9 NM_016134 aminopeptidase 
5，—’A, 10 NM_002950 ribophorin I 
5,_，A’ 11 BE048508 ESTs, Weakly similar to UDP-GLUCURONOSYLTRANSFERASE 2B17 PRECURSOR 
5,_广’ 12 NM_000242 mannose-binding lectin (protein C) 2，soluble (opsonic defect) 
5，_,A’13 NM一016255 Autosomal Highly Conserved Protein 
5，_��14 AL049365 ribosomal protein S18 
5，_A 15 NM_012190 formyltetrahydrofolate dehydrogenase 
5’_A16 AK026623 cDNA: FLJ22970 fis, clone KAT10766 
5，_�’ 17 NM_001024 ribosomal protein S21 
5，_’A,18 XM_010156 ribosomal protein LIO (RPLIO) 
5’_/ \I9 NM_001923 damage-specific DNA binding protein 1 (127KD) 
5，_�,20 NM_000990 ribosomal protein L27a 
5，_��21 NM_021130 peptidylprolyl isomerase A (cyclophilin A) 
5，_，A,22 NM_00 1344 defender against cell death 1 
5’_’A’23 XM_009113 ribosomal protein L18 (RPL18) 
5’_’A，24 NM_0 18973 dolichyl-phosphate mannosyltransferase polypeptide 3 
5，—，A,25 NM_004364 CCAAT/enhancer binding protein (C/EBP), alpha 
5’_,A’26 AK026741 ribosomal protein S4, X-linked 
5,_’A，27 NM_016400 Huntingtin interacting protein K 
5,—’A,28 NM一001512 glutathione S-transferase A4 
5’_A29 NM_000981 ribosomal protein LI9 
5,_A30 NM_001909 cathepsin D (lysosomal aspartyl protease) 
5，_’A’31 XM_007650 beta-2-microglobulin (B2M) 
5’_A32 NM_00381 0 tumor necrosis factor (ligand) superfamily, member 10 
6，_>#,1 ALl 62081 GTPase Rabl4 
6 ’ _ ’ # ’ 2 NM_003246 thrombospondin 1 
6’_，#，3 NM_005525 hydroxysteroid (11 -beta) dehydrogenase 1 
6’_，#,4 AB028980 ubiquitin specific protease 24 
6’—’#’5 NM_006888 calmodulin 1 (phosphorylase kinase, delta) 
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6’_’#，6 NM_000340 solute carrier family 2 (facilitated glucose transporter), member 2 
6，_’#’7 NM—000488 serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1 
6，_’#,8 NM_002438 mannose receptor, C type 1 
6,_>#，9 NM_012461 TERFl (TRFl)-interacting nuclear factor 2 
6，_，#，10 NM一000506 coagulation factor II (thrombin) 
6，_，#，11 NM_001271 chromodomain helicase DNA binding protein 2 
6,—,#’12 NM一001875 carbamoyl-phosphate synthetase 1, mitochondrial 
6,_’#，13 AF001542 PRO 1073 protein 
6’_,#，14 NM—002108 histidine ammonia-Iyase 
6’_,#’ 15 XM_011411 major histocompatibility complex, class II，DR beta 5 (HLA-DRB5) 
6，_,#, 16 NM_006732 FBJ murine osteosarcoma viral oncogene homolog B 
6 , _ , # , 17 NM_005662 voltage-dependent anion channel 3 
6，_’#, 18 NM_005518 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 (mitochondrial) 
6,」#，19 NM一002635 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 
6’_’#’20 NM_015270 adenylate cyclase 6 
6,_，#，21 AB023195 KIAA0978 protein 
6’一,#’22 AL137576 hypothetical protein DKFZp564L0864 similar to HIATl 
6’一，#’23 NM—003750 eukaryotic translation initiation factor 3，subunit 10 (theta, 150/170kD) 
6,_’#,24 NM—002765 phosphoribosyl pyrophosphate synthetase 2 
6，_，#，25 NM_020154 chromosome 11 hypothetical protein 0RF3 
6’_’#，26 AB037744 KIAA1323 protein 
6’一，#’27 NM_014166 HSPC126 protein 
6,_,#’28 NM_013384 tumor metastasis-suppressor 
6，一,#’29 U23028 eukaryotic translation initiation factor 2B, subunit 5 (epsilon, 82kD) 
6’_,#，30 XM_012549 ribosomal protein L13 (RPL13) 
6，_>#’31 NM_0 16213 thyroid hormone receptor interactor 4 
6，_^ #，32 XM_002464 heat shock 60kD protein 1 (chaperonin) (HSPDl) 
6，_，A’ 1 NM一003299 tumor rejection antigen (gp96) 1 
6,_’A，2 Y16359 Calonectris diomedea random amplified polymorphic DNA 
6’_A3 NM_003578 sterol 0-acyltransferase 2 
6，_A4 NM_000284 pyruvate dehydrogenase (lipoamide) alpha 1 
6,_’A,5 NM一000689 aldehyde dehydrogenase 1 family, member Al 
6’_’A，6 NM_032237 hypothetical protein FLJ23356 
6’_A7 Z24724 H.sapiens polyA site DNA 
6,一八8 NM_005804 nuclear RNA helicase, DECD variant of DEAD box family 
6,一，A,9 NM_005625 syndecan binding protein (syntenin) 
6 ,_A10 AK025784 cDNA: FLJ22131 fis, clone HEP20245 
6，一’A,11 AK025557 cDNA: FLJ21904 fis, clone HEP03585 
6,_’八，12 NM_016061 CGI-127 protein 
6’_A 13 NM_000985 ribosomal protein LI7 
6’_,A’14 AC004686 chromosome 17, clone hRPC. 1073_F 15 
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6’_/\ 15 NM_005666 H factor (complement)-!ike 3 
6,_A16 NM_001791 cell division cycle 42 (GTP-binding protein, 25kD) 
6’_,A’ 17 NM_016476 anaphase promoting complex subunit 11 (yeast APC11 homolog) 
6,一,A, 18 NM_003167 dehydroepiandrosterone (DHEA) -preferring, member 1 
6’_’A’ 19 NM_006268 requiem, apoptosis response zinc finger gene 
6，_,A，20 AFl 16606 Finkei-Biskis-Reilly murine sarcoma virus 
6’_，A’21 NM一006816 endoplasmic reticulum glycoprotein 
6，_A22 NM_003516 H2A histone family, member O 
6,_’A’23 NM_006096 N-myc downstream regulated 
6,_A24 NM_000972 ribosomal protein L7a 
6，_’A,25 NM_000454 superoxide dismutase 1’ soluble (amyotrophic lateral sclerosis 1 (adult)) 
6，_’A，26 NM_001020 ribosomal protein S16 
6’_，A’27 NM_002512 non-metastatic cells 2, protein (NM23B) expressed in 
6，_，、28 NM_001827 CDC28 protein kinase 2 
6，—广,29 BF131637 metallothionein 2A 
6，_A30 NM_000567 C-reactive protein, pentraxin-related 
6,_>a，3i ZZBC004319 glyceraldehyde-3-phosphate dehydrogenase 
6，_’A,32 XM_005762 adipose specific 2 (APM2) 
7’_，#, 1 NM_000562 complement component 8，alpha polypeptide 
7’一,#’2 NM一000353 tyrosine aminotransferase 
7，_,#，3 NM_016057 CGI-120 protein 
7’_，#’4 NM一001912 cathepsin L 
7’_,#’5 NM_005190 cyclin C 
7,_>#,6 NM一000638 vitronectin (serum spreading factor, somatomedin B, complement S-protein) 
7,_，#’7 AL031685 clone RP5-963K23 on chromosome 20q 13.11 -13.2 
7，_，#’8 NM_007192 chromatin-specific transcription elongation factor, 140 kDa subunit 
7,_,#,9 AB028981 KIAA1058 protein 
7，_，#，10 NM_001159 aldehyde oxidase 1 
7，_，#，11 X02761 fibronectin 1 
7,_,#,12 NM_018434 goliath protein 
7，JU3 NM_000035 aldolase B, fructose-bisphosphate 
7’_,#，14 AL137759 hypothetical protein FLJ23511 
7，_，#，15 AC009225 BAC clone RP11-I56A1 from 2 
7，_,#，16 NM_000773 cytochrome P450, subfamily HE (ethanol-inducible) 
"7’_’#,17 XM_0I1544 Williams-Beuren syndrome chromosome region 1 (WBSCRl) 
7,_’#，18 NM_002790 proteasome (prosome, macropain) subunit, alpha type, 5 
7,_,#,19 NM_001710 B-factor, properdin 
7’_’#，20 XM一003950 guanine nucleotide binding protein (G protein) 
7，_，#，21 AA947306 Chromosome 7 clone RP11-138A9 
7,_’#，22 XM_002844 procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 (PL0D2) 
7’_,#,23 NM_002954 ribosomal protein S27a 
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24 NM_004060 cyclin G1 
7’_，#，25 AK025140 cDNA: FLJ21487 fis, clone COL05419 
7’_，#，26 XM_009998 ribosomal protein L3 (RPL3) 
7，_，#，27 NM_005080 X-box binding protein 1 
7,_,#,28 NM_014751 KIAA0429 gene product 
7’_>#’29 NM_000183 hydroxyacyl-Coenzyme A dehydrogenase 
7’-’#’30 NM_003031 seven in absentia (Drosophila) homolog 1 
7,_,#,31 NM_001354 aldo-keto reductase family 1’ member C2 
7，_，#’32 NM_016304 60S ribosomal protein L30 isolog 
7’_,A’1 NM_002835 protein tyrosine phosphatase, non-receptor type 12 
7’一’A’2 NM_003145 signal sequence receptor, beta (translocon-associated protein beta) 
7 ’ _ , � 3 NM_001354 aldo-keto reductase family 1, member C2 
7’_，、4 NM_005783 ATP binding protein associated with cell differentiation 
7，_,A，5 NM_000305 paraoxonase 2 
7，_’A’6 NM一000126 electron-transfer-flavoprotein, alpha polypeptide (glutaric aciduria II) 
7,_A7 AFl 13008 ribosomal protein S20 
7’_，A，8 ALl 17352 clone RP5-876B10 on chromosome lq42.12-43 
7’_，A’9 NM_003129 squalene epoxidase 
7 ’ _ � �1 0 AK025794 cDNA: FLJ22141 fis, clone HEP21327 
7’_,A，11 NM_013372 cysteine knot superfamily 1, BMP antagonist 1 
7,_，A,12 ALl 17354 clone RP5-976013 on chromosome lp21.2-22.2 
7’_’A，13 NM_012248 selenophosphate synthetase 2 
7，_，A,14 AK025446 DKFZP564M182 protein 
7,_，A，15 NM_006471 myosin, light polypeptide, regulatory, non-sarcomeric (20kD) 
7，_,A，16 AK026207 cDNA: FLJ22554 fis, clone HSI01092 
7，_，A, 17 NM_005980 S100 calcium-binding protein P 
7’_A18 AK025643 hypothetical protein 
7’_，A, 19 NM_006597 heat shock 70kD protein 8 
7，_’A’20 X87949 heat shock 70kD protein 5 (glucose-regulated protein, 78kD) 
7’_，A’21 NM_014880 KIAA0022 gene product 
7,_，A，22 M76729 collagen, type V, alpha 1 
7 , _ � ’2 3 BC008442 transmembrane 4 superfamily member 1 
7，一,,24 NM_001009 ribosomal protein S5 
7,_，A,25 XM_007282 ribosomal protein S29 (RPS29) 
7，_，A，26 NM_006398 diubiquitin 
7,_,A，27 NM_014610 KIAA0088 protein 
7 , _ �2 8 NM_001022 ribosomal protein S19 
7’_A29 NM_003792 endothelial differentiation-related factor 1 
7，_，A’30 NM_001316 chromosome segregation 1 (yeast homolog)-like 
7’_A31 NM_012068 activating transcription factor 5 
7，_，A,32 NM_003646 diacylglycerol kinase, zeta (104kD) 
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8，一’1 NM_000669 alcohol dehydrogenase IC (class I), gamma polypeptide 
8,_，#，2 NM—012343 nicotinamide nucleotide transhydrogenase 
8,_,#,3 AL049969 cDNA DKFZp564A072 
8，_>#’4 NM_001085 serine (or cysteine) proteinase inhibitor, member 3 
8’_’#’5 NM_002802 proteasome (prosome, macropain) 26S subunit, ATPase, 1 
8，_’#，6 NM_000042 apolipoprotein H (beta-2-glycoprotein I) 
8，_>#’7 AK026741 ribosomal protein S4, X-linked 
AF090936 clone HQ0582 
8’_’#’9 N M _ 0 0 0 1 8 6 H factor I (complement) 
8’_，#, 10 D29750 alpha satellite in centromeric region of chromosome 21 
8,_,#，11 NM_000477 albumin 
8,_，#,12 NM—000067 carbonic anhydrase II 
8,一,#’13 vol270 R.norvegicus genes for 18S, 5.8S, and 28S ribosomal RNAs 
8’_’#，14 M35878 insulin-like growth factor binding protein 3 
8’_’#’15 NM_005398 protein phosphatase 1, regulatory (inhibitor) subunit 5 
8’一’#,16 AK027365 cDNAFLJ 14459 fis, clone HEMBB1002409 
8’_’#’ 17 NM_007107 signal sequence receptor, gamma (translocon-associated protein gamma) 
8，_，#,18 D87438 KIAA0251 protein 
8，_,#,19 BC004215 eukaryotic translation elongation factor 1 gamma 
8’_’#，20 NM_001746 calnexin 
8,_,#,21 NM_024293 hypothetical protein MGC3035 
8，_，#，22 NM_014182 HSPC160 protein 
8’_,#，23 U66589 ribosomal protein L5 
8，_,#’24 NM—005998 chaperonin containing TCPl, subunit 3 (gamma) 
8’_，#’25 XM_010020 thyroid autoantigen 70kD (Ku antigen) (G22P1) 
8，_,#’26 NM_004859 clathrin, heavy polypeptide (He) 
8，_,#，27 NM_002107 H3 histone, family 3A 
8，_，#，28 NM—002106 H2A histone family, member Z 
8’_J’29 NM_002529 neurotrophic tyrosine kinase, receptor, type 1 
8’_,#，30 NM_001111 adenosine deaminase, RNA-specific 
8,_,#’31 AK000561 cDNAFLJ20554 fis, clone KAT11807 
8，_，#，32 NM_004897 multiple inositol polyphosphate histidine phosphatase, 1 
8，_A 1 NM_001182 aldehyde dehydrogenase 7 family, member A1 
8’_/\2 NM_016142 steroid dehydrogenase homolog 
8’-’A’3 D00099 ATPase, Na+/K+ transporting, alpha 1 polypeptide 
NM_007315 signal transducer and activator of transcription l ,91kD 
8�_/\5 AK021659 cDNA FLJl 1597 fis�clone HEMBA1003856 
8，一，A,6 AB050427 Macaca fascicularis brain cDNA, clone:QnpA-21739 
8’_’A’7 NM_032205 hypothetical protein FLJ21615 
8’一,,8 U82670 chromosome Xq28 psHMGl? pseudogene 
8’_，A’9 NM_002901 reticulocalbin 1，EF-hand calcium binding domain 
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8，_A10 NM_014362 3-hydroxyisobutyryl-Coenzytne A hydrolase 
8 , _ , , U NM_013995 lysosomal-associated membrane protein 2 
8，_，A,12 NM_005048 parathyroid hormone receptor 2 
8，_，A,13 NM_032231 hypothetical protein FLJ22875 
8，_� 14 BC007261 ribosomal protein L9 
8,—’A, 15 NM_031858 ovarian carcinoma antigen CA125 
8，_’A’ 16 NM_003610 RAEl (RNA export 1 ’ S.pombe) homolog 
8’ J �1 7 AKOO1313 ribosomal protein, large, PO 
8’_，A’ 18 NM—005345 heat shock 70kD protein 1A 
8，_，A’19 AK023362 ribosomal protein S8 
8’_广’20 XM_008905 ribosomal protein L28 (RPL28) 
8 , _ � �2 1 NM_0043 71 coatomer protein complex, subunit alpha 
8’_，A，22 ZZ999999 apolipoprotein-E 
8，—,A,23 NM_016534 apoptosis-related protein PNAS-1 
8,—，A，24 NM_005234 nuclear receptor subfamily 2, group F, member 6 
8’_，A’25 Ml 1949 pancreatic secretory trypsin inhibitor (PSTI) 
8,_，A，26 NM_032231 hypothetical protein FU22875 
8，一’A,27 NM_002268 karyopherin alpha 4 (importin alpha 3) 
8,_A28 XM一005833 vimentin (VIM) 
8，一,A,29 NM_004494 hepatoma-derived growth factor (high-mobility group protein l-like) 
8，_�30 ZZ999999 CDC37 (cell division cycle 37, S. cerevisiae, homolog) (CDC37) 
8’_,A,31 XM_011089 ribosomal protein S3A (RPS3A) 
8,_A32 NM一001938 down-regulator of transcription 1，TBP-binding (negative cofactor 2) 
9，_，#’ I NM_020529 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha 
9,_，#，2 NM_000667 alcohol dehydrogenase 1A (class I), alpha polypeptide 
9’_’#，3 NM_000778 cytochrome P450, subfamily IVA, polypeptide 11 
9 , j # � 4 NM_000609 stromal cell-derived factor 1 
9’_’#，5 NM_006833 C0P9 subunit 6 (MOV34 homolog, 34 kD) 
9’_>#’6 AK024951 complement component 1 ’ r subcomponent 
9’_，#’7 NM_000484 amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease) 
9,_，#，8 NM_001063 transferrin 
9，_，#，9 AL 109959 mRNA full length insert cDNA clone EUROIMAGE 1019273 
9’_’#, 10 NM_006741 protein phosphatase I，regulatory (inhibitor) subunit 1A 
9’_,#’11 NM一002118 major histocompatibility complex, class II, DM beta 
9’一,#’12 NM_005040 prolylcarboxypeptidase (angiotensinase C) 
9,_，#，13 NM_005778 RNA binding motif protein 5 
9’—’#，14 NM_000066 complement component 8’ beta polypeptide 
9，_,#’ 15 XM—008947 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu antigen R) 
9，_，#, 16 NM_024863 hypothetical protein FLJ21174 
9 ’ _ A n AL049796 clone RP4-561L24 on chromosome 1 p22-31.1 
9，_，#,18 NM_003359 UDP-glucose dehydrogenase 
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9，_’#，19 BG749845 metallothionein IE (functional) 
9’_,#，20 XM一003864 hexosaminidase B (beta polypeptide) (HEXB) 
9,_,#,21 NM_014020 LR8 protein 
9’J f ’22 AL138836 EGF-like-domain, multiple 5 
9,_,#,23 N M _ 0 1 5 4 I 5 D K F Z P 5 6 4 B 1 6 7 protein 
9’—’#’24 ZZ999777 Negative control 13 no insert linearized pT-Adv vector control 
9’—’#’25 NM_005607 PTK2 protein tyrosine kinase 2 
9’_,#’26 NM_002858 ATP-binding cassette, sub-family D (ALD), member 3 
9’_，#,27 NM_003739 aldo-keto reductase family 1, member C3 
9，_,#’28 X87949 heat shock 70kD protein 5 (glucose-regulated protein, 78kD) 
9’_，#’29 NM_003187 TATA box binding protein (TBP)-associated factor, RNA polymerase II’ G, 32kD 
9，—，#,30 X02761 fibronectin 1 
9,_，#’31 AB046818 KIAA1598 protein 
9，—，#’32 NM一006745 sterol-C4-methyl oxidase-like 
NM_0I8584 hypothetical protein PRO 1489 
9 ,_A2 AB020631 PCFl Ip homolog 
9’_A3 NM_014819 KIAA0438 gene product 
9 , _ �4 NM_006644 heat shock 105kD 
9 , _ � ’5 NM_004815 PTPLl-associated RhoGAP 1 
9,_,A,6 BG328983 ribosomal protein L44 
9’_，a’7 AV763874 ESTs, Weakly similar to S19560 proline-rich protein MP4 - mouse [M.musculus] 
9’_’A’8 NM一018571 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2 
9 ,_A9 NM_003588 cullin 4B 
9 ’ � �, 1 0 NM_006044 histone deacetylase 6 
9’_广，11 NM_031314 heterogeneous nuclear ribonucleoprotein C (C1/C2) 
9’_，A,12 NM_032275 hypothetical protein DKFZp547I082 
9 ,_ ,M3 NM_014041 HSPC033 protein 
14 AC008519 chromosome 5 clone CTC-460G13 
9，_’a,15 AC019173 BAC clone RPI1-185H6 from 4 
9 ,_ ,M6 Z70723 paraoxonase 1 
9’—,A，17 ZZBC009238 Housekeeping gene control 25, alpha-tubulin 
9,_,A，18 ZZ999999 H S P C O B m R N A 
9’_A 19 XM_007398 golgi autoantigen, golgin subfamily a, 5 (G0LGA5) 
9’_ / \20 NM_0 16640 programmed cell death 9 
9，_A21 NM_004451 estrogen-related receptor alpha 
9’_A22 ZZ999999 CDC2-related protein kinase 7 (CrkRS) 
9，_,A，23 D31887 KIAA0062 protein 
9, 一，A， 2 4 AL050388 cDNA DKFZp564M2422 
9，_，A’25 NM_005406 Rho-associated, coiled-coil containing protein kinase 1 
9，_,A，26 ZZ999999 bladder cancer associated protein (BLCAP) 
9’_,A’27 NM_003878 gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
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9，_广’28 AK027136 cytochrome c oxidase subunit IV 
9’_’A，29 ZZ999999 casein kinase 2, beta polypeptide (CSNK2B) 
9,_’A’30 NM_001664 ras homolog gene family, member A 
9，_，A，31 NM_000482 apolipoprotein A-IV 
9,_,A,32 zzNM_001013 Housekeeping gene control 26, ribosomal protein S9 (RPS9) 
10,_,#,1 AL359334 EST from clone 628609 
10’一’#’2 NM_001734 complement component 1, s subcomponent 
10’_，#’3 NM_000014 aIpha-2-macroglobulin 
10,_,#,4 NM—002842 protein tyrosine phosphatase, receptor type, H 
10’_’#，5 NM_001903 catenin (cadherin-associated protein), alpha 1 (102kD) 
10’j#’6 NM_014730 KIAA0152 gene product 
10’_，#，7 XM—004236 solute carrier family 22 (organic cation transporter), member 1 (SLC22A1) 
10,_’#，8 NM_000371 transthyretin (prealbumin, amyloidosis type I) 
10,_式9 AL138726 clone RP1-139G21 on chromosome 6 
10，_’#’ 10 AFl 19841 peroxisomal trans 2-enoyl CoA reductase; putative short chain alcohol dehydrogenase 
10’ j#’ l l NM_021870 fibrinogen, gamma polypeptide 
10，_，#，12 AF278532 netrin 4 
10,_,#, 13 NM_013267 breast cell glutaminase 
10,_，#，14 NM_030754 serum amyloid A2 
10’_’#’15 AK021720 cDNAFLJ11658 fis, clone HEMBA1004577 
10,_,#, 16 NM—006206 platelet-derived growth factor receptor, alpha polypeptide 
10,_,#, 17 NM_000120 epoxide hydrolase 1 ’ microsomal (xenobiotic) 
10’_’#,18 NM_006178 N-ethylmaleimide-sensitive factor 
10,_,#’19 AFl 16272 T-cell activation protein (PGRl) 
10’_’#’20 NM一000903 diaphorase (NADH/NADPH) (cytochrome b-5 reductase) 
10,_,#,21 AC004098 chromosome 17, clone HCIT305D20 
10,_,#,22 NM一001863 cytochrome c oxidase subunit VIb 
10，_，#，23 NM_014633 KIAAO155 gene product 
10’_’#’24 NM_017453 staufen (Drosophila, RNA-binding protein) 
10’_A25 NM_003029 SHC (Src homology 2 domain-containing) transforming protein 1 
10,_,#,26 X59405 membrane cofactor protein (CD46, trophoblast-lymphocyte cross-reactive antigen) 
10，_A27 AI057233 clone RP11-385L2 on chromosome 6 
10,_,#，28 NM_002302 leukocyte cell-derived chemotaxin 2 
10’_’#’29 NM_024670 suppressor of variegation 3-9 (Drosophila) homolog 2; hypothetical protein FLJ23414 
10’一’#，30 NM_000582 secreted phosphoprotein 1 (osteopontin) 
10,_,#,31 NM_001266 carboxylesterase 1 (monocyte/macrophage serine esterase 1) 
10，_’#,32 NM一015423 aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 
10，一’A, 1 AFl 13676 serine (or cysteine) proteinase inhibitor, member 1 
1 0，_A2 NM一00643 5 interferon induced transmembrane protein 2 (1-8D) 
10’_A3 NM_018509 hypothetical protein PRO 1855 
10’-’ A, 4 AK026463 beta-2-microglobulin 
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10’一广，5 NM_001072 UDP glycosyltransferase 1 family, polypeptide A6 
10，_,A,6 NM_003336 ubiquitin-conjugating enzyme E2A (RAD6 homolog) 
10,_,A,7 NM_032210 hypothetical protein FLJ21858 
10’_A8 NM_006837 C0P9 (constitutive photomorphogenic, Arabidopsis, homolog) subunit 5 
10’_，A’9 AK022354 cDNAFLJ 12292 fis, clone MAMMA1001812 
10’_，A,10 AK026026 cDNA: FLJ22373 fis, clone HRC06741 
10,_广’ 11 NM_014713 lysosomal-associated protein transmembrane 4 alpha 
10，—’A’12 AL049385 cDNA DKFZp586M14I8 
10,_,A，13 NM一032636 hypothetical protein MGC1780 
10’_，A，M AF218029 H3 histone, family 3B (H3.3B) 
10’_A 15 NM_002019 fms-related tyrosine kinase 1 
1 0 , 1 6 NM_017693 hypothetical protein FLJ20159 
10，_,A，17 XM_011453 p53-induced protein PIGPCI (PIGPC1) 
10’- , ’ 18 AL050391 cDNA DKFZp586A181 
10，_/\19 NM_001614 actin, gamma 1 
10’_’A，20 ZZ999999 GDP dissociation inhibitor 1 (GDI 1) 
10’_A21 AF323540 apolipoprotein L 
10’-’A,22 Z2999999 cathepsin B (CTSB) 
10,—,A，23 XM_002255 ribosomal protein S27a (RPS27A) 
10’_A24 D26069 centaurin beta2 
10，_广’25 ZZ999999 keratin 8 (KRT8) 
10’_/\26 NM_000984 ribosomal protein L23a 
10’_/\27 NM_002823 prothymosin, alpha (gene sequence 28) 
10’一，A,28 NM一000883 IMP (inosine monophosphate) dehydrogenase 1 
10,_八29 NM_015921 divalent cation tolerant protein CUTA 
10’一广’30 NM_002952 ribosomal protein S2 
10’_’A’31 NM_006559 GAP-associated tyrosine phosphoprotein p62 (Sam68) 
10’-，A,32 XM一002143 hepatitis B virus x-interacting protein (9.6kD) (XIP) 
11 I NM_001737 complement component 9 
1 l , j # ’ 2 NM_002966 SI00 calcium-binding protein AlO 
11,_A3 NM_001354 aldo-keto reductase family 1, member C2 
4 AP205218 NSl-binding protein 
11，_>#，5 NM_003330 thioredoxin reductase 1 
11，_,#’6 AB032261 stearoyl-CoA desaturase (delta-9-desaturase) 
11’_A7 XM_009284 ubiquitin A-52 residue ribosomal protein fusion product 1 (UBA52) 
1 l ’ j# ’8 XM_002778 fatty acid binding protein 1, liver (FABPl) 
1 l ’ j # ,9 AK024225 ribosomal protein L39 
11，_>#’ 10 NM_000994 ribosomal protein L32 
11，_,#，11 NM_000463 UDP glycosyltransferase 1 family, polypeptide Al 
11，—,#，12 ALl 36643 ubiquilin 1 
11’_>#’13 XM_003584 quinqid dihydropteridine reductase (QDPR) 
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I 14 XM_001602 ubiquinol-cytochrome c reductase hinge protein (UQCRH) 
11，_，#,15 XM_005084 phosphoglucomutase 1 
11’_’#’16 AK022030 cDNA FLJ 11968 fis, clone HEMBB1001133 
II 17 ZZ999777 Housekeeping gene control 21, Beta-actin 
11，_A18 ZZ999777 Housekeeping gene control 21, Beta-actin 
11 ’_，#，19 ZZ999777 Negative control 11 no template PCR 
I 20 ZZ999777 Negative control 11 no template PCR 
II ’_’#’21 NM_005807 proteoglycan 4’ (megakaryocyte stimulating factor, articular superficial zone protein) 
11 ’_A22 AK002173 cDNA FLJ11311 fis, clone PLACE 1010102 
11’_，#’23 NM_013436 NCK-associated protein 1 
ll，—,#’24 XM_006994 ADP-ribosylation factor-like I (ARLl) 
11，_,#,25 NM_002013 FK506-binding protein 3 (25kD) 
11’_>#’26 NM—000884 IMP (inosine monophosphate) dehydrogenase 2 
11 ’_’#’27 NM_000898 monoamine oxidase B 
11，_’#’28 AL136109 hypothetical protein FLJ 13964 
11’_’#，29 NM_022333 TIAl cytotoxic granule-associated RNA-binding protein-like 1 
11’_’#，30 NM_000062 serine (or cysteine) proteinase inhibitor, clade G (CI inhibitor), member 1 
11 ,_,#,31 NM_006391 RAN binding protein 7 
11 ’—A32 AF208111 IL-17B receptor 
n ’ _ / \ l NM_0I6586 MBIP protein 
11,一’A，2 NM_018150 hypothetical protein FLJ 10597 
11 ’ _广 ’ 3 NM_017693 hypothetical protein FLJ20159 
11 ’_A4 NM_015999 CGI-45 protein 
n，_A5 AF009341 E6-AP ubiquitin-protein ligase (UBE3A) exon 16 
ll�_/\6 D86961 lipoma HMGIC fusion partner-like 2 
11 ’_’A’7 NM_003051 solute carrier family 16 (monocarboxylic acid transporters), member 1 
I 1’_A8 NM_001482 glycine amidinotransferase (L-arginine:glycine amidinotransferase) 
11’_’A，9 XM_003294 alpha-2-HS-glycoprotein (AHSG) 
1 1 � ’ 10 NM_000143 fumarate hydratase 
ll，_Aii NM_000613 hemopexin 
11, J A, 12 NM_002194 inositol polyphosphate-1 -phosphatase 
n’_，A，l3 NM_002997 syndecan 1 
1 1 � - � 14 ZZ999777 Negative control 13，no insert linearized pT-Adv vector control 
II ,_’A’ 丨 5 NM 一 0 0 0 0 4 0 apolipoprotein C-III 
11 ’一’A, 16 ZZ999777 Negative control 13, no insert linearized pT-Adv vector control 
‘1 丄丨 7 ZZ999777 Housekeeping gene control 21 ’ Beta-actin 
11 18 ZZ999777 Housekeeping gene control 21，Beta-actin 
11，_’A，19 ZZ999777 Negative control 11, no template PCR 
11 , _A20 ZZ999777 Negative control 11, no template PCR 
11，_，A’21 NM_002893 retinoblastoma-binding protein 7 
11’-’A,22 NM_006367 adenylyl cyclase-associated protein 
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11，_A23 NM—014052 GW128 protein 
11 ,_A24 NM_004905 anti-oxidant protein 2 
11，_，A，25 NM_003897 immediate early response 3 
I 1，_A26 ZZ999999 ribosomal protein S14 (H. sapiens) (LOC65671) 
11，_，A’27 AF090094 ornithine decarboxylase antizyme 1 
II ’_’A’28 NM_004404 neural precursor cell expressed, developmentally down-regulated 5 
11 ’_’A，29 NM_002810 proteasome (prosome, macropain) 26S subunit, non-ATPase, 4 
11’_，A’30 NM_014752 KIAA0102 gene product 
11,A，31 NM_004484 glypican 3 
11 ,_’A，32 NM_003406 tyrosine 3-monooxygenase, zeta polypeptide 
12，_，#,1 AFl 19868 retinol-binding protein 4, interstitial 
12,_,#,2 D31885 ADP-ribosylation factor-like 6 interacting protein 
12,_，#,3 NM_016002 CGI-49 protein 
12,_,#,4 NM_002568 poly(A)-binding protein, cytoplasmic 1 
12’—，#’5 AK024103 cDNAFLJ 14041 fis, clone HEMBA1005780 
12’_’#,6 AK025736 3-hydroxy-3-methylgIutaryl-Coenzyme A synthase 1 (soluble) 
12，_>#’7 NM_017823 hypothetical protein FLJ20442 
12，_’#，8 NM_021078 GCN5 (general control of amino-acid synthesis, yeast, homolog)-!ike 2 
12’_，#’9 NM_014762 seladin-1 
12,_,#, 10 NM_001011 ribosomal protein S7 
12，_’#’n NM_003374 voltage-dependent anion channel 1 
12’_，#,12 NM_000185 serine (or cysteine) proteinase inhibitor, CI 761 member 1 
12’_’#，13 NM_005537 inhibitor of growth family, member 1 
12’_X14 NM_003142 Sjogren syndrome antigen B (autoantigen La) 
1 1 5 NM一007273 B-cell associated protein 
12,_,#,16 NM一022977 fatty-acid-Coenzyme A ligase, long-chain 4 
12,_,#,17 ZZ999777 Housekeeping gene control 21, Beta-actin 
12，_J’18 ZZ999777 Housekeeping gene control 21, Beta-actin 
12，_，#,19 ZZ999777 Negative control 11, no template PCR 
12,_,#,20 ZZ999777 Negative control 11, no template PCR 
12,—’#’21 BC008782 nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 2 
12’—，#，22 NM—002614 PDZ domain containing 1 
12,_,#,23 AL 132773 attractin 
12’_’#，24 NM_000412 histidine-rich glycoprotein 
1 2 , j # � 2 5 NM_007355 heat shock 90kD protein 1, beta 
12’_’#,26 NM一001697 ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 
I2’_丸27 BC005137 calmodulin 2 (phosphorylase kinase, delta) 
12，_，#’28 NM_002860 pyrroline-5-carboxylate synthetase (glutamate gamma-semialdehyde synthetase) 
12，_，#，29 XM_001352 farnesyl diphosphate synthase 
12,_A30 NM_000249 mutL (E. coli) homolog 1 (colon cancer, nonpolyposis type 2) 
12’_’#’31 NM_002857 peroxisomal farnesylated protein 
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12,_,#,32 AL135787 NADP dependent leukotriene b4 12-hydroxydehydrogenase 
12,_/\1 NM_001552 insulin-like growth factor-binding protein 4 
12，_/\2 XM—010560 ribosomal protein S27 (metallopanstimulin 1)(RPS27) 
12,_’A’3 XM_001439 aldo-keto reductase family 7’ member A3 (aflatoxin aldehyde reductase) (AKR7A3) 
I2，_,A’4 NM_004874 BCL2-associated athanogene 4 
12，_A5 NM_001671 asialoglycoprotein receptor 1 
12,—�,6 ZZ999777 Negative control 13, no insert linearized pT-Adv vector control 
12’��’7 ZZ999999 erythrocyte membrane protein band 4.9 (dematin) (EPB49) 
12,_，a，8 AJ249921 apolipoprotein C-I 
12’_，A,9 N M _ 0 2 0 3 9 6 BCL2-丨ike 10 (apoptosis facilitator) 
12，_A10 NM_000045 arginase, liver 
12’_’A’11 AC008134 3q26.2-27 BAC RPCI11-263C16 
12，��’ 12 ZZ999777 Negative control 13 no insert linearized pT-Adv vector control 
12，—’A, 13 NM一001486 glucokinase (hexokinase 4) regulatory protein 
12，—’A, 14 ZZ999999 retinoblastoma-binding protein 2 (RBBP2) 
12’_/ \I5 XM_009292 interferon, gamma-inducible protein 30 (IFI30) 
12’-’�,16 NM_001831 clusterin 
12，_，A’ 17 ZZ999777 Housekeeping gene control 11, Beta-actin 
12’一,A’ 18 2x999117 Housekeeping gene control 21, Beta-actin 
12，_�,19 ZZ999777 Negative control I I , no template PCR 
1 2,_，a，20 ZZ999777 Negative control 11, no template PCR 
1 2’_’A，2 1 NM_000253 microsomal triglyceride transfer protein (large polypeptide, 88kD) 
12,_，A，22 NM_006360 dendritic cell protein 
12’_,A’23 AB037790 heme-regulated initiation factor 2-alpha kinase 
12’_’A’24 NM_004539 asparaginyl-tRNA synthetase 
12，_,A，25 AC026776 chromosome 21 clone CTC-304G18 
12，_’A’26 ZZNM_020992 PDZ and LIM domain 1 (elfin) 
12，_,A，27 NM_016097 HSPC039 protein 
12’-’A,28 zzNM_021630 PDZ-LIM protein mystique 
12’_’A’29 ZZ999999 hepatocellular carcinoma associated ring finger protein mRNA 
12，_A30 ZZ999777 Negative control 12, d H 2 0 only 
12’_，A,31 ZZ999777 Negative control 12, d H 2 0 only 
12’_广’32 ZZ999777 Negative control 12’ d H 2 0 only 
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Candidate genes differentially expressed in HCC 
Patient A: 
Gene up-regulated in HCC : 
Dominating Average Literature 
Acession No. Gene identity Library ratio cited 
Proteins involved in other metabolism 
Hs.174151 aldehyde oxidase 1 RS 3 3 
Hs.50966 carbamoyl-phosphate synthetase 1, mitochondrial Rs 3 . 3 
Hs.75183 cytochrome P450, subfamily HE (ethanol-inducible) Rs 3.0 4 , 7 & 8 
Hs.329704 cytochrome P450, subfamily IlIA (niphedipine oxidase), Rs 3.1 
polypeptide 3 
Hs. 178738 cytochrome P450, subfamily IlIA (niphedipine oxidase), Rs 2.7 3 
polypeptide 4 
Hs.170171 glutamate-ammonia ligase (glutamine synthase) Ts 7 .4 
Hs. 119597 stearoyl-CoA desaturase (delta-9-desaturase) Ts 3 . 7 5 & 9 
Secretory proteins 
HS .75990 haptoglobin RS 4 1 
Hs.275215 hydroxysteroid (11-beta) dehydrogenase 1 Rs 2.1 
Hs.111779 secreted protein, acidic, cysteine-rich (osteonectin) Ts 2.7 
Protein involved in transcription and translation 
Hs. 181307 H3 histone, family 3A Ts 4 2 
Gene down-regulated in HCC : 
Dominating Average Literature 
Acession No. Gene identity Library ratio cited 
Membrane associated protein 
XM_004236 solute carrier family 22 (organic cation transporter), Rs 3 .4 
member 1 (SLC22A1) 
Secretory proteins 
Hs.184411 albumin Rs 3 . I 2 , 7 & 8 
HS . 74561 alpha-2-macroglobulin RS 3 0 1 4 & 7 
HS .93194 apolipoprotein A-l R 2 3 2 
Hs. 194366 transthyretin (prealbumin, amyloidosis type I) Rs 2 2 2 & 8 
Miscellaneous proteins 
Hs.1290 complement component 9 r s 3 1 5 
XM一013095 thymosin, beta 4, X chromosome (TMSB4X) Ts 2.2 
Novel protein 




G e n e up-regulated in H C C : 
D o m i n a t i n g A v e r a g e L i t e r a t u r e 
A c e s s i o n N o . G e n e i d e n t i t y L i b r a r y r a t i o c i t e d 
P r o t e i n s i n v o l v e d in s i g n a l t r a n s d u c t i o n / c e l l c y c l e r e g u l a t i o n 
H s . 2 1 7 4 9 3 a n n e x i n A 2 j s 5 . 8 
H s . 2 5 0 6 5 5 p ro thymos in , a lpha ( g e n e s e q u e n c e 2 8 ) T 4 . 8 
H s . 1 1 9 3 0 1 S 1 0 0 ca lc ium-b ind ing prote in A 1 0 (annex in II l igand, Ts 1 5 . 5 
ca lpact in I, light po lypept ide (p11 ) ) 
H s . 2 7 5 2 4 3 S 1 0 0 ca lc ium-b ind ing protein A 6 (calcycl in) Ts 1 7 . 3 
E x t r a c e l l u l a r m a t r i x p r o t e i n 
H s . 3 1 3 s e c r e t e d p h o s p h o p r o t e i n 1 (os teopont in , b o n e s ia loprote in Ts 2 . 8 5 
I, ea r ly T - l y m p h o c y t e act ivat ion 1) 
P r o t e i n i n v o l v e d in o t h e r m e t a b o l i s m 
Hs . 1 1 9 5 9 7 s t e a r o y l - C o A d e s a t u r a s e ( d e l t a - 9 - d e s a t u r a s e ) Ts 2 . 7 5 & 9 
P r o t e i n s i n v o l v e d in t r a n s c r i p t i o n a n d t r a n s l a t i o n 
H s . 1 8 1 3 0 7 H 3 h is tone, fami ly 3 A j s 2 . 9 
X M _ 0 1 0 5 5 0 r i b o s o m a l prote in L 7 ( R P L 7 ) j s 2 . 4 
H s . 2 7 5 8 6 5 r i b o s o m a l prote in S 1 8 Ts 2 7 
M i s c e l l a n e o u s p r o t e i n s 
H s . 5 5 9 9 E G F - l i k e - d o m a i n , mul t ip le 5 j s 4 . 0 
H s . 7 4 3 3 5 h e a t s h o c k 9 0 k D prote in 1, be ta Ts 2 7 
X M _ 0 1 3 0 9 5 t h y m o s i n , b e t a 4 , X c h r o m o s o m e ( T M S B 4 X ) , Ts 3 5 
N o v e l p r o t e i n 
H s . 2 7 7 4 3 1 hypothet ica l prote in F L J 2 3 3 5 6 j s 1 0 . 9 
G e n e d o w n - r e g u l a t e d in H C C : 
D o m i n a t i n g A v e r a g e L i t e r a t u r e 
A c e s s i o n N o . G e n e i d e n t i t y L i b r a r y r a t i o c i t e d 
P r o t e i n s i n v o l v e d in s i g n a l t r a n s d u c t i o n / c e l l c y c l e r e g u l a t i o n 
Hs . 1 5 5 7 4 2 g lyoxy la te r e d u c t a s e / h y d r o x y p y r u v a t e r e d u c t a s e R s 3 . 2 
H s . 2 7 8 5 6 8 H fac tor ( c o m p l e m e n t ) - l i k e 1 Ts 3 1 
C y t o s k e l e t a l r e l a t e d p r o t e i n 
H s . 2 2 5 7 v i t ronect in ( s e r u m s p r e a d i n g factor , s o m a t o m e d i n B, R s 6 . 6 1 
c o m p l e m e n t S - p r o t e i n ) 
P r o t e i n i n v o l v e d i n e n e r g y m e t a b o l i s m 
H s . 2 5 A T P s y n t h a s e , H + t ranspor t ing , m i tochondr ia l F 1 c o m p l e x , Ts 2 . 5 
b e t a po lypep t ide 
P r o t e i n s i n v o l v e d in o t h e r m e t a b o l i s m 
X M - 0 0 5 3 0 9 2 ,4-c l ienoyl C o A r e d u c t a s e 1, m i tochondr ia l ( D E C R 1 ) Ts 2 . 8 
135 
Appendix 
H s . 2 3 4 2 3 4 a l d o l a s e B, f r u c t o s e - b i s p h o s p h a t e R s 1 0 . 7 2 , 5 & 8 
H s . 1 7 4 2 2 0 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I I C ( m e p h e n y t o i n R s 4 . 8 4 , 5 , 6 & 8 
4 - h y d r o x y l a s e ) , p o l y p e p t i d e 8 
H S . 7 5 1 8 3 c y t o c h r o m e P 4 5 0 , s u b f a m i l y ME (e thano l - induc ib le ) R s 7 .4 4 , 7 & 8 
H s . 3 2 9 7 0 4 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I l IA ( n i p h e d i p i n e o x i d a s e ) , R s 5 . 8 
p o l y p e p t i d e 3 
X M _ 0 0 2 7 7 8 fat ty ac id b inding prote in 1, l iver ( F A B P 1 ) T s 1 0 . 6 
H s . 2 7 5 2 1 5 hydroxys te ro id ( 1 1 - b e t a ) d e h y d r o g e n a s e 1 R s 6 . 9 2 , 5 , 7 & 8 
Secretory proteins 
H s . 1 8 4 4 1 1 a l b u m i n RS 9 8 
H s . 7 6 1 7 7 a l p h a - 1 -m ic rog lobu l in /b ikun in p r e c u r s o r R 8 . 7 
X M _ 0 0 3 2 9 4 a l p h a - 2 - H S - g l y c o p r o t e i n ( A H S G ) T s 6 . 3 1 , 4 & 7 
H s . 7 4 5 6 1 a l p h a - 2 - m a c r o g l o b u l i n RS 1 0 . 1 2 
H S . 9 3 1 9 4 apo l ipopro te in A - l R 4 6 
H s . 2 6 8 5 7 1 apo l ipopro te in C - l Ts 9 .5 7 
H s . 7 3 8 4 9 apo l ipopro te in C - l 11 R 5 7 2 & 8 
H s . 1 0 1 2 c o m p l e m e n t c o m p o n e n t 4 - b i n d i n g prote in , a l p h a Ts 3 . 0 
H s . 9 0 7 6 5 f ib r inogen , A a l p h a p o l y p e p t i d e R S 8.3 8 
H s . 7 6 4 5 f ib r inogen , B b e t a p o l y p e p t i d e R S 3 4 
H s . 1 9 8 2 4 6 g r o u p - s p e c i f i c c o m p o n e n t (v i tamin D b inding prote in ) T 6 . 0 
H s . 7 6 4 6 1 re t ino l -b ind ing pro te in 4 , interstit ial R 1 2 . 5 2 
H s . 1 9 4 3 6 6 t rans thyre t in ( p r e a l b u m i n , a m y l o i d o s i s t y p e I) R s 1 0 . 1 2 & 8 
Protein involved in transcript ion and translat ion 
H s . 1 8 1 1 6 5 e u k a r y o t i c t rans la t ion e l o n g a t i o n fac tor 1 a l p h a 1 Ts 2 . 4 
Miscel laneous proteins 
H s . 2 7 8 9 9 3 a m i n o p e p t i d a s e 丁s 2.6 
HS .1290 complement component 9 RS 3 3 5 
M17614 transferrin gene, exon 17 RS 13 2 
Novel proteins 
Hs. 12969 hypothetical protein FLJ23094 RS 8 8 
Hs. 151973 hypothetical protein FLJ23511 Rs 2 5 
Hs.22412 hypothetical protein MGC3035 Ts 2 4 
AB037799 KIAA1378 j s A2 
AC026794 EST 了$ ^ ^ 
AF090936 EST Rs 29.9 




G e n e up-regulated in HCC: 
D o m i n a t i n g A v e r a g e L i t e r a t u r e 
A c e s s i o n N o . G e n e i d e n t i t y L i b r a r y r a t i o c i t e d 
E x t r a c e l l u l a r m a t r i x p r o t e i n 
H s . 3 1 3 s e c r e t e d p h o s p h o p r o t e i n 1 (os teopont in , b o n e s ia loprote in I, Ts 1 2 . 2 5 
ear ly T - l y m p h o c y t e act ivat ion 1) 
P r o t e i n s i n v o l v e d in o t h e r m e t a b o l i s m 
H s . 7 8 1 8 3 a l d o - k e t o r e d u c t a s e fami ly 1, m e m b e r C 3 ( 3 - a l p h a Ts 3 . 7 
hydroxystero id d e h y d r o g e n a s e , t ype II) 
H s . 8 0 7 0 6 d i a p h o r a s e ( N A D H / N A D P H ) ( c y t o c h r o m e b - 5 r e d u c t a s e ) Ts 8 . 6 
P r o t e i n i n v o l v e d in t r a n s c r i p t i o n a n d t r a n s l a t i o n 
X M _ 0 1 0 5 5 0 r i b o s o m a l prote in L 7 ( R P L 7 ) j s 2 6 
H s . 2 7 5 8 6 5 r i b o s o m a l prote in S 1 8 j s 2 2 
H s . 8 1 0 2 r i b o s o m a l prote in S 2 0 Ts 2 8 2 
H s . 3 0 1 5 4 7 r i b o s o m a l prote in S 7 丁s 2 9 
Miscellaneous proteins 
Hs.74335 heat s h o c k 9 0 k D prote in 1 , be ta Ts 3 3 
X M _ 0 1 3 0 9 5 t h y m o s i n , b e t a 4 , X c h r o m o s o m e ( T M S B 4 X ) , Ts 2 . 6 
N o v e l p r o t e i n s 
H s . 2 7 7 4 3 1 hypothet ica l prote in F L J 2 3 3 5 6 Ts 1 1 6 
A C 0 0 4 0 9 8 E S T Ts 2 b 
G e n e down- regu la ted in HCC: 
D o m i n a t i n g A v e r a g e L i t e r a t u r e 
A c e s s i o n N o . G e n e i d e n t i t y L i b r a r y r a t i o c i t e d 
M e m b r a n e a s s o c i a t e d p r o t e i n 
X M _ 0 0 4 2 3 6 so lu te carr ier f ami ly 2 2 (o rgan ic cat ion t ranspor ter ) , m e m b e r R s 3 .4 
1 ( S L C 2 2 A 1 ) 
P r o t e i n s i n v o l v e d i n o t h e r m e t a b o l i s m 
H s . 7 3 8 4 3 a lcoho l d e h y d r o g e n a s e 1 A (c lass I), a l p h a po lypept ide R s 7 . 4 4 
H s . 2 3 4 2 3 4 a l d o l a s e B, f r u c t o s e - b i s p h o s p h a t e RS 4 2 
H s . 1 7 4 2 2 0 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I IC ( m e p h e n y t o i n Rs 4 8 
4 - h y d r o x y l a s e ) , po lypep t ide 8 
H s . 7 5 1 8 3 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I IE (e thano l - induc ib le ) R s 6 . 0 2 ’ 5 & 8 
H s . 3 2 9 7 0 4 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I I IA (n iphed ip ine o x i d a s e ) , R s 7 . 2 4 , 5 , 6 & 8 
p o l y p e p t i d e 3 
H s . 1 7 8 7 3 8 c y t o c h r o m e P 4 5 0 , s u b f a m i l y I I IA (n iphed ip ine o x i d a s e ) , R s 5 . 9 4, 7 & 8 
p o l y p e p t i d e 4 
H s . 2 7 5 2 1 5 hydroxystero id ( 1 1 - b e t a ) d e h y d r o g e n a s e 1 RS 6 3 
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H s . 2 7 8 8 9 6 U D P glycosyl t ransferase 1 family, polypept ide A 1 Ts 2 . 8 3 
S e c r e t o r y p r o t e i n s 
Hs. 1 8 4 4 1 1 a lbumin r 5 ^ 7 2 
H s . 7 6 1 7 7 a lpha-1 -microglobul in/bikunin precursor R 2 . 6 
X M _ 0 0 3 2 9 4 a lpha-2 -HS-g lycopro te in ( A H S G ) Ts 2 . 9 2 , 5 , 7 & 8 
H s . 9 3 1 9 4 apol ipoprotein A - l r 3 1 
H s . 2 6 8 5 7 1 apol ipoprotein C - l Ts 2 4 
H s . 7 3 8 4 9 apol ipoprotein C - l 11 R 4 2 2 
H s . 1 2 5 2 apol ipoprotein H (beta-2-g lycoprote in I) RS 3.7 
H s . 9 0 7 6 5 f ibrinogen, A a lpha polypept ide RS 3 . I 7 
H s . 7 6 4 5 f ibrinogen, B beta polypept ide RS 3 . 6 7 
H s . 7 5 4 3 1 f ibrinogen, g a m m a polypept ide R s 3 3 2 & 8 
H s . 7 6 4 6 1 retinol-binding protein 4 , interstitial ( A F 1 1 9 8 6 8 ) R 2 . 3 
Hs. 1 9 4 3 6 6 transthyret in (prea lbumin, amylo idosis type I) RS 3.7 2 & 8 
P r o t e i n i n v o l v e d in t r a n s c r i p t i o n a n d t r a n s l a t i o n 
H S . 2 0 1 6 7 5 R N A binding motif protein 5 RS 2 . 9 
M i s c e l l a n e o u s p r o t e i n s 
H s . 1 2 9 0 c o m p l e m e n t c o m p o n e n t 9 Rs 2 5 5 
M 1 7 6 1 4 transferrin g e n e , exon 17 RS 3 g g 
N o v e l p r o t e i n s 
Hs. 1 2 9 6 9 hypothet ical protein F L J 2 3 0 9 4 RS 24 
A F 0 9 0 9 3 6 E S T p g 2 5 
Dominating Library: 
Rs : S u b t r a c t e d - n o r m a l c D N A l ibrary 
Ts : S u b t r a c t e d - H C C c D N A l ibrary 
R: H u m a n s u r r o u n d i n g n o r m a l c o u n t e r p a r t c D N A l ibra ry 
T : H u m a n H C C c D N A l ibrary . 
Literature cited: 
1.Delpuech et al.�2002 
2. K i m et al.’ 2 0 0 1 
3 . K o n d o h etal., 1999 
4丄au etal., 2 0 0 0 
5. O k a b e etal, 2 0 0 1 
6. Sh i ro t a etal., 2 0 0 1 
7. X u etal., 2 0 0 1 a 
8. X u etal” 2 0 0 1 b 
9. Li etal., 2 0 0 0 
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The restriction map and multiple cloning site (MCS) of green fluorescence 
protein (GFP) expression vector, pEGFP-Cl. 
Ase\ 
A/jaU f SnaB I 
/ ^ ^ 111 (597) 
/ t M v lE^^A^ Age I ( 6 0 1 ) 
fco01091 / /HSVTK E G F P \ \ 
鋼 ^ 丨柳A pEGFP-CI 
A 4.7 k b • ^ S K H 闘 
\ \Kan7 p o l y A / * ^ MCS 
\ \ NEE/ F, / / \ (1330-1417) 
Mlu I (1642) 
Stu\ 
(2577) 
Eiup •'现 1 如 丨細 彳舰 i»o IXC laac i«o MOPS 
SspEI Bglll Xltoi ttfldlll f«?R| Pst\ Sail _ � �pa l 
FEN 36II I Aspm I / BSP1201 xma 1 " " 
SAC II Sm I 
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The restriction map and multiple cloning site (MSC) of yeast-two hybrid 
pGBKTT vector. 
‘ p G B K T ? ' 卯 細 滥 、 I I 
7,3 kb 
A c-Myc epitope tag 
MATCHMAKERS' DNA-BD Vector 
I �� tSc—A-i_r_ GAW DNA-eindincj Domain 
T C A T C G G A A G A G A G T A G T A A C A A A G G T C A A A G A C A G T T G A C T G T A T W C C G G A A T T T 
a. j . 
1212 T7 Saquencing Pnmer 
• 77 Pfoniotar c-Mvc Epitope Tag 
G T A A T A C G A C T C A C T A T A G G G C G A G C C G C C A T C ^ G A G G A G C A G A A G C T G A T C T C A G A G G A G G A C C T ^ START 
in w t s 
I2B1 
C A T ^ G C C A T ^ A G G C C G A A T T C C C G G G G A T C C G T C G ^ C T G C ^ C G G C C G C A T M C T ^ C A T A A C C C C 
Ndel A/col Sfi\ fcoRI SnrnV 权抓HI Sal\ Pst\ ^ 爾 
„, . Xma I “ • 17 Tomiflator 
T T G G G G C C T C I M A C G G G T C T T G A G G G G T T F M G C G C G C T T G C A G C C A A G C T A A T T C C G G G C G A A T T T C N A T G A T T T STOP !«f3i 
1430 
M G A T T T T T A T T A T T M A T A A G T T A T A A A A A A A A T A A G T G W A C A A A T M A A A G T G A C T C T T A G G T T T T A M A C G A A A A 
^ 3' DNA-BD Sequancina Primer 
MATCHMAKER DNA-BD Vector 
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